Page last updated: 2024-11-05

arsenic trioxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tetraarsenic Oxide: A form of As2O3 that exists as As4O6 in the solid state. It dissociates to As2O3 upon heating to the vapor phase above 800 degrees Celsius. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Arsenic Trioxide: An inorganic compound with the chemical formula As2O3 that is used for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA in patients who have relapsed from, or are resistant to, conventional drug therapy. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID518605
CHEMBL ID2362016
CHEBI ID30621
MeSH IDM0049263
PubMed CID261004
CHEMBL ID1200978
MeSH IDM0049263
PubMed CID14888
MeSH IDM0049263

Synonyms (63)

Synonym
tricyclo[3.3.1.1~3,7~]tetraarsoxane
2,4,6,8,9,10-hexaoxa-1,3,5,7-tetraarsatricyclo[3.3.1.13,7]decane
2,4,6,7,8,10-hexaoxa-1,3,5,7-tetraarsatricyclo[3.3.1.13,7]decane
arsenic oxide (as4o6)
tetraarsenic oxide
as2o3
as4o6
CHEBI:30621 ,
tricyclo[3.3.1.1(3,7)]tetraarsoxane
HMS2093H20
nsc-759274
nsc759274
pharmakon1600-01505957
arseneous oxide
12505-67-8
2,4,6,8,9,10-hexaoxa-1,3,5,7-tetraarsatricyclo[3.3.1.1<3,7>]decane
2,4,6,7,8,10-hexaoxa-1,3,5,7-tetraarsatricyclo[3.3.1.1<3,7>]decane
KTTMEOWBIWLMSE-UHFFFAOYSA-N
arsentrioxid
CHEMBL2362016
SBI-0206862.P001
DTXSID40925001
arsenic(iii) oxide
nsc92859
DB01169
arsenic(iii) oxide, 99.995% trace metals basis
arsenic(iii) oxide, puriss. p.a., acs reagent, 99.95-100.05% (rt)
CHEMBL1200978
AKOS015903780
arsenic(iii)oxide,arsenic trioxide,arsenous acid anhydride,arsenous acid,arsenic sesquioxide,white arsenic
IKWTVSLWAPBBKU-UHFFFAOYSA-N
mfcd00003433
arsenic(iii) oxide, puratronic(r)
arsenic(iii) oxide, primary standard
arsenic(iii) oxide, reagentplus(r), >=99.0%
arsenic(iii) oxide, elec. gr.
arsenic(iii) oxide, acs reagent (primary standard)
arsenic(iii) oxide, saj first grade, >=99.0%
arsenic(iii) oxide, certified reference material for titrimetry, certified by bam, according to iso 17025, >99.5%
arsenic(iii) oxide, p.a., 99.0%
J-006219
arsenic-trioxide
NCGC00164639-02
bdbm50591825
arsenic oxide (as2o3)
un1561
einecs 215-481-4
rcra waste no. p012
arsenous oxide [iso]
arsenious acid anhydride
arsenic trioxide
ec 215-481-4
arsenic trioxide [un1561] [poison]
arsenic(iii) trioxide
arsenic trioxide [usan:jan]
tox21_112255
dtxcid60820620
dtxsid0020103 ,
cas-1327-53-3
arsenic oxidearsenous trioxide
sr-01000944371
SR-01000944371-1
arsenic(3+);oxygen(2-)

Research Excerpts

Overview

Arsenic trioxide (ATO) is an approved therapy for the treatment of acute promyelocytic leukemia. The extension of arsenic-based therapies to other types of malignancies, notably tumor-forming cancers, has been slow.

ExcerptReferenceRelevance
"Arsenic trioxide (ATO) is an effective anti-cancer drug. "( The whole transcriptome analysis and the circRNA-lncRNA network construction in arsenic trioxide-treated mice myocardium.
Bai, Y; Chao, Y; Dong, C; Gao, Y; Jiang, Y; Li, X; Shang, D; Shen, X; Shi, C; Xu, J; Yang, B; Zhi, F, 2022
)
2.39
"Arsenic trioxide (ATO) is an approved therapy for the treatment of acute promyelocytic leukemia, but the extension of arsenic-based therapies to other types of malignancies, notably tumor-forming cancers, has been slow. "( Realgar and arsenene nanomaterials as arsenic-based anticancer agents.
Hollow, SE; Johnstone, TC, 2023
)
2.35
"Arsenic trioxide (ATO) is an efficacious therapeutic agent for APL, and the mechanism involves the binding with PML and degradation of PML-RARα protein."( Pyrrolidine Dithiocarbamate Enhances the Cytotoxic Effect of Arsenic Trioxide on Acute Promyelocytic Leukemia Cells.
Chen, W; Ge, Z; Han, J; Yu, S, 2023
)
1.87
"Arsenic trioxide (ATO) is a highly toxic arsenical which has been successfully exploited for treating acute promyelocytic leukemia (APL). "( Arsenic trioxide (ATO) up-regulates cytochrome P450 1A (CYP1A) enzymes in murine hepatoma Hepa-1c1c7 cell line.
Alqahtani, MA; El-Ghiaty, MA; El-Kadi, AOS, 2023
)
3.8
"Arsenic trioxide (ATO) is a great discovery in the treatment of acute promyelocytic leukemia (APL), which has been used in an increasing number of malignant diseases. "( Open a new epoch of arsenic trioxide investigation: ATOdb.
Jiang, Y; Li, J; Li, X; Liu, Y; Shao, T; Shen, X; Xu, J; Xu, Y; Zhi, F, 2023
)
2.68
"Arsenic trioxide is an effective drug in the treatment of hematologic malignancies, but it has no obvious therapeutic effect on liver cancer. "( Long non-coding RNA ROR confers arsenic trioxide resistance to HepG2 cells by inhibiting p53 expression.
Li, X; Sun, D; Zhang, Z; Zhao, T, 2020
)
2.28
"Arsenic trioxide (ATO) is a therapeutic agent used to treat acute promyelocytic leukemia (APL), a disease caused by a chromosomal translocation of the retinoic acid receptor α (RARα) gene that can occur reciprocally with the promyelocytic leukemia (PML) gene. "( Interplay of Ubiquitin-Like Modifiers Following Arsenic Trioxide Treatment.
Lamoliatte, F; McManus, FP; Rinfret Robert, C; Thibault, P, 2020
)
2.26
"Arsenic trioxide (ATO) is an ancient Chinese medicine used for its therapeutic properties with several autoimmune diseases."( Arsenic trioxide ameliorates experimental autoimmune encephalomyelitis in C57BL/6 mice by inducing CD4
An, K; Lan, TS; Qi, ZQ; Xia, JJ; Xue, MJ; Yu, SN; Zhong, JY, 2020
)
2.72
"Arsenic trioxide (ATO) is an excellent therapy for acute promyelocytic leukemia; however, its use is limited due to its cardiotoxicity. "( Crocin ameliorates arsenic trioxide‑induced cardiotoxicity via Keap1-Nrf2/HO-1 pathway: Reducing oxidative stress, inflammation, and apoptosis.
Chu, L; Chu, X; Han, X; Li, J; Liang, Y; Shi, J; Zhang, J; Zhang, X; Zheng, B, 2020
)
2.33
"Arsenic trioxide (ATO) is a frontline chemotherapy drug used in the therapy of acute promyelocytic leukemia. "( Mechanisms underlying the protective effect of tannic acid against arsenic trioxide‑induced cardiotoxicity in rats: Potential involvement of mitochondrial apoptosis.
Chu, L; Chu, X; Han, X; Jin, W; Li, M; Li, Z; Xue, Y; Zhang, J, 2020
)
2.24
"Arsenic trioxide (ATO) is a potent chemotherapeutic agent, which can target multiple signaling and have substantial efficacy on HCC."( Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal.
Carroll, SL; Feng, G; Jiang, T; Jiang, X; Kong, D; Liu, B; Liu, J; Lou, C; Zhao, B, 2020
)
1.51
"Arsenic trioxide (ATO) is an important agent for the treatment of relapsed and newly diagnosed APL."( Mechanistic effects of arsenic trioxide on acute promyelocytic leukemia and other types of leukemias.
Yousefnia, S, 2021
)
1.65
"Arsenic trioxide (ATO) is a well-accepted chemotherapy agent in managing promyelocytic leukemia. "( Metformin ameliorates arsenic trioxide hepatotoxicity via inhibiting mitochondrial complex I.
Chen, K; Feng, T; Ling, S; Liu, J; Liu, P; Shan, Q; Song, P; Xiang, P; Xie, H; Xu, X; Zhang, X; Zheng, S; Zhou, L, 2017
)
2.21
"Arsenic trioxide (ATO) is a known anti-acute promyelocytic leukemia (APL) reagent, whose clinical applications are limited by its serious cardiac toxicity and fatal adverse effects, such as sudden cardiac death resulting from long QT syndrome (LQTS). "( Downregulation of Long Non-Coding RNA Kcnq1ot1: An Important Mechanism of Arsenic Trioxide-Induced Long QT Syndrome.
Bai, Y; Chai, L; Chu, Q; Du, W; Jiang, Y; Li, A; Li, G; Li, Y; Pavlov, V; Qin, Y; Sun, X; Tuguzbaeva, G; Wang, H; Wang, Z; Yang, B; Yue, E, 2018
)
2.15
"Arsenic trioxide is an effective chemotherapeutic agent for the treatment of acute promyelocytic leukemia. "( Eugenol, a plant-derived phenolic nutraceutical, protects thiol (SH) group in myocardium from ROS-mediated oxidation under chemotherapeutic stress induced by arsenic trioxide - a in vivo model study.
Abhilash, S; Arathi, P; Binu, P; Gifty, K; Nair, RH; Vineetha, RC, 2018
)
2.12
"Arsenic trioxide (ATO) is a well-recognized antileukemic drug used for the treatment of newly diagnosed and relapsed acute promyelocytic leukemia (APL). "( Transcriptomic analysis of the PI3K/Akt signaling pathway reveals the dual role of the c-Jun oncogene in cytotoxicity and the development of resistance in HL-60 leukemia cells in response to arsenic trioxide.
Roszak, J; Smok-Pieniążek, A; Stępnik, M, 2017
)
2.09
"Arsenic trioxide (ATO) is an effective component of traditional Chinese medicine arsenic. "( [Preparation and
Han, SP; Huang, AH; Li, FZ; Lu, YP; Ma, R; Zheng, HS, 2018
)
1.92
"Arsenic trioxide (ATO) is a successful chemotherapeutic drug for blood cancers via selective induction of apoptosis; however its efficacy in solid tumors is limited. "( Nanodiamond autophagy inhibitor allosterically improves the arsenical-based therapy of solid tumors.
Cui, Z; Fan, C; Kong, H; Shi, J; Wang, L; Xia, K; Yan, Q; Zhang, J; Zhang, Y; Zhu, Y; Zuo, X, 2018
)
1.92
"Arsenic trioxide is an approved chemotheraputic agent for the treatment of acute promyelocytic leukemia (APL). "( Identification of Key Potential Targets and Pathway for Arsenic Trioxide by Systemic Bioinformatics Analysis in Pancreatic Cancer.
Liu, S; Liu, Z; Pang, Y, 2019
)
2.2
"Arsenic trioxide is a traditional drug that has shown excellent efficacy when applied as cancer therapy."( Arsenic trioxide inhibits EMT in hepatocellular carcinoma by promoting lncRNA MEG3 via PKM2.
Fan, Z; Fu, T; He, J; Liu, R; Lv, L; Qu, X; Wang, J; Yang, G; Zhang, W, 2019
)
2.68
"Arsenic trioxide (As2O3) is an environmental toxicant as well as an effective anti cancer agent against many types of cancers. "( Myocardial toxicity of acute promyelocytic leukaemia drug-arsenic trioxide.
Abhilash, M; Abhilash, S; Manju, A; Mathews, VV; Nair, RH; Paul, MV, 2013
)
2.08
"Arsenic trioxide (As(2)O(3)) is an environmental toxicant and a potent antineoplastic agent. "( Resveratrol protects against arsenic trioxide-induced nephrotoxicity by facilitating arsenic metabolism and decreasing oxidative stress.
Li, Y; Liu, L; Ma, D; Xue, J; Yu, M; Zhang, W; Zhang, Z, 2013
)
2.12
"Arsenic trioxide (ATO) is an ancient Chinese medicine, which is used to treat psoriasis, asthma, and acute promyelocytic leukemia."( Arsenic trioxide alleviates airway hyperresponsiveness and promotes apoptosis of CD4+ T lymphocytes: evidence for involvement of the ER stress-CHOP pathway.
Chen, P; Gong, S; Ji, X; Li, J; Li, K; Liu, S; Liu, Y; Ma, L; Wang, G; Xiang, X; Xu, L; Zeng, H; Zhang, L, 2013
)
2.55
"Arsenic trioxide (As2O3) is an important environmental toxin. "( Attenuation of arsenic retention by resveratrol in lung of arsenic trioxide-exposed rats.
Ge, M; Liu, J; Liu, Y; Ma, D; Xue, J; Yao, C; Zhang, W; Zhang, Z, 2013
)
2.08
"Oral arsenic trioxide (ATO) is a standard treatment for acute promyelocytic leukaemia."( Effect of therapeutic arsenic exposure on pulmonary function.
Au, WY; Han, L; Ho, JC; Ip, MS; Kwong, YL, 2013
)
0.84
"Arsenic trioxide (As2O3) is a known environmental toxicant and potent chemotherapeutic agent. "( Neuroprotective effect of resveratrol on arsenic trioxide-induced oxidative stress in feline brain.
Cheng, Y; Gao, L; Jiang, H; Ma, D; Wang, M; Xue, J; Zhang, Z, 2014
)
2.11
"Arsenic trioxide (ATO) is an effective therapy for relapsed acute promyelocytic leukemia (APL) patients; however, the optimal treatment strategy remains unclear, and knowledge of the prognostic factors is still limited. "( Outcomes and prognostic factors of first relapsed acute promyelocytic leukemia patients undergoing salvage therapy with intravenous arsenic trioxide and chemotherapy.
Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Suo, S; Tong, H; Tong, Y; Yu, W, 2014
)
2.05
"Arsenic trioxide (ATO) is a very effective drug for the treatment of acute promyelocytic leukemia (APL) but it leads to cardiotoxicity mediated through alterations in various cardiac ion channels and by increasing the intracellular calcium level and reactive oxygen species (ROS)."( Polyphenol-rich apple (Malus domestica L.) peel extract attenuates arsenic trioxide induced cardiotoxicity in H9c2 cells via its antioxidant activity.
Girija, S; Raghu, KG; Soumya, RS; Vineetha, VP, 2014
)
1.36
"Arsenic trioxide paste is a cytotoxic agent and may cause harmful adverse effects on adjacent periodontium and supporting hard tissue if leakage occurs, or it is used carelessly."( Gingival and localized alveolar bone necrosis related to the use of arsenic trioxide paste--two case reports.
Chen, G; Sung, PT, 2014
)
1.36
"Arsenic trioxide (ATO) is a promising antitumor agent used to treat acute promyelocytic leukemia (APL) and, recently solid tumor. "( Arsenic trioxide exerts a double effect on osteoblast growth in vitro.
Liu, SZ; Liu, Y; Qiao, GF; Xu, WX; Yan, J; Zhang, Y, 2014
)
3.29
"Arsenic trioxide (As2O3) is a known cytotoxic environmental toxicant and a potent chemotherapeutic agent."( Resveratrol, a natural antioxidant, has a protective effect on liver injury induced by inorganic arsenic exposure.
Chen, Y; Cheng, B; Cheng, Y; Gao, L; Jiang, H; Jiang, J; Shan, A; Yu, H; Zhang, Z, 2014
)
1.12
"Arsenic trioxide (ATO) is a highly effective agent for the treatment of acute promyelocytic leukemia (APL). "( Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide.
Carlin, RF; Curcio, TJ; Feldman, EJ; Gale, L; Kligfield, PD; Provenzano-Gober, JL; Ritchie, EK; Roboz, GJ; Samuel, M, 2014
)
2.06
"Arsenic trioxide is an old drug and has been used for a long time in traditional Chinese and Western medicines. "( Endoplasmic reticulum stress contributes to arsenic trioxide-induced intrinsic apoptosis in human umbilical and bone marrow mesenchymal stem cells.
Chen, HP; Chiu, YJ; King, YA; Kuo, DH; Lu, CC; Yang, JS, 2016
)
2.14
"Arsenic trioxide (As2O3) is an active ingredient in Traditional Chinese Medicine, but the therapeutic potential of As2O3 in osteosarcoma remains largely unexplored."( Stathmin is key in reversion of doxorubicin resistance by arsenic trioxide in osteosarcoma cells.
Feng, L; Feng, T; Huang, Y; Qi, W; Qiao, G; Shen, Z; Yao, Y, 2014
)
1.37
"Arsenic trioxide (ATO) is an approved treatment for acute promyelocytic leukemia (APL). "( Cotylenin A and arsenic trioxide cooperatively suppress cell proliferation and cell invasion activity in human breast cancer cells.
Honma, Y; Kasukabe, T; Kato, N; Kumakura, S; Okabe-Kado, J, 2015
)
2.21
"Arsenic trioxide (ATO) is a currently clinically used anticancer drug and displays its anticancer activities by inhibiting Akt activation."( Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
He, C; Jiang, H; Jiang, X; Ma, L; Sun, X; Xu, L; Zhai, B; Zhao, D, 2015
)
2.58
"Arsenic trioxide (As2O3) is a potent anticancer drug for the treatment of acute promyelocytic leukemia. "( Resveratrol synergistically triggers apoptotic cell death with arsenic trioxide via oxidative stress in human lung adenocarcinoma A549 cells.
Chen, C; Gu, S; Jiang, X; Zhang, Z, 2015
)
2.1
"Arsenic trioxide (ATO) is a traditional Asian medicine, and a phase II study has shown that treatment with ATO alone was not effective against HCC."( Metformin sensitizes hepatocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating Bcl2 expression.
Ling, S; Sun, D; Tian, Y; Wang, L; Yang, X, 2015
)
1.39
"Arsenic trioxide (ATO) is a multi-target drug approved by the Food and Drug Administration as the first-line chemotherapeutic agent for the treatment of acute promyelocytic leukemia. "( TG-interacting factor transcriptionally induced by AKT/FOXO3A is a negative regulator that antagonizes arsenic trioxide-induced cancer cell apoptosis.
Cheng, YL; Huang, HS; Liu, ZM; Tseng, HY; Wu, WJ; Yeh, BW, 2015
)
2.07
"Arsenic trioxide (As2O3) is an inorganic arsenical-containing toxic compound."( The Role of Oxidative Stress in Gastrointestinal Tract Tissues Induced by Arsenic Toxicity in Cocks.
Guo, G; Guo, Y; Hu, Z; Tian, L; Xing, M; Zhang, K; Zhang, W; Zhao, P, 2015
)
1.14
"Arsenic trioxide (As2O3) is an existing form of As."( Heat Shock Protein Alteration in the Gastrointestinal Tract Tissues of Chickens Exposed to Arsenic Trioxide.
Chai, H; Guo, G; Sun, X; Xing, M; Zhang, K; Zhang, W; Zhao, P, 2016
)
1.38
"Arsenic trioxide (ATO) is an effective drug used in acute promyelocytic leukemia (AML). "( Expression of cyclin A in A549 cell line after treatment with arsenic trioxide.
Grzanka, A; Klimaszewska-Wiśniewska, A; Krajewski, A; Litwiniec, A; Żuryń, A, 2015
)
2.1
"Arsenic trioxide (ATO) is an efficient drug for the treatment of the patients with acute promyelocytic leukemia (APL). "( Morphine Attenuated the Cytotoxicity Induced by Arsenic Trioxide in H9c2 Cardiomyocytes.
Amini-Khoei, H; Amiri, S; Dehpour, AR; Haj-Mirzaian, A; Hosseini, MJ; Jahanabadi, S; Khedri, M; Mehr, SE; Mohammadi-Asl, A; Momeny, M; Rahimi-Balaei, M, 2016
)
2.13
"Arsenic trioxide (As2O3) is a well-known anticancer drug and is approved by the FDA for its use in acute promyelocytic leukemia. "( Biocompatible arsenic trioxide nanoparticles induce cell cycle arrest by p21(WAF1/CIP1) expression via epigenetic remodeling in LNCaP and PC3 cell lines.
Bhatt, P; Jadhav, V; Ray, P; Sachdeva, G, 2016
)
2.24
"Arsenic trioxide (ATO) is a therapeutic agent for acute promyelocytic leukemia (APL) which induces PML-RARA protein degradation via enhanced UBE2I-mediated sumoylation. "( PCGF2 negatively regulates arsenic trioxide-induced PML-RARA protein degradation via UBE2I inhibition in NB4 cells.
Chung, H; Jo, S; Kim, S; Lee, H; Lee, YL, 2016
)
2.17
"Arsenic trioxide (ATO) is a classic apoptosis-inducing agent used to treat acute promyelocytic leukemia. "( Cucurbitacin B synergistically enhances the apoptosis-inducing effect of arsenic trioxide by inhibiting STAT3 phosphorylation in lymphoma Ramos cells.
Chen, D; Chi, J; Ding, X; Hao, J; Ji, W; Liu, C; Liu, X; Niu, Y; Wang, X; Wu, X; Yang, X; Zhu, C, 2017
)
2.13
"Arsenic trioxide (ATO) is a potent antitumor agent used to treat acute promyelocytic leukemia, and recently solid tumors including bladder cancers. "( Protein kinase C is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in human bladder cancer cells.
An, R; Dong, X; Duan, G; Pan, S; Sun, X; Wang, Y, 2009
)
2.08
"Arsenic trioxide (ATO) is an inorganic arsenic derivative that is highly effective against PML-RARalpha-positive leukemia but much less against other hematological malignancies. "( MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells.
Duzkale, H; Freireich, EJ; Golemovic, M; Johansen, M; Kantarjian, H; Manshouri, T; Orsolic, N; Quintás-Cardama, A; Verstovsek, S; Zingaro, RA, 2010
)
1.8
"Arsenic trioxide (As(2)O(3)) is a frontline drug for treatment of acute promyelocytic leukemia and is in clinical trials for treatment of other malignancies, including multiple myeloma; however, efforts to expand clinical utility to solid tumors have been limited by toxicity. "( Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide.
Ahn, R; Chen, H; O'Halloran, TV; Thompson, DH; Van den Bossche, J, 2009
)
2.01
"Arsenic trioxide (ATO) is a widely used drug for acute promyelocytic leukemia (APL)."( Synergistic mitosis-arresting effects of arsenic trioxide and paclitaxel on human malignant lymphocytes.
Chen, GQ; Duan, XF; Wang, XD; Wu, YL; Xu, HZ; Yan, H; Zhao, M; Zhuang, HY, 2010
)
1.35
"Arsenic trioxide (ATO/As2O3) is a promising drug for patients with a relapse of acute promyelocytic leukemia (APL); however, it frequently causes fatal arrhythmias. "( Evaluation of adverse cardiac effects induced by arsenic trioxide, a potent anti-APL drug.
Bhadauria, S; Prathapan, A; Raghu, KG; Sharma, S; Singh, R; Yadav, GK, 2009
)
2.05
"Arsenic trioxide (ATO) is an effective therapeutic agent for acute promyelocytic leukemia (APL) and other hematopoietic malignancies. "( Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines.
Jiang, J; Liu, XS; Peng, CY; Zheng, HT, 2010
)
2.09
"Arsenic trioxide (As(2)O(3)) is an active ingredient in traditional Chinese medicine. "( Arsenic trioxide inhibits osteosarcoma cell invasiveness via MAPK signaling pathway.
Changliang, P; Tingting, R; Wei, G; Xinchang, L; Yi, Y, 2010
)
3.25
"Arsenic trioxide (As(2)O(3)) is a highly effective treatment for patients with relapsed acute promyelocytic leukemia (APL); its role as consolidation treatment for patients in first remission has not been defined. "( Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.
Appelbaum, FR; Couban, S; Coutre, S; Feusner, JH; Gallagher, RE; Gregory, J; Larson, RA; Moser, B; Powell, BL; Rowe, JM; Stock, W; Stone, RM; Tallman, MS; Willman, CL, 2010
)
3.25
"Arsenic trioxide (ATO) is a first-line anti-cancer agent for acute promyelocytic leukemia, and induces apoptosis in other solid cancer cell lines including breast cancer cells. "( Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation.
Cox, AJ; Davis, BH; Davis, KT; Fang, G; Hock, JM; Li, X; Liu, Y; Sullivan, C, 2010
)
1.8
"Arsenic trioxide (ATO) is a well-known inhibitor of cell proliferation. "( Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2.
Han, Y; Hou, J; Hu, X; Jiang, W; Meng, X; Shi, J; Tang, S; Tao, Y; Tricot, G; Wu, X; Wu, Y; Zangari, M; Zhan, F, 2010
)
3.25
"Arsenic trioxide (ATO) is a strong inducer of apoptosis in malignant hematological cells. "( E3 ubiquitin ligase Cbl-b potentiates the apoptotic action of arsenic trioxide by inhibiting the PI3K/Akt pathway.
Jing, L; Jinglei, Q; Kezuo, H; Xiujuan, Q; Xuejun, H; Ye, Z; Yingchun, L; Yuee, T; Yunpeng, L, 2011
)
2.05
"Arsenic trioxide (As₂O₃) is a highly effective treatment for patients with refractory/relapsed acute promyelocytic leukemia (APL), but resistance to As₂O₃ has recently been seen. "( Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.
Atsumi, A; Goto, E; Hayakawa, F; Kiyoi, H; Naoe, T; Tomita, A, 2011
)
2.04
"ATO (arsenic trioxide) is a multi-target drug that has been effectively used as an anticancer drug in acute promyelocytic leukaemia."( Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.
Hong, DY; Huang, HS; Liu, ZM; Tseng, JT, 2011
)
1.08
"Arsenic trioxide is a frequently used chemical in cancer treatment research and its action to various malignant cells has been extensively studied and published."( Arsenic trioxide versus tetraarsenic oxide in biomedical research: misunderstandings and misinterpretations.
Falnoga, I; Slejkovec, Z; van Elteren, JT, 2012
)
2.54
"Arsenic trioxide (As(2)O(3)) is an effective treatment for relapsed or refractory acute promyelocytic leukemia (APL). "( Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors.
Chang, JY; Chen, KL; Chen, LT; Chen, SN; Cheng, YT; Kuo, CC; Liu, JF; Liu, TW; Pan, WY; Shiah, HS; Wu, CM; Yang, YN, 2011
)
2.16
"Arsenic trioxide (As(2)O(3)) is an effective therapeutic against acute promyelocytic leukemia and certain solid tumors. "( Arsenic trioxide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors.
Calderon, PB; Dauguet, N; Diepart, C; Feron, O; Gallez, B; Grégoire, V; Jordan, BF; Karroum, O; Leveque, P; Magat, J; Stockis, J; Verrax, J, 2012
)
3.26
"Arsenic trioxide, believed to be a carcinogen and a teratogen, has found its niche in the treatment of acute promyelocytic leukemia (APL). "( Parenthood in patients with acute promyelocytic leukemia after treatment with arsenic trioxide: a case series.
Bagel, B; Gujral, S; Gupta, S; Khattry, N; Menon, H; Nair, R; Subramanian, PG, 2012
)
2.05
"Arsenic trioxide (ATO) is an inorganic arsenic derivative that is very effective against acute promyelocytic leukemia. "( The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells.
Andreeff, M; Cheng, X; Freireich, EJ; Gao, MZ; Golemovic, M; Kantarjian, HM; Quintás-Cardama, A; Verstovsek, S; Zingaro, R, 2012
)
1.82
"Arsenic trioxide (As(2)O(3)) is an environmental pollutant and potent toxicant to humans. "( Resveratrol attenuates hepatotoxicity of rats exposed to arsenic trioxide.
Ge, M; Liu, L; Xue, J; Yu, M; Zhang, W; Zhang, Z, 2013
)
2.08
"Arsenic trioxide (As(2)O(3)) is an effective drug in the treatment of leukaemia and many solid tumours. "( Mitigation of hepatotoxic effects of arsenic trioxide through omega-3 fatty acid in rats.
Abhilash, M; Abhilash, S; Manju, A; Mathews, VV; Nair, RH; Paul, MS, 2014
)
2.12
"Arsenic trioxide combined TACE is an effective treatment method in treating primary liver cancer with pulmonary metastases."( [The clinical therapeutic effects of arsenic trioxide combined with transcatheter arterial chemoembolization in treating primary liver cancer with pulmonary metastases].
Cheng, HT; Guo, CY; Hu, HT; Li, HL; Luo, JP; Meng, YL; Xiao, JC; Yao, QJ, 2012
)
2.09
"Arsenic trioxide (As2O3) is a highly effective agent for treatment of acute promyelocytic leukemia (APL). "( Genistein ameliorates adverse cardiac effects induced by arsenic trioxide through preventing cardiomyocytes apoptosis.
Du, Z; Fan, Y; Hang, P; Liu, Y; Pan, Z; Wang, C; Wang, N; Zhang, Y, 2013
)
2.08
"Arsenic trioxide (ATO) is a novel agent to treat acute promyelocytic leukemia (APL). "( The cytotoxicity of arsenic trioxide to normal hematopoietic progenitors and leukemic cells is dependent on their cell-cycle status.
Chang, IY; Hsieh, RK; Huang, MJ; Lin, CP; Liu, HJ, 2002
)
2.08
"Arsenic trioxide (As2O3) is an anticancer drug that has been reported to induce apoptosis and inhibit differentiation in human plasmacytoma and normal plasma/B cells without significant myelosuppression. "( An exploratory investigation of the effect of arsenic trioxide on anti-Gal antibody production in baboons.
Alwayn, IP; Basker, M; Cooper, DK; Correa, L; Gollackner, B; Harper, D; Knosalla, C; Mauiyyedi, S; Ryan, D; Salomon, G; Thall, A, 2003
)
2.02
"Arsenic trioxide (As(2)O(3)) is an effective treatment for acute promyelocytic leukemia (APL), but is less effective against other leukemias. "( Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines.
Côté, S; Davison, K; Mader, S; Miller, WH, 2003
)
2.02
"Arsenic trioxide is an effective treatment for patients with acute promyelocytic leukemia (APL) who have relapsed from or are refractory to all-trans-retinoic acid and anthracycline chemotherapy. "( Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Barbey, JT; Pezzullo, JC; Soignet, SL, 2003
)
2.16
"Arsenic trioxide is a toxic metalloid and carcinogen that is also used as an anticancer drug, and for this reason it is important to identify the routes of arsenite uptake by cells. "( Arsenic trioxide uptake by hexose permeases in Saccharomyces cerevisiae.
Boles, E; Liu, Z; Rosen, BP, 2004
)
3.21
"Arsenic trioxide (As2O3) is a new drug used to treat the patients with solid tumor,but the mechanism is still unclear. "( [Arsenic trioxide induced cell apoptosis by mitochondria dependent pathway in KB and KBv200 cells].
Chen, LM; Ding, Y; Fu, LW; Huang, M; Li, YF; Liang, YJ; Wang, XD, 2004
)
2.68
"Arsenic trioxide (As2O3) is an effective therapy for acute promyelocytic leukemia (APL), and there has been promising activity noted in other hematologic and solid tumors. "( The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future.
Evens, AM; Gartenhaus, RB; Tallman, MS, 2004
)
2.11
"Arsenic trioxide (As2O3) is an effective drug for treatment of acute promyelocytic leukemia (APL) and malignant tumors. "( Significance of intracellular arsenic trioxide for therapeutic response in acute promyelocytic leukemia.
Jena, RK; Sahu, GR, 2005
)
2.06
"Arsenic trioxide is a potent chemotherapeutic agent by virtue of its ability to selectively trigger apoptosis in tumor cells. "( Indirect effects of Bax and Bak initiate the mitochondrial alterations that lead to cytochrome c release during arsenic trioxide-induced apoptosis.
Gogvadze, V; McConkey, DJ; Mirnikjoo, B; Nutt, LK; Orrenius, S; Uthaisang, W, 2005
)
1.98
"Arsenic trioxide (ATO) is a novel agent for acute promylocytic leukemia (APL). "( Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo.
Chow, J; Huang, M; Lee, C; Lin, C; Lin, Y; Liu, C; Liu, HE, 2006
)
1.97
"Arsenic trioxide (As2O3, ATO) is a recently developed drug for the effective treatment of acute promyelocytic leukemia (APL). "( Hypoxia inducible factor-1alpha and leukemic cell differentiation.
Chen, GQ; Huang, Y; Jiang, Y; Liu, W; Peng, ZG; Song, LP; Zhao, Q, 2006
)
1.78
"Arsenic trioxide (As2O3) is a highly effective agent in the treatment of acute promyelocytic leukemia (APL), whereas other hematopoietic tumors are less responsive to this agent and mechanisms underlying As2O3,-resistance are poorly understood. "( Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4.
Bellincampi, L; Bernardini, S; Bonati, A; Federici, G; Lo Coco, F; Lunghi, P; Mann, K; Miller, WH; Noguera, NI; Nuccetelli, M, 2006
)
1.78
"Arsenic trioxide (As2O3) is a potent inducer of apoptosis of leukemic cells in vitro and in vivo, but the precise mechanisms by which it mediates such effects are not well defined. "( Activation of the mitogen- and stress-activated kinase 1 by arsenic trioxide.
Arthur, JS; Kannan-Thulasiraman, P; Katsoulidis, E; Platanias, LC; Tallman, MS, 2006
)
2.02
"Arsenic trioxide (As2O3) is a potent antitumor agent used to treat acute promyelocytic leukemia (APL) and, more recently, solid tumors. "( Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice.
Dong, X; Jiang, H; Krissansen, GW; Liu, B; Pan, S; Qiao, H; Sun, X, 2006
)
2.1
"Arsenic trioxide is a low-toxic and effective remedy for treatment of stage III osteosarcoma and Ewing sarcoma."( [Preliminary report of combination chemotherapy including Arsenic trioxide for stage III osteosarcoma and Ewing sarcoma].
Guo, W; Tang, S; Tang, XD; Yang, Y, 2006
)
2.02
"Arsenic trioxide [ATO] is a pluripotent drug with potentials to have pro-oxidant, angiogenesis inhibitor, flow inhibitor and radiation sensitizer properties."( A phase I study to study arsenic trioxide with radiation and hyperthermia in advanced head and neck cancer.
Huilgol, NG, 2006
)
2.08
"Arsenic trioxide (ATO) is a potent anti-leukemic chemotherapeutic agent for acute promyelocytic leukemia (APL) that results from a t (15, 17) chromosomal translocation that produces PML-RARalpha, a fusion protein between a tumor suppressor PML and the retinoic acid receptor RARalpha. "( ATR, PML, and CHK2 play a role in arsenic trioxide-induced apoptosis.
Chung, JH; Jeong, JH; Joe, Y; Kang, H; Kim, MK; Motoyama, N; Pandolfi, PP; Yang, S, 2006
)
2.06
"Arsenic trioxide (As(2)O (3)) is a new promising regimen for patients with a relapse of acute promyelocytic leukemia (APL), but causes life-threatening arrhythmias. "( Arrhythmogenic effects of arsenic trioxide in patients with acute promyelocytic leukemia and an electrophysiological study in isolated guinea pig papillary muscles.
Hayashi, H; Katoh, H; Naito, K; Ohnishi, K; Satoh, H; Takeshita, A; Terada, H; Uehara, A; Yamazaki, K, 2006
)
2.08
"Arsenic trioxide (ATO) is an effective agent for the salvage of patients with recurrent APL, and gemtuzumab ozogamicin (GO) has shown activity in patients with APL."( Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
Aribi, A; Cortes, JE; Estey, EH; Faderl, SH; Garcia-Manero, G; Kantarjian, HM; Koller, CA; Kornblau, SM; Laddie, NM; Thomas, DA, 2007
)
1.36
"Arsenic trioxide (ATO) is an effective chemotherapeutic agent for the treatment of acute promyelocytic leukemia (APL) and is being tested in phase II studies in various types of cancers."( Arsenic trioxide induces p53-dependent apoptotic signals in myeloma cells with SiRNA-silenced p53: MAP kinase pathway is preferentially activated in cells expressing inactivated p53.
Akay, C; Gazitt, Y; Kircelli, F, 2007
)
2.5
"Arsenic trioxide (ATO) is an effective treatment for acute promyelocytic leukemia (APL) and potentially for human T-cell leukemia virus type I (HTLV-I) associated adult T-cell leukemia/lymphoma (ATL). "( Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity.
Abdallah, M; Bazarbachi, A; Darwiche, N; Dbaibo, GS; de Thé, H; El-Sabban, M; Hermine, O; Kfoury, Y; Kozhaya, L; Nasr, R; Panjarian, S, 2007
)
3.23
"Arsenic trioxide (As(2)O(3)) is an effective agent for the treatment of relapsed acute promyelocytic leukemia (APL). "( Acute intestinal pseudo-obstruction after induction treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
Ahn, HS; Kang, HJ; Park, JA; Shin, HY; Yun, JH, 2008
)
2
"Arsenic trioxide (ATO) is an effective cancer therapeutic drug for acute promyelocytic leukemia and has potential anticancer activity against a wide range of solid tumors. "( Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
Chew, EH; Holmgren, A; Lu, J, 2007
)
2.02
"Arsenic trioxide (As2O3) is an effective therapy in acute promyelocytic leukemia (APL), but its use in other malignancies is limited by the higher concentrations required to induce apoptosis. "( Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity.
Bismar, TA; Diaz, Z; Laurenzana, A; Mann, KK; Miller, WH; Schipper, HM, 2007
)
2.04
"Arsenic trioxide (ATO) is a known environmental toxicant and a potent chemotherapeutic agent. "( Dithiothreitol abrogates the effect of arsenic trioxide on normal rat liver mitochondria and human hepatocellular carcinoma cells.
Kumar, R; Mukhopadhyay, AK; Paul, MK, 2008
)
2.06
"Arsenic trioxide (As(2)O(3)) is a potent inducer of apoptosis of leukemic cells in vitro and in vivo, but the mechanisms that mediate such effects are not well understood. "( Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses.
Altman, JK; Glaser, H; Hay, N; Jordan, A; Katsoulidis, E; Kroczynska, B; Platanias, LC; Redig, AJ; Sassano, A; Tallman, MS; Yoon, P, 2008
)
2.01
"Arsenic trioxide (As(2)O(3)) is a new drug used to treat solid tumors. "( [Inhibitory effect of arsenic trioxide on proliferation of human hepatocellular carcinoma cell line SMMC-7721 and the mechanism].
Cui, XP; Li, P; Lu, MD; Shen, AG; Wang, Y, 2007
)
2.1
"Arsenic trioxide is an effective treatment for patients with acute promyelocytic leukaemia (APL) who have relapsed from or are refractory to all trans-retinoic acid and anthracycline chemotherapy. "( QT prolongation: a case of arsenical pericardial and pleural effusion.
Antonioli, E; Cas, LD; D'Aloia, A; Raddino, R; Vizzardi, E; Zanini, G, 2008
)
1.79
"Arsenic trioxide (As(2)O(3)) is a potent inducer of apoptosis of malignant cells in vitro and in vivo, but the precise mechanisms by which it mediates such effects are not well defined. "( Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2.
Altman, JK; Carayol, N; Dolniak, B; Fukunaga, R; Katsoulidis, E; Platanias, LC; Redig, AJ; Tallman, MS; Ueda, T; Watanabe-Fukunaga, R, 2008
)
2.15
"Arsenic trioxide (ATO) is an effective therapeutic agent for the treatment of acute promyelocytic leukemia, but successful application of this agent may occasionally require the use of sensitizing strategies. "( Quercetin decreases intracellular GSH content and potentiates the apoptotic action of the antileukemic drug arsenic trioxide in human leukemia cell lines.
Aller, P; Ramos, AM, 2008
)
2
"Arsenic trioxide (ATO) is a potent anti-tumor agent used to treat acute promyelocytic leukemia (APL), and more recently solid tumors including gliomas. "( Intravenous administration of arsenic trioxide encapsulated in liposomes inhibits the growth of C6 gliomas in rat brains.
Dong, X; Liu, Y; Sun, X; Zhang, J; Zhang, X; Zhao, S; Zou, H, 2008
)
2.08
"Arsenic trioxide (As2O3) is a novel anticancer agent, which has been found to induce remission in acute promyelocytic leukaemic patients following daily intravenous administration. "( Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells.
Chen, JC; Chen, YC; Kuo, ML; Yang, CH, 1999
)
3.19
"Arsenic trioxide (As2O3) is a useful drug for the treatment of acute promyelocytic leukemia (APL), acting through a complex mechanism involving the induction of apoptosis. "( In vitro exposure of acute promyelocytic leukemia cells to arsenic trioxide (As2O3) induces the solitary expression of CD66c (NCA-50/90), a member of the CEA family.
Annunziata, M; Boccuni, P; Cimino, R; Copia, C; Costantini, S; Del Vecchio, L; Dello Russo, A; Di Noto, R; Ferrara, F; Lo Pardo, C, 1999
)
1.99
"Arsenic Trioxide (As2O3) is an effective agent for treating acute promyelocytic leukemia achieving a complete remission rate of about 60% to 90%. "( Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
Chang, IY; Huang, MJ; Lin, WY; Sheu, YT, 2000
)
2.03
"Arsenic trioxide is an effective treatment for acute promyelocytic leukemia, but resistance to metalloid salts is found in humans. "( The MRP1-mediated effluxes of arsenic and antimony do not require arsenic-glutathione and antimony-glutathione complex formation.
Garnier-Suillerot, A; Petroutsa, M; Salerno, M, 2002
)
1.76

Effects

Arsenic trioxide (ATO) has a long history and it is recognized as both poison and drug for more than two thousand years. It has a different mode of action, possibly related to its effects on sulfhydryl-rich proteins.

Arsenic trioxide (As(2)O(3) has shown considerable efficacy in treating hematological malignancies with induction of programmed cell death (PCD) type I, apoptosis. It has been used successfully for the treatment of refractory acute promyelocytic leukemia and has shown promise to treat myelodysplastic syndrome.

ExcerptReferenceRelevance
"Arsenic trioxide (ATO) has a long history and it is recognized as both poison and drug for more than two thousand years. "( Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia.
Hua, HY; Naranmandura, H; Wang, QQ; Zhu, HH, 2020
)
2.25
"Arsenic trioxide (ATO) has a long history of efficacy as an antileukemic agent. "( Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.
Beran, M; DiPersio, J; Greenberg, P; List, A; Rosenfeld, CS; Slack, J; Vey, N, 2003
)
2.06
"Arsenic trioxide (As2O3) has a long history of use in medicine. "( Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside.
Körper, S; Rojewski, MT; Schrezenmeier, H, 2004
)
3.21
"Arsenic trioxide has a different mode of action, possibly related to its effects on sulfhydryl-rich proteins, resulting in dysplastic leukaemic promyelocytes, ending up in apoptotic cell death."( [Arsenic trioxide, a new drug for the treatment of acute promyelocytic leukemia resistant to tretinoine].
Haanen, C; Vermes, I, 1999
)
1.93
"Arsenic trioxide (ATO) has been shown to be effective in treating acute promyelocytic leukemia. "( TP53 inhibitor PFTα increases the sensitivity of arsenic trioxide in TP53 wildtype tumor cells.
Wang, H; Wang, X; Xu, L; Zhang, J, 2022
)
2.42
"Arsenic trioxide (ATO) has been found to be effective in acute promyelocytic leukemia. "( Arsenic trioxide-induced cardiotoxicity triggers ferroptosis in cardiomyoblast cells.
Chen, H; Gao, C; He, H; Li, J; Lin, W; Liu, S; Lu, J; Wang, L; Wu, Y; Yuan, Y; Zhang, R; Zhang, X; Zhang, Y; Zheng, H; Zheng, X,
)
3.02
"Arsenic trioxide (ATO) has efficient anticancer effect on hepatocellular carcinoma (HCC) in clinical trials, but its off-target distribution and side effects have limited its use. "( Albumin-Embellished Arsenic Trioxide-Loaded Polymeric Nanoparticles Enhance Tumor Accumulation and Anticancer Efficacy via Transcytosis for Hepatocellular Carcinoma Therapy.
Cai, X; Chen, D; Han, S; Huang, Y; Wei, Y; Xu, Z, 2022
)
2.49
"Arsenic trioxide (ATO) has been identified the cytotoxicity in NB cells but the potential mechanism remains unclear."( Arsenic trioxide increases apoptosis of SK-N-BE (2) cells partially by inducing GPX4-mediated ferroptosis.
Chen, Y; Feng, C; Li, C; Li, P; Li, Y; Peng, X; Weng, W; Wu, Y; Xiong, X; Zhou, D; Zhu, Y, 2022
)
2.89
"Arsenic trioxide (ATO) has evolved from an environmental threat to a successful therapy for acute promyelocytic leukemia (APL) and probably for solid tumors in the future. "( Down-regulation of hepatic cytochromes P450 1A1 and 1A2 by arsenic trioxide (ATO) in vivo and in vitro: A role of heme oxygenase 1.
Alqahtani, MA; El-Ghiaty, MA; El-Kadi, AOS, 2022
)
2.41
"Arsenic trioxide (ATO) has been for APL chemotherapy, but recently several ATO-resistant cases have been reported worldwide."( p53 as a unique target of action of cisplatin in acute leukaemia cells.
Kumar, S; Tchounwou, PB, 2022
)
1.44
"Arsenic trioxide (ATO) has shown to be effective in HCC."( Nanocarrier-based delivery of arsenic trioxide for hepatocellular carcinoma therapy.
Cheng, M; Li, B; Li, F; Piao, JG; Sun, J; Wei, Y; Ye, T; Zheng, H; Zhou, M, 2022
)
1.73
"Arsenic trioxide (ATO) has immunological effects and has demonstrated potential in preclinical SSc models."( Arsenic trioxide demonstrates efficacy in a mouse model of preclinical systemic sclerosis.
Allanore, Y; Avouac, J; Cauvet, A; Decellas, A; Guignabert, C; Ottaviani, M; Rieger, F; Rongvaux-Gaïda, D; Thuillet, R; Tu, L, 2023
)
3.07
"Arsenic trioxide (ATO) has remarkably enhanced therapeutic efficacy in treating both newly diagnosed and relapsed patients suffering from Acute Promyelocytic Leukemia (APL). "( Will Arsenic Trioxide Benefit Treatment of Solid Tumor by Nano- Encapsulation?
Fu, X; Li, YS; Liang, QR; Luo, RG; Tang, Q; Yu, LL; Zhao, J, 2020
)
2.51
"Arsenic trioxide (ATO) has been recognized as a drug for the treatment of various diseases in traditional medicine for more than two thousand years. "( Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases.
Jiang, Y; Naranmandura, H; Wang, QQ, 2020
)
2.31
"Arsenic trioxide (ATO) has been shown to induce hepatic injury. "( Protective Effects of Crocetin on Arsenic Trioxide-Induced Hepatic Injury: Involvement of Suppression in Oxidative Stress and Inflammation Through Activation of Nrf2 Signaling Pathway in Rats.
Chu, L; Chu, X; Liang, Y; Liu, Y; Ma, D; Wang, H; Zhang, J; Zheng, B, 2020
)
2.28
"Arsenic trioxide has shown a strong anti-tumor effect with little toxicity when used in the treatment of acute promyelocytic leukemia (APL). "( Arsenic trioxide as a novel anti-glioma drug: a review.
Fang, Y; Zhang, Z, 2020
)
3.44
"Arsenic trioxide (ATO) has a long history and it is recognized as both poison and drug for more than two thousand years. "( Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia.
Hua, HY; Naranmandura, H; Wang, QQ; Zhu, HH, 2020
)
2.25
"Arsenic trioxide (ATO) has been shown to have antitumor effect in different tumors, although the underlying mechanisms are not fully understood. "( Antiangiogenic effect of arsenic trioxide in HUVECs by FoxO3a-regulated autophagy.
Bai, L; Cao, Y; Huang, Q; Shao, X; Sun, Z; Wang, L; Wu, M; Wu, Y; Xing, Y; Zhao, Y, 2021
)
2.37
"Arsenic trioxide (ATO) has become an established component of treatment protocols for acute promyelocytic leukemia (APL) with excellent efficacy and no relevant sustained toxicity. "( Arsenic trioxide in pediatric cancer - a case series and review of literature.
Abele, M; Döring, M; Ebinger, M; Handgretinger, R; Hartmann, U; Lang, P; Müller, SL; Queudeville, M; Schleicher, S, 2021
)
3.51
"Arsenic trioxide (ATO) has been successfully applied in the treatment of acute promyelocytic leukemia (APL). "( Monomethylated arsenic was the Major methylated arsenic in Red blood cells of acute promyelocytic leukemia patients treated with arsenic trioxide.
Chen, H; Gao, C; Gao, Y; Guo, M; Guo, S; Hai, X; Lin, L; Wang, X; Wu, Z, 2021
)
2.27
"Arsenic trioxide (ATO) has been known as common environmental pollution, and is deemed to a threat to global public health. "( Protective effects of curcumin on ATO-induced nephrotoxicity in ducks in relation to suppressed autophagy, apoptosis and dyslipidemia by regulating oxidative stress.
Hu, L; Huang, R; Jiang, X; Lan, J; Tang, Z; Wan, F; Wu, S; Yu, W; Zhang, X; Zhong, G, 2021
)
2.06
"Arsenic trioxide (ATO) has been used for the treatment of acute promyelocytic leukemia (APL). "( Arsenic trioxide reduces the expression of E2F1, cyclin E, and phosphorylation of PI3K signaling molecules in acute leukemia cells.
Kumar, S; Tchounwou, PB, 2021
)
3.51
"Arsenic trioxide (As2O3) has been verified as a breakthrough in the management of acute promyelocytic leukemia in recent decades. "( Mechanism of As2O3-Induced Action Potential Prolongation and Using hiPS-CMs to Evaluate the Rescue Efficacy of Drugs With Different Rescue Mechanism.
Feng, L; Li, B; Li, F; Liu, Y; Shi, Y; Wang, J; Yan, M, 2017
)
1.9
"Arsenic trioxide (As2O3, ATO) has been reported effective in many hematologic malignancies in recent studies, however, the mechanism and effects of ATO in MCL still need further research."( The antitumor effects of arsenic trioxide in mantle cell lymphoma via targeting Wnt/β‑catenin pathway and DNA methyltransferase-1.
Feng, L; Li, XY; Li, Y; Liu, X; Wang, X; Zhang, L, 2017
)
1.48
"Arsenic trioxide (ATO) has been reported to exert its anti-cancer activities in human cancers. "( Arsenic trioxide inhibits cell growth and motility via up-regulation of let-7a in breast cancer cells.
Cao, T; Huang, H; Lian, C; Ma, J; Shi, Y; Wang, Z; Xia, J; Yang, Y, 2017
)
3.34
"Arsenic trioxide (ATO) has been reported to inhibit the activity of Ten-eleven translocation methylcytosine dioxygenase (TET). "( The suppressive effect of arsenic trioxide on TET2-FOXP3-Lyn-Akt axis-modulated MCL1 expression induces apoptosis in human leukemia cells.
Chang, LS; Chen, YJ; Huang, CH; Lee, YC; Shi, YJ; Wang, LJ, 2018
)
2.22
"Arsenic trioxide (ATO) has been verified as a breakthrough with respect to the management of acute promyelocytic leukemia (APL) in recent decades but associated with some serious adverse phenomena, particularly cardiac functional abnormalities. "( The Cardiotoxicity Induced by Arsenic Trioxide is Alleviated by Salvianolic Acid A via Maintaining Calcium Homeostasis and Inhibiting Endoplasmic Reticulum Stress.
Du, Y; Sun, G; Sun, X; Wang, M; Wang, R; Wang, S; Xie, X; Ye, J; Ye, T; Zhang, J, 2019
)
2.25
"Arsenic trioxide (ATO) has been well recognized as an anti-tumor agent for various human cancers. "( Synergistic anti-tumor effects of arsenic trioxide and blue LED irradiation on human osteosarcoma.
Bamba, D; Feng, C; Gao, M; Gong, R; He, M; Idiiatullina, E; Lei, H; Li, X; Liu, S; Ma, T; Pavlov, V; Xu, C; Xu, Z; Yan, G; Yang, L; Yu, M; Yuan, Y; Zagidullin, N; Zhang, L; Zheng, Q, 2019
)
2.24
"Arsenic trioxide (ATO) has been recommended as the first-line agent for the treatment of acute promyelocytic leukaemia (APL), due to its substantial anticancer effect. "( Arsenic trioxide blocked proliferation and cardiomyocyte differentiation of human induced pluripotent stem cells: Implication in cardiac developmental toxicity.
Bao, Z; Cai, B; Carvalho, K; Ding, F; Han, Z; Hua, B; Huang, Q; Jin, M; Li, B; Li, Y; Liu, S; Liu, Y; Ma, W; Wang, N; Wang, X; Xu, Z; Yan, G; Yang, F; Yu, M; Yu, Y; Zagidullin, N; Zhang, B; Zhang, L, 2019
)
3.4
"Arsenic trioxide (ATO), which has been proved to successfully treat acute promyelocytic leukemia (APL), was recently reported to show therapeutic potential in solid tumors including HCC."( Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex.
He, LJ; Jia, YL; Nan, X; Pei, XT; Wang, DX; Wang, HY; Xi, JF; Xu, YC; Yue, W; Zeng, Q; Zhang, B; Zhou, JN, 2019
)
2.68
"Arsenic trioxide (ATO) has demonstrated preclinical evidence of activity in the treatment of infiltrating astrocytomas."( A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood.
Cohen, KJ; Fisher, PG; Gibbs, IC; Gore, L; Hayashi, RJ; Macy, ME, 2013
)
2.16
"Arsenic trioxide has received approval for use in patients with relapsed acute promyelocytic leukemia for remission induction."( The evolving use of arsenic in pharmacotherapy of malignant disease.
Bradley, TP; Budman, DR; Kritharis, A, 2013
)
1.11
"Arsenic trioxide (As2O3) has been recently established as one of the most effective drugs for the treatment of patients with acute promyelocytic leukemia. "( Anticancer activity in human multiple myeloma U266 cells: synergy between cryptotanshinone and arsenic trioxide.
Chen, Z; Liu, P; Naranmandura, H; Rehman, K; Wang, WW; Xu, S; Zhang, M; Zhang, YF, 2013
)
2.05
"Arsenic trioxide (As(2)O(3)) has shown substantial efficacy in the treatment of patients with acute promyelocytic leukemia, a specific subtype of acute myeloid leukemia (AML). "( Low-dose 1,25-dihydroxyvitamin D(3) combined with arsenic trioxide synergistically inhibits proliferation of acute myeloid leukemia cells by promoting apoptosis.
Bae, JY; Kim, I; Kim, JW, 2013
)
2.09
"Arsenic trioxide (As2O3) has been used in the treatment of acute promyelocytic leukemia (APL) and many malignant solid tumors. "( Arsenic trioxide induced endoplasmic reticulum stress in laryngeal squamous cell line Hep-2 cells.
An, L; Li, X; Yang, X, 2014
)
3.29
"Arsenic trioxide (As₂O₃) has recently been identified as an effective drug in different types of cancer therapy. "( [Arsenic trioxide: impact on the growth and differentiation of cancer cells and possible use in cancer therapy].
Hoffman, E; Mielicki, WP, 2013
)
2.74
"Arsenic trioxide (ATO) has demonstrated clinical efficacy in leukemia and in vitro activity in various solid tumors."( Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
Fong, BM; Ho, JC; Lam, SK; Li, YY; Mak, JC; Zheng, CY, 2013
)
1.46
"Arsenic trioxide (ATO) has bcr-abl suppressing activity in vitro, without cross-resistance to imatinib."( VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia.
Fei, J; Feng, M; Li, Y; Luo, X; Zhang, Y; Zhu, X, 2013
)
1.36
"Arsenic trioxide (ATO) has been shown to be the most effective single agent in acute promyelocytic leukaemia (APL) and has been approved for the treatment of relapsed patients both in the US and Europe. "( ATRA + ATO: has a new standard of care been established in low-risk acute promyelocytic leukaemia?
Breccia, M; Cicconi, L; Lo-Coco, F, 2014
)
1.85
"Arsenic trioxide (As2O3) has been demonstrated to suppress tumorigenesis in human glioma. "( Arsenic trioxide targets miR-125b in glioma cells.
Cai, Y; Chen, C; Chen, S; Huang, J; Lu, X; Wang, Z; Wu, Q; Yang, Q; Zhu, L, 2014
)
3.29
"Arsenic trioxide (As2O3) has been recognized as a potential chemotherapeutic agent, yet the details concerning its mechanism of action in solid cancers remain undetermined. "( Inactivation of Akt by arsenic trioxide induces cell death via mitochondrial-mediated apoptotic signaling in SGC-7901 human gastric cancer cells.
Gao, YH; Ma, YY; Yang, SM; Yang, Y; Yang, YM; Zhang, HP; Zhang, XY, 2014
)
2.16
"Arsenic trioxide (ATO) has been successfully used to treat leukemia and some solid malignant tumors. "( Heme oxygenase-1 silencing increases the sensitivity of human osteosarcoma MG63 cells to arsenic trioxide.
Bai, J; Gu, J; Li, R; Li, W; Li, X; Mu, Y; Wang, X; Wang, Y; Yue, Z; Zhang, H; Zhong, L, 2014
)
2.07
"Arsenic trioxide (ATO) has been shown to suppress TYMS in a colonic cancer model."( Downregulation of thymidylate synthase with arsenic trioxide in lung adenocarcinoma.
Ho, JC; Kwong, YL; Lam, SK; Li, YY; Mak, JC; Zheng, CY, 2014
)
1.38
"Arsenic trioxide (ATO) has been found effective in several types of cancer cells, including acute promyelocytic leukemia, and recently in hepatocellular carcinoma (HCC). "( Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro.
Fang, ZT; Li, S; Liu, R; Qian, S; Qu, XD; Wang, GZ; Wang, JH; Wang, LL; Yang, GW; Yang, MJ; Zhang, W; Zhang, WS; Zhu, L, 2014
)
3.29
"Arsenic trioxide (As2O3) has remarkable therapeutic efficacy against leukemia. "( Trivalent methylated arsenic metabolites induce apoptosis in human myeloid leukemic HL-60 cells through generation of reactive oxygen species.
Fu, YJ; Naranmandura, H; Rehman, K; Sun, TF; Sun, WH; Wang, QQ; Wu, B; Wu, Y; Zhang, YF; Zhou, XY, 2014
)
1.85
"Arsenic trioxide has been demonstrated as an effective anti-cancer drug against leukemia and solid tumors both in vitro and in vivo. "( Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma.
Chen, X; Jiang, H; Li, Y; Liang, Y; Liu, J; Liu, L; Lu, Z; Meng, X; Pan, S; Qi, S; Song, X; Sun, B; Wang, J; Xie, C; Yin, D; Zheng, T, 2014
)
2.17
"Arsenic trioxide (ATO) has been used successfully for treatment of APL patients, and both induction and consolidated therapy have resulted in complete remission."( Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells.
Kumar, S; Tchounwou, PB; Yedjou, CG, 2014
)
2.57
"Arsenic trioxide (ATO) has been shown to inhibit cell proliferation, induce apoptosis and genotoxicity in many cells."( Enhancement of arsenic trioxide-mediated changes in human induced pluripotent stem cells (IPS).
Ekunwe, S; Graham, B; Leggett, SS; Ndebele, K; Rogers, C; Sims, J; Stevens, J; Wells, P, 2014
)
1.48
"Arsenic trioxide (As2O3) has been used in the clinic for the treatment of acute promyelocytic 1eukemia and some solid tumors. "( Arsenic trioxide exerts anti-lung cancer activity by inhibiting angiogenesis.
Chen, K; Huang, H; Li, B; Sun, GY; Yang, MH; Zang, YS; Zhao, XW, 2014
)
3.29
"Arsenic trioxide (As2O3) has shown therapeutic effects in some leukemias and solid cancers. "( Arsenic trioxide inhibits cell proliferation and human papillomavirus oncogene expression in cervical cancer cells.
Gao, P; Wang, H; Zheng, J, 2014
)
3.29
"Arsenic trioxide (ATO) has been approved by the US Food and Drug Administration for the treatment of acute promyelocytic leukemia."( E2F1 downregulation by arsenic trioxide in lung adenocarcinoma.
Ho, JC; Lam, SK; Leung, LL; Li, YY; Zheng, CY, 2014
)
1.43
"Arsenic trioxide (ATO) has been shown to suppress thymidylate synthase (TYMS) in lung adenocarcinoma and colorectal cancer, and induce apoptosis in acute promyelocytic leukemia."( Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma.
Ho, JC; Lam, SK; Li, YY; Zheng, CY, 2015
)
1.39
"Arsenic trioxide (ATO) has demonstrated anticancer activity in different malignancies, especially acute promyelocytic leukemia, with a wide array of putative mechanisms. "( Arsenic trioxide-induced cytotoxicity in small cell lung cancer via altered redox homeostasis and mitochondrial integrity.
Ho, JC; Lam, SK; Li, YY; Zheng, CY, 2015
)
3.3
"Arsenic trioxide (ATO) has been demonstrated to suppress human cancer cell growth by targeting Gli1."( Arsenic trioxide inhibits growth of human chondrosarcoma cells through G2/M arrest and apoptosis as well as autophagy.
Guo, W; Jiao, G; Ren, C; Ren, T; Yang, K, 2015
)
2.58
"Arsenic trioxide (ATO) has potent clinical activity in the treatment of patients with acute promyelocytic leukemia (APL), but is much less efficacious in acute myeloid leukemia (AML) lacking t(15;17) translocation. "( The mechanism of synergistic effects of arsenic trioxide and rapamycin in acute myeloid leukemia cell lines lacking typical t(15;17) translocation.
Banfic, H; Dembitz, V; Lalic, H; Ostojic, A; Visnjic, D; Vrhovac, R, 2015
)
2.13
"Arsenic trioxide (As2O3) has been widely used in the treatment of acute promyelocytic leukemia and has been observed to exhibit therapeutic effects in various types of solid tumor. "( Arsenic trioxide inhibits breast cancer cell growth via microRNA-328/hERG pathway in MCF-7 cells.
An, B; Hao, Y; Li, L; Song, G; Wang, L; Wang, Y; Wei, T; Yin, C, 2015
)
3.3
"Arsenic trioxide has been established for use in both relapsed and front-line treatment of acute promyelocytic leukemia. "( Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
Eyler, R; Moeller, J; Patel, K; Perreault, S; Pham, T; Podoltsev, N; Russell, K, 2016
)
2.33
"Arsenic trioxide (ATO) has been found to exert anti-cancer activity in various human malignancies. "( Arsenic Trioxide Inhibits Cell Growth and Invasion via Down- Regulation of Skp2 in Pancreatic Cancer Cells.
Gao, JK; Long, B; Su, JN; Wang, LX; Wang, ZW; Ye, XT; Yin, XY; Zhou, XX, 2015
)
3.3
"Arsenic trioxide (ATO) has been used to treat patients with acute promyelocytic leukemia. "( VEGFA Expression Is Inhibited by Arsenic Trioxide in HUVECs through the Upregulation of Ets-2 and miRNA-126.
Bi, Y; Ge, HY; Han, ZJ; Liu, P; Sun, WJ; Tian, P; Xue, DX; Yang, ZH, 2015
)
2.14
"Arsenic trioxide has been proven to trigger apoptosis in human hepatocellular carcinoma cells. "( Endoplasmic reticulum stress mediates the arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.
Chang, JP; Liu, C; Sun, SB; Tao, XC; Yang, SM; Yang, TY; Yang, Y; Yang, YM; Zhang, HP; Zhang, XY, 2015
)
2.12
"Arsenic trioxide (As2O3) has been found to display anticancer activity against many types of tumors and has been developed into an anticancer drug in clinical treatments. "( Evaluation of the change in sphingolipids in the human multiple myeloma cell line U266 and gastric cancer cell line MGC-803 treated with arsenic trioxide.
Chen, Z; Ma, X; Shen, L; Yu, Y; Zhang, G; Zhou, L; Zhu, F; Zou, J, 2015
)
2.06
"Arsenic trioxide (As2O3) has been reported to reduce MDR in various types of cancer, but the mechanisms involving Ras and p-glycoprotein (P-gp) remain to be fully elucidated."( Downregulation of P-gp, Ras and p-ERK1/2 contributes to the arsenic trioxide-induced reduction in drug resistance towards doxorubicin in gastric cancer cell lines.
He, XJ; Liu, BL; Yu, L; Zhang, BY; Zhao, YY, 2015
)
1.38
"Arsenic trioxide has in vitro and in vivo radiosensitizing properties. "( Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
Carrasquillo, JA; Cheung, NK; Kramer, K; Kushner, BH; Larson, SM; Modak, S; Pandit-Taskar, N; Zanzonico, P, 2016
)
3.32
"Arsenic trioxide (As2O3) has shown effectiveness in treatment of leukemia but is also associated with reproductive toxicity. "( The Coadministration of N-Acetylcysteine Ameliorates the Effects of Arsenic Trioxide on the Male Mouse Genital System.
Anselmo-Franci, JA; Barbosa Junior, F; Borges, Cdos S; da Silva, RF; Kempinas, Wde G; Kiguti, LR; Missassi, G; Pupo, AS; Villela E Silva, P, 2016
)
2.11
"Arsenic trioxide has achieved great clinical success in the treatment of acute promyelocytic leukemia (APL). "( A facile route to core-shell nanoparticulate formation of arsenic trioxide for effective solid tumor treatment.
Chi, X; Gao, J; Liu, H; Shan, H; Zhang, Z; Zhao, Z; Zhou, H; Zhu, X, 2016
)
2.12
"Arsenic trioxide (ATO) has become part of standard reinduction and is often followed by auto-HCT."( Autologous transplant remains the preferred therapy for relapsed APL in CR2.
Alimoghaddam, K; Devlin, S; Douer, D; Esteve, J; Ganzel, C; Ghavamzadeh, A; Kuk, D; Mathews, V; Mohty, M; Nagler, A; Polge, E; Rowe, JM; Tallman, MS; Wang, H; Weisdorf, D; Zhang, MJ, 2016
)
1.16
"Arsenic trioxide (ATO) has been selected as a promising treatment not only in leukemia but also in solid tumors. "( Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma.
Dong, J; Hao, J; Huang, C; Lan, C; Lang, M; Li, X; Ren, H; Wang, H; Wang, X; Yang, S; Yang, Y; Yu, M, 2016
)
3.32
"Arsenic trioxide has shown the excellent therapeutic efficiency for acute promyelocytic leukemia. "( Oxidative stress-mediated intrinsic apoptosis in human promyelocytic leukemia HL-60 cells induced by organic arsenicals.
Chen, XY; Fan, XY; Jiang, FL; Liu, Y; Liu, YJ; Zhong, HM, 2016
)
1.88
"Arsenic trioxide (ATO) has been shown to efficiently and selectively target leukaemic blasts as well as solid tumour cells."( Arsenic trioxide potentiates the effectiveness of etoposide in Ewing sarcomas.
Boehme, KA; Handgretinger, R; Kluba, T; Nitsch, J; Riester, R; Schleicher, SB; Traub, F, 2016
)
2.6
"Arsenic trioxide (ATO) has demonstrated clinical efficacy in acute promyelocytic leukemia (APL) and in vitro activity in various solid tumors. "( SurvivinT34A increases the therapeutic efficacy of arsenic trioxide in mouse hepatocellular carcinoma models.
Cheng, L; Cheng, P; Huang, A; Liao, D; Ma, J; Tong, A; Wei, Y; Yue, D, 2016
)
2.13
"Arsenic trioxide (As2O3) has recently received a great deal of attention because of its capacity to cause complete remission of acute promyelocytic leukemia (APL). "( Arsenic trioxide impairs spermatogenesis via reducing gene expression levels in testosterone synthesis pathway.
Chiou, TJ; Chu, ST; Huang, YC; Liao, CJ; Tzeng, WF, 2008
)
3.23
"Arsenic trioxide (As2O3) has been introduced to the treatment of acute promyelocytic leukemia (APL), and has also been shown to induce apoptosis in a variety of solid tumor cell lines, including non-small cell lung cancer. "( Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases.
Jang, HY; Jeong, ET; Jo, HJ; Kim, EJ; Kim, HJ; Kim, HR; Lee, KK; Park, JH; Shim, H; Yang, SH, 2008
)
2.09
"Arsenic trioxide (As(2)O(3)) has established clinical activity in acute promyelocytic leukaemia and has pre-clinical data suggesting activity in lymphoid malignancies. "( Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study.
Ahuja, HG; Bailey, HH; Chang, JE; Kahl, BS; Kim, K; Kolesar, JM; Rodriguez, GA; Sanchez, FA; Voorhees, PM; Werndli, J, 2009
)
2.13
"Arsenic trioxide has remarkable efficacy in acute promyelocytic leukemia and is approved by the US Food and Drug Administration for this indication."( Arsenic and old lace: novel approaches in elderly patients with acute myeloid leukemia.
Roboz, GJ, 2008
)
1.07
"Arsenic trioxide (As(2)O(3)) has been widely accepted as the second-best choice for the treatment of relapsed and refractory acute promyelocytic leukemia (APL) patients. "( Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia.
Horikoshi, A; Iriyama, N; Kaise, T; Miyashita, SI; Shikino, O; Toyoda, H; Yoshino, Y; Yuan, B, 2009
)
2.16
"Arsenic trioxide has potent antiproliferative and proapoptotic effects in pancreatic cancer cell lines."( Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium.
Aklilu, M; Kindler, HL; Nattam, S; Vokes, EE, 2008
)
2.51
"Arsenic trioxide (ATO) has been successfully used for the treatment of acute promyelocytic leukemia (APL) and has activity in multiple myeloma (MM)."( Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis.
Boise, LH; Cejas, PJ; Gutman, D; Lee, KP; Morales, AA, 2009
)
1.33
"Arsenic trioxide (ATO) has recently emerged as a promising therapeutic agent in leukemia because of its ability to induce apoptosis. "( Heat shock protein inhibitors, 17-DMAG and KNK437, enhance arsenic trioxide-induced mitotic apoptosis.
Lee, TC; Wu, YC; Yen, WY; Yih, LH, 2009
)
2.04
"Arsenic trioxide (As(2)O(3)) has recently been successfully used to treat all trans retinoic acid (ATRA) resistant relapsing acute promyelocytic leukemia. "( Modulation of p53, c-fos, RARE, cyclin A, and cyclin D1 expression in human leukemia (HL-60) cells exposed to arsenic trioxide.
Tchounwou, PB; Yedjou, CG, 2009
)
2.01
"Arsenic trioxide (ATO) has been proposed as an option for the treatment of relapsing or refractory multiple myeloma. "( The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review.
Illmer, T; Röllig, C, 2009
)
2.14
"Arsenic trioxide has been used as a therapeutic agent for acute promyelocytic leukemia and recently for some solid tumors. "( The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells.
Chen, X; Liu, LX; Zhang, M, 2009
)
2.02
"Arsenic trioxide (As(2)O(3)) has been established to be an effective agent for treating acute promyleocytic leukemia. "( Arsenic trioxide inhibits the growth of human lung cancer cell lines via cell cycle arrest and induction of apoptosis at both normoxia and hypoxia.
Li, B; Liu, YA; Qu, GP; Xiu, QY; Zhang, LZ, 2009
)
3.24
"Arsenic trioxide (As(2)O(3)) has potent antileukemic properties in vitro and in vivo, but the mechanisms by which it generates its effects on target leukemic cells are not well understood. "( Arsenic trioxide-dependent activation of thousand-and-one amino acid kinase 2 and transforming growth factor-beta-activated kinase 1.
Altman, JK; Dolniak, B; Glaser, H; Goussetis, DJ; Kroczynska, B; McNeer, JL; Platanias, LC; Sassano, A, 2010
)
3.25
"Arsenic trioxide has been established as a first-line agent for treating acute promyelocytic leukemia. "( The conformation change of Bcl-2 is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in SGC7901 human gastric cancer cells.
Bai, Y; Li, Q; Ye, A; Zhang, Q; Zheng, Y; Zhou, M, 2010
)
2.06
"Arsenic trioxide has been successfully used to treat malignant, hematopoietic diseases and is known to act by induction of apoptosis and inhibition of cellular proliferation."( Arsenic trioxide inhibits DNA methyltransferase and restores expression of methylation-silenced CDKN2B/CDKN2A genes in human hematologic malignant cells.
Fan, LP; Fu, HY; Shen, JZ; Shen, SF; Wu, Y; Zhou, HR, 2010
)
2.52
"Arsenic trioxide (ATO) has shown great promise in the treatment of patients with relapsed or refractory acute promyelocytic leukemia (APL). "( Combination therapy with arsenic trioxide for hematological malignancies.
Takahashi, S, 2010
)
2.11
"Arsenic trioxide has shown remarkable biological activity against bladder cancer in some clinical studies. "( MicroRNA-dependent regulation of PTEN after arsenic trioxide treatment in bladder cancer cell line T24.
An, RH; Cao, Y; Ding, Q; Guo, GY; Wang, Y; Yu, SL, 2011
)
2.07
"Arsenic trioxide has been an effective chemotherapeutic drug in cancer therapy for many years."( microRNA expression alteration after arsenic trioxide treatment in HepG-2 cells.
Chen, X; Jiang, HC; Liu, LX; Meng, XZ; Pan, SH; Wang, JB; Zhang, WH; Zheng, TS, 2011
)
1.36
"Arsenic trioxide (ATO) has been effectively used as a therapeutic agent to treat acute promyelocytic leukemia and solid tumors, via induction of cell cycle arrest or apoptosis. "( Involvement of glycogen synthase kinase-3β in arsenic trioxide-induced p21 expression.
Cheng, YL; Huang, HS; Liu, ZM, 2011
)
2.07
"Arsenic trioxide (ATO) has been proven to be highly effective in adults with newly diagnosed or relapsed acute promyelocytic leukemia (APL). "( Long-term remission after first-line single-agent treatment with arsenic trioxide of relapsed acute promyelocytic leukemia in an 8-year-old boy.
Ebinger, M; Feuchtinger, T; Gessler, P; Handgretinger, R; Hildenbrand, S; Lang, P; Scheel-Walter, HG; Schwarze, CP, 2011
)
2.05
"Arsenic trioxide (As(2)O(3)) has been shown to inhibit invasion/migration in cancer cells. "( Arsenic trioxide inhibits invasion/migration in SGC-7901 cells by activating the reactive oxygen species-dependent cyclooxygenase-2/matrix metalloproteinase-2 pathway.
Huang, D; Liu, Y; Qi, Y; Zhang, W; Zhang, X; Zhang, Y, 2011
)
3.25
"Arsenic trioxide has become the treatment of choice for patients with acute promyelocytic leukaemia. "( Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia.
Ducas, J; Ducas, RA; Seftel, MD; Seifer, C, 2011
)
2.07
"Arsenic trioxide (ATO) has shown anticancer activity against a variety of solid tumor models through induction of apoptosis, promotion of cellular differentiation, and inhibition of cellular invasive ability. "( Arsenic trioxide inhibits HCCLM3 cells invasion through de novo ceramide synthesis and sphingomyelinase-induced ceramide production.
Bian, J; Guo, J; Wang, Y; Wu, H; Wu, X; Zhang, C; Zhang, S; Zhou, J, 2012
)
3.26
"Arsenic trioxide (As2O3) has considerable efficacy in treating solid tumors with induction of apoptosis."( Arsenic oxide targets stem cell marker CD133/prominin-1 in gallbladder carcinoma.
Ai, Z; Liu, H; Lv, C; Pan, H; Suo, T; Tong, S; Wang, Y, 2011
)
1.09
"Arsenic trioxide (As₂O₃) has potential anti-cancer activity against a wide range of carcinomas via apoptosis induction or oncoprotein degradation. "( JWA enhances As₂O₃-induced tubulin polymerization and apoptosis via p38 in HeLa and MCF-7 cells.
Li, A; Shen, L; Xu, W; Ye, J; Zhou, J, 2011
)
1.81
"Arsenic trioxide (As2O3) has shown therapeutic efficacy in the treatment of haematological and solid cancer and has been demonstrated to effectively induce apoptosis of HPV-infected cervical cancer cells in vitro."( Arsenic trioxide induces cervical cancer apoptosis, but specifically targets human papillomavirus-infected cell populations.
Ghali, L; Iles, RK; Li, D; Liu, S; Wen, X; Zhang, Y, 2012
)
2.54
"Arsenic trioxide (As(2)O(3)) has shown remarkable efficacy for the treatment of multiple myeloma (MM). "( Arsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6.
Du, J; Fu, W; Hou, J; Qu, X; Xi, H; Zhang, C; Zou, J, 2012
)
3.26
"Arsenic trioxide (ATO) has been successfully used as a treatment for acute promyelocytic leukemia (APL) for more than a decade. "( Mitochondrial myopathy caused by arsenic trioxide therapy.
Benoilid, A; Broly, F; Echaniz-Laguna, A; Fornecker, LM; Goullé, JP; Lannes, B; Mousson de Camaret, B; Vinzio, S, 2012
)
2.1
"Arsenic trioxide (As(2)O(3)) has been reported to have potent antitumor effects in vitro and in vivo by inducing cell death via cell cycle arrest and apoptosis in leukemia cells, but the mechanisms of As(2)O(3)-mediated cell death are not fully understood. "( Antitumor effect of arsenic trioxide in human K562 and K562/ADM cells by autophagy.
Chen, J; Cheng, J; Wei, HL; Xie, B, 2012
)
2.15
"Arsenic trioxide has been reported to inhibit cell growth and induce apoptotic cell death in many human cancer cells including breast cancer. "( Arsenic trioxide inhibits cell growth and induces apoptosis through inactivation of notch signaling pathway in breast cancer.
Ahmad, A; Bao, B; Chen, Z; Li, Y; Mei, C; Miele, L; Sarkar, FH; Wang, Z; Xia, J; Yang, Q, 2012
)
3.26
"Arsenic trioxide (ATO) has been long used as a chemotherapeutic agent because of its significant anticancer property. "( Arsenic trioxide toxicity in H9c2 myoblasts--damage to cell organelles and possible amelioration with Boerhavia diffusa.
Prathapan, A; Raghu, KG; Soumya, RS; Vineetha, VP, 2013
)
3.28
"Arsenic trioxide (ATO) has been tested in relapsed/refractory multiple myeloma with limited success. "( Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma.
Boise, LH; Cai, Y; Lee, KP; Matulis, SM; Morales, AA; Yehiayan, L, 2012
)
2.04
"Arsenic trioxide has been successfully used as a therapeutic in the treatment of acute promyelocytic leukemia (APL). "( Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Cao, F; Chen, B; Le, XC; Lu, X; Shen, S; Yuan, C; Zhou, J, 2013
)
2.06
"Arsenic trioxide (ATO) has proved to be even more effective than ATRA as a single agent, and is now routinely used for the treatment of the 20%-30% of patients who manifest disease relapse after initial treatment with ATRA and chemotherapy."( Role of arsenic trioxide in acute promyelocytic leukemia.
Iland, HJ; Seymour, JF, 2013
)
1.55
"Arsenic trioxide (ATO) has been demonstrated to induce apoptosis in retinoblastoma cells, however, mechanisms responsible for this phenomenon are not fully understood. "( Arsenic trioxide induced apoptosis in retinoblastoma cells by abnormal expression of microRNA-376a.
Chen, XL; Gu, RD; Han, F; He, B; Huang, JM; Shi, SY; Wu, JH; Zhang, Y, 2013
)
3.28
"Arsenic trioxide has shown substantial efficacy in treating both newly diagnosed and relapsed patients with acute promyelocytic leukemia (APL). "( Mechanisms of action of arsenic trioxide.
Lee, JS; Miller, WH; Schipper, HM; Singer, J; Waxman, S, 2002
)
2.06
"Arsenic trioxide (As2O3) has been reported to induce apoptosis in human T-cell leukemia virus type-I (HTLV-I) infected T-cell lines and fresh adult T-cell leukemia (ATL) cells and to induce G1 phase accumulation in HTLV-I infected T-cell lines. "( Arsenic trioxide induces apoptosis in HTLV-I infected T-cell lines and fresh adult T-cell leukemia cells through CD95 or tumor necrosis factor alpha receptor independent caspase activation.
Arima, T; Hanada, S; Ikeda, R; Ishitsuka, K; Ohno, N; Suzuki, S; Takatsuka, Y; Takeshita, T; Takeuchi, S; Uozumi, K; Utsunomiya, A, 2002
)
3.2
"Arsenic trioxide has recently been shown to inhibit growth and induce apoptosis in acute promyelocytic leukemia (APL), but little is known about the molecular mechanisms mediating these effects. "( Arsenic trioxide-induced apoptosis in U937 cells involve generation of reactive oxygen species and inhibition of Akt.
Bae, JH; Choi, YJ; Kim, SP; Kwon, TK; Mun, KC; Park, JW; Song, DK; Suh, SI, 2002
)
3.2
"Arsenic trioxide (As(2)O(3)) has been found to induce apoptosis in leukemia cell lines and clinical remissions in patients with acute promyelocytic leukemia. "( Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines.
Holland, JF; Jiang, JD; Ling, YH; Perez-Soler, R, 2002
)
3.2
"Arsenic trioxide (As(2)O(3)) has been found effective in the treatment in the treatment of acute promyelocytic leukemia (APML). "( Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience.
Balasubramanian, P; Chandy, M; George, B; Mathews, V; Shaji, RV; Srivastava, A, 2002
)
3.2
"Arsenic trioxide (As(2)O(3)) has recently been shown to be effective to inhibit the growth and to induce apoptosis in acute promyelocytic leukemia (APL) but not in acute myeloid leukemia (AML) cells. "( Involvement of tumor necrosis factor (TNF-alpha) in arsenic trioxide induced apoptotic cell death of murine myeloid leukemia cells.
Fung, M; Leung, KN; Mak, NK; Wong, RN, 2002
)
2.01
"Arsenic trioxide (As2O3) has been implicated as a promising anticancer agent for treatment of many cancers including acute promylocytic leukemia. "( Down-regulation of human papillomavirus E6/E7 oncogene by arsenic trioxide in cervical carcinoma cells.
Kim, EJ; Lee, SY; Myoung, J; Namkoong, SE; Park, JS; Um, SJ, 2002
)
2
"Arsenic trioxide (As2O3) has been successfully used to treat the patients with acute promyelocyutic leukemia in clinic, and for the experimental studies of liver cancer, colorectal cancer, gastric cancer, etc. "( [Primary study of arsenic trioxide inhibits abdomino-metastatic tumor formation of human ovarian carcinoma in nude mice and its mechanisms].
Huang, SG; Jiang, S; Kong, BH; Yang, RF, 2002
)
2.09
"Arsenic trioxide (ATO) has been shown to induce differentiation and apoptosis in acute promyelocytic leukemia (APL) cells concomitant with down-regulation of the PML-RARalpha fusion protein, a product of the t(15:17) translocation characteristic of APL leukemic cells. "( Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.
Gazitt, Y; Hilsenbeck, S; Liu, Q, 2003
)
3.2
"Arsenic trioxide (ATO) has demonstrated efficacy and safety in patients with first and subsequent relapsed or refractory APL, regardless of the disease-free interval."( Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation.
DiPersio, J; Douer, D; Giralt, S; Hu, W; Lill, M, 2003
)
2.48
"Arsenic trioxide has drawn renewed interest in onco-haematological therapy. "( [Arsenic trioxide in the treatment of acute promyelocytic leukaemia].
Andueza Granados, K; Barcia Romero, MJ; Ercilla Liceaga, M; Fernández González, I,
)
2.48
"Arsenic trioxide (As(2)O(3)) has been found to be remarkably effective in the treatment of patients with acute promyelocytic leukemia (APL). "( Arsenic trioxide-induced apoptosis is independent of stress-responsive signaling pathways but sensitive to inhibition of inducible nitric oxide synthase in HepG2 cells.
Kang, HK; Kang, HW; Kang, JH; Kang, SH; Kim, SJ; Lee, YK; Park, DB; Song, JH, 2003
)
3.2
"Arsenic trioxide (As2O3) has been used as an effective chemotherapy agent for some human cancer, such as acute promyelocytic leukemia. "( P53-induced gene 11 (PIG11) involved in arsenic trioxide-induced apoptosis in human gastric cancer MGC-803 cells.
Cao, EH; Liang, XQ; Qin, JF; Zhang, Y,
)
1.84
"Arsenic trioxide (ATO) has a long history of efficacy as an antileukemic agent. "( Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.
Beran, M; DiPersio, J; Greenberg, P; List, A; Rosenfeld, CS; Slack, J; Vey, N, 2003
)
2.06
"Arsenic trioxide (As2O3 [ATO]) has been established as highly effective therapy for patients with APL, even for those with disease refractory to ATRA."( Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.
Han, ZC; Liu, P, 2003
)
1.27
"Arsenic trioxide (As(2)O(3)) has been used successfully in the treatment of acute promyelocytic leukemia. "( Arsenic trioxide induces apoptosis in peripheral blood T lymphocyte subsets by inducing oxidative stress: a role of Bcl-2.
Chiplunkar, S; Gollapudi, S; Gupta, S; Kim, C; Kim, D; Yel, L, 2003
)
3.2
"Arsenic trioxide has recently been shown to be translocated by mouse mAQP7 and rat rAQP9."( Arsenic trioxide uptake by human and rat aquaglyceroporins.
Agre, P; Carbrey, JM; Liu, Z; Rosen, BP, 2004
)
2.49
"Arsenic trioxide has shown substantial efficacy in treating patients with relapsed or refractory acute promyelocytic leukemia (APL) as well as solid tumors. "( Combined effect of arsenic trioxide and sulindac sulfide in A549 human lung cancer cells in vitro.
Brown, SL; Jiang, TT; Kim, JH, 2004
)
2.09
"Arsenic trioxide (ATO) has been reported to be an effective chemotherapeutic agent for acute promyelocytic leukemia (APL), and, recently, anti-tumor effect has been demonstrated in solid tumors. "( Study of arsenic trioxide-induced vascular shutdown and enhancement with radiation in solid tumor.
Amano, M; Ando, S; Griffin, RJ; Hasegawa, T; Monzen, H; Williams, BW,
)
1.99
"Arsenic trioxide (ATO) has been implicated as a promising anticancer agent by inhibiting cell growth and inducing apoptosis in certain types of cancer cells. "( Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor kappaB.
Chen, CA; Cheng, CH; Chou, CH; Hsieh, CY; Huang, YJ; Kuo, ML; Lai, KP; Wei, LH, 2005
)
3.21
"Arsenic trioxide (As(2)O(3)) has shown considerable efficacy in treating hematological malignancies with induction of programmed cell death (PCD) type I, apoptosis. "( Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3.
Germano, IM; Kanzawa, T; Kondo, S; Kondo, Y; Xiao, L; Zhang, L, 2005
)
3.21
"Arsenic trioxide (As2O3) has a long history of use in medicine. "( Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside.
Körper, S; Rojewski, MT; Schrezenmeier, H, 2004
)
3.21
"Arsenic trioxide (As2O3) has been identified as a very potent anti-acute leukemic agent. "( Proteomic analysis of nuclear matrix proteins during arsenic trioxide induced apoptosis in leukemia K562 cells.
Chen, Y; Hao, JZ; Wang, ZH; Yu, D, 2005
)
2.02
"Arsenic trioxide has shown great promise in the treatment of patients with relapsed or refractory acute promyelocytic leukemia (APL). "( Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
Douer, D; Tallman, MS, 2005
)
3.21
"Arsenic trioxide (ATO) has been established to be an effective agent for treating newly diagnosed and relapsed acute promyelocytic leukemia (APL) patients. "( Effect of arsenic trioxide (ATO) on human lung carcinoma PG cell line: ATO induced apoptosis of PG cells and decreased expression of Bcl-2, Pgp.
Han, B; Kakudo, K; Tang, W; Wang, X; Zhang, J; Zhang, Q; Zhou, G, 2004
)
2.17
"Arsenic trioxide has been used successfully for the treatment of refractory acute promyelocytic leukemia and has shown promise in the treatment of myelodysplastic syndrome (MDS), although it is not a labeled indication. "( Acute lung injury induced by arsenic trioxide in a patient with refractory myelodysplastic syndrome.
Balk, RA; Hassaballa, HA; Lateef, OB; Silver, MR, 2005
)
2.06
"Arsenic trioxide has recently been shown to inhibit growth and induce apoptosis in a variety of hematologic malignancies, but very little is known about its effects on solid tumors and especially on neuroblastoma cells that have self-differentiating characteristics. "( Morphological and biochemical changes induced by arsenic trioxide in neuroblastoma cell lines.
Ahn, HS; Jung, YJ; Kie, JH; Lee, MY; Ryu, KH; Seoh, JY; Shin, HY; Woo, SY; Yoo, ES,
)
1.83
"Arsenic trioxide (As(2)O(3)), has been used for centuries in traditional Chinese medicine; it has considerable efficacy in the treatment of relapsed acute promyelocytic leukemia, inducing partial differentiation and promoting apoptosis of malignant promyelocytes. "( Arsenic trioxide induces apoptosis in cisplatin-sensitive and -resistant ovarian cancer cell lines.
Cui, B; Huang, S; Jiang, J; Kong, B; Ma, D; Qu, X; Wang, B; Wang, W; Yang, Q; Yang, X; Zhang, Y,
)
3.02
"Arsenic trioxide (As2O3) has recently been used to treat acute promyelocytic leukaemia and has activity in vitro against several solid tumour cell lines where the induction of differentiation and apoptosis are the prime effects. "( Inhibition of mitogen-activated protein kinase kinase enhances apoptosis induced by arsenic trioxide in human breast cancer MCF-7 cells.
Li, A; Liu, Q; Wang, X; Ye, J; Zhou, J, 2005
)
2
"Arsenic trioxide (As(2)O(3)) has been shown to synergize with IFN-alpha in arresting cell growth and inducing apoptosis of ATLL cells in vitro."( The efficacy of combined therapy of arsenic trioxide and alpha interferon in human T-cell leukemia virus type-1-infected squirrel monkeys (Saimiri sciureus).
Bazarbachi, A; Contamin, H; de Thé, H; Gessain, A; Heraud, JM; Hermine, O; Kazanji, M; Mahieux, R; Merien, F; Mortreux, F; Pouliquen, JF; Wattel, E, 2006
)
1.33
"Arsenic trioxide (As(2)O(3)) has been found to be effective for relapsed or refractory acute promyelocytic leukaemia, but its clinical use is burdened by QT prolongation, Torsade de pointes tachycardias, and sudden cardiac death. "( Choline-modulated arsenic trioxide-induced prolongation of cardiac repolarization in Guinea pig.
Bai, YL; Chu, WF; Dong, DL; Liu, Y; Sun, HL; Wang, XH; Yang, BF; Zhou, J, 2006
)
2.11
"Arsenic trioxide (As2O3) has been shown to induce apoptosis and differentiation in NPC xenografts."( Arsenic trioxide reduces the invasive and metastatic properties of nasopharyngeal carcinoma cells in vitro.
Chen, JY; Du, CW; Hong, CQ; Hong, X; Li, DR; Lin, YC; Lin, ZZ; Peng, X; Wen, BG; Wu, MY; Xie, LX; Zhang, H, 2006
)
2.5
"Arsenic trioxide monotherapy has moderate activity against MDS, with a manageable adverse effect profile. "( Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
Douer, D; Hainsworth, JD; List, AF; Mason, J; Rizzieri, D; Saleh, M; Schiller, GJ; Slack, J, 2006
)
2.07
"Arsenic trioxide (ATO) has been established as a therapeutic agent for relapsed acute promyelocytic leukemia patients, and has been used for MM patients in clinical trials."( Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines.
Emi, N; Iida, S; Kajiguchi, T; Naoe, T; Ueda, R; Yamamoto, K, 2006
)
1.29
"Arsenic trioxide (ATO) has been used to treat acute promyelocytic leukemia (APL), but the oxidative DNA damage occurring in patients has not been fully elucidated. "( Increased oxidative DNA products in patients with acute promyelocytic leukemia during arsenic therapy.
Emi, N; Kajiguchi, T; Kinoshita, T; Naoe, T; Ninomiya, M; Yamamoto, K, 2006
)
1.78
"Arsenic trioxide (ATO) has been found to be an effective treatment for acute promyelocytic leukemia patients and is being tested for treating other hematologic malignancies. "( Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide.
Blusztajn, A; Kenific, C; Ren, R; Shackelford, D; Waxman, S, 2006
)
2.02
"Arsenic trioxide (As2O3) has been approved for the treatment of acute promyelocytic leukemia (APML) and it is a promising candidate for the treatment of patients with lymphoproliferative disorders, such as relapsed or refractory multiple myeloma and myelodysplastic syndromes. "( Arsenic trioxide induces apoptosis via the mitochondrial pathway by upregulating the expression of Bax and Bim in human B cells.
Baysan, A; Gollapudi, S; Gupta, S; Su, H; Yel, L, 2007
)
3.23
"Arsenic trioxide (As(2)O(3)) has anticancer properties; however, its use also leads to neuro-, hepato- or nephro-toxicity, and therefore, it is important to understand the mechanism of As(2)O(3) toxicity. "( Arsenic trioxide (As2O3) induced calcium signals and cytotoxicity in two human cell lines: SY-5Y neuroblastoma and 293 embryonic kidney (HEK).
Büsselberg, D; Florea, AM; Splettstoesser, F, 2007
)
3.23
"Arsenic trioxide (As2O3) has demonstrated effectiveness in treating acute promyelocytic leukemia (APL). "( Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: a clinical experience.
Ardalan, B; Lima, M; Subbarayan, PR, 2007
)
3.23
"Arsenic trioxide has the capacity to kill multidrug-resistant neuro-blastoma cells in vitro and in vivo and the drug is currently being evaluated in clinical trials."( Arsenic trioxide and neuroblastoma cytotoxicity.
Karlsson, J; Påhlman, S; Pettersson, HM; Pietras, A; Øra, I, 2007
)
2.5
"Arsenic trioxide (ATO) has Bcr-Abl suppressing activity in vitro."( Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells.
Härtel, N; Hehlmann, R; Hochhaus, A; Konig, H; La Rosée, P; Lorentz, C; Melo, JV; Schatz, M; Schultheis, B, 2007
)
1.31
"Arsenic trioxide has been used to treat lymphoma experimentally since it was used to treat acute promyelocytic leukemia successfully. "( [Progression of foundational and clinical studies on use of arsenic trioxide in treatment of lymphoma--review].
Li, HM; Li, LH, 2007
)
2.02
"Arsenic trioxide has been known to regulate many biological functions such as cell proliferation, apoptosis, differentiation, and angiogenesis in various cell lines. "( Intracellular GSH level is a factor in As4.1 juxtaglomerular cell death by arsenic trioxide.
Han, YH; Kim, SH; Kim, SZ; Park, WH, 2008
)
2.02
"Arsenic trioxide has demonstrated remarkable activity in the treatment of acute promyelocytic leukemia (APL), for which it can bring about complete remissions (CR) in > 80% of patients with relapsed disease, and molecular remission in 90% of those who enter a CR."( New data with arsenic trioxide in leukemias and myelodysplastic syndromes.
Sekeres, MA, 2007
)
1.42
"Arsenic trioxide (ATO) has been studied in adults with newly diagnosed or relapsed APL with excellent response rates both when used as a single agent or in combination with ATRA or ATRA plus chemotherapy."( All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Estey, E; Kopp, L; Quezada, G; Wells, RJ, 2008
)
1.36
"Arsenic trioxide (As2O3) has been used medicinally for thousands of years. "( Arsenic trioxide: safety issues and their management.
Au, WY; Kwong, YL, 2008
)
3.23
"Arsenic trioxide (As(2)O(3)) has recently been shown to be effective against leukemias, so we studied whether As(2)O(3) induces apoptosis of CTCL cells in vitro."( Arsenic trioxide down-regulates antiapoptotic genes and induces cell death in mycosis fungoides tumors in a mouse model.
Döbbeling, U; Dummer, R; Hassel, JC; Navarini, AA; Oberholzer, PA; Qin, JZ; Tun-Kyi, A, 2008
)
2.51
"Arsenic trioxide (ATO) has been recommended for the treatment of refractory cases of acute promyelocytic leukemia (APL). "( Differential effect of ascorbic acid and n-acetyl-L-cysteine on arsenic trioxide-mediated oxidative stress in human leukemia (HL-60) cells.
Brown, E; Rogers, C; Tchounwou, PB; Yedjou, CG,
)
1.81
"Arsenic trioxide (As2O3) has considerable efficacy in treating solid tumors with induction of apoptosis with largely unknown mechanisms. "( Down-regulation of beta1,4GalT V at protein level contributes to arsenic trioxide-induced glioma cell apoptosis.
Chen, H; Ge, Y; Gu, J; Jiang, J; Liu, D; Wei, Y; Xu, J; Yun, X; Zhou, F, 2008
)
2.03
"Arsenic trioxide (As2O3) has recently been shown to induce complete remission in acute promyelocytic leukemia (APL). "( The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.
Fujisawa, S; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Shigeno, K; Takeshita, A; Takeshita, K; Zhang, W, 1998
)
1.99
"Arsenic trioxide (As2O3) has been demonstrated to be effective for the treatment of acute promyelocytic leukemia (APL) and to inhibit proliferation and produce apoptosis in the APL cell line NB4. "( Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines.
Alemany, M; Caen, JP; Han, ZC; Levin, J; Lu, M; Sequeira-Le Grand, A; Sulpice, E, 1999
)
2.15
"Arsenic trioxide has recently been reported to be successful in the treatment of promyelocytic leukemia. "( Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia.
Carmignani, A; Fazzi, R; Galimberti, S; Papineschi, F; Petrini, M; Testi, R, 1999
)
1.75
"Arsenic trioxide has recently been introduced as a promising new agent to treat refractory acute promyelocytic leukemia (APL). "( Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia.
Agis, H; Edelhäuser, M; Fonatsch, C; Geissler, K; Lechner, K; Mitterbauer, G; Seewann, HL; Thalhammer, R; Valent, P; Weltermann, A, 1999
)
2.05
"Arsenic trioxide has a different mode of action, possibly related to its effects on sulfhydryl-rich proteins, resulting in dysplastic leukaemic promyelocytes, ending up in apoptotic cell death."( [Arsenic trioxide, a new drug for the treatment of acute promyelocytic leukemia resistant to tretinoine].
Haanen, C; Vermes, I, 1999
)
1.93
"Arsenic trioxide (As(2)O(3)) has been shown to inhibit the proliferation of hematologic malignant cells. "( Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1.
Hyun, JM; Jung, CW; Kim, BK; Kim, ES; Lee, YY; Park, WH; Seol, JG, 1999
)
2.15
"Arsenic trioxide (As2O3) has been shown to be even more effective than all-trans retinoid (ATRA) in the treatment of acute promyelocytic leukemia (APL). "( The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
Zhang, P,
)
1.96
"arsenic trioxide has obvious antitumor activity on HepA liver tumor-bearing mice. "( [Antitumor effect of arsenic trioxide on mice experimental liver cancer].
Chen, H; Pan, Q; Qin, S, 2000
)
2.07
"Arsenic trioxide (As2O3) has been demonstrated to be effective for the treatment of acute promyelocytic leukemia (APL) and to inhibit proliferation and produce apoptosis in the APL cell line NB4. "( The effects of arsenic trioxide (As2O3) on human megakaryocytic leukemia cell lines. With a comparison of its effects on other cell lineages.
Alemany, M; Levin, J, 2000
)
2.1
"Arsenic trioxide(As2O3) has proved highly effective in treating both refractory or primary cases of acute promyelocytic leukemia (APL). "( Successful treatment of all-trans retinoic acid resistant and chemotherapy naïve acute promyelocytic patients with arsenic trioxide--two case reports.
Chang, IY; Huang, MJ; Lin, CP; Lin, WY, 2000
)
1.96
"Arsenic trioxide (As(2)O(3)) has recently been used successfully in the treatment of acute promyelocytic leukemia and has been shown to induce partial differentiation and apoptosis of leukemic cells in vitro. "( Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis.
Dias, S; Lam, G; Lane, WJ; Rafii, S; Roboz, GJ; Soignet, SL; Warrell, RP, 2000
)
3.19
"Arsenic trioxide (AT) has been the object of renewed interest as a therapeutic since studies in China in the late 1980s confirmed its efficacy in the treatment of acute promyelocytic leukemia (APL). "( Arsenicals in hematologic cancers.
Novick, SC; Warrell, RP, 2000
)
1.75
"Arsenic trioxide has significant selective apoptosis-inducing effect on the human hepatocarcinoma cells, which is regulated by several genes. "( [An experimental study on arsenic trioxide-selectively induced human hepatocarcinoma cell lines apoptosis and its related genes].
Chen, H; Liu, L; Liu, W; Ma, J; Qin, S; Wang, J, 2000
)
2.05
"Arsenic trioxide has also surfaced as an effective induction therapy for relapsed APL."( Acute progranulocytic leukemia.
Powell, BL, 2001
)
1.03
"Arsenic trioxide has recently been used in the treatment of both relapsed and de novo acute promyelocytic leukaemia (APML). "( Molecular remission without blood product support using all-trans retinoic acid (ATRA) induction and combined arsenic trioxide/ATRA consolidation in a Jehovah's Witness with de novo acute promyelocytic leukaemia.
Cobcroft, R; Gill, D; Kennedy, GA; Marlton, P, 2000
)
1.96
"Arsenic trioxide (As2O3) has been shown to inhibit the proliferation of hematologic malignant cells. "( Potential role of caspase-3 and -9 in arsenic trioxide-mediated apoptosis in PCI-1 head and neck cancer cells.
Hyun, JM; Jung, CW; Kim, BK; Kim, ES; Lee, YY; Park, WH; Seol, JG, 2001
)
2.02
"Arsenic trioxide, As2O3 (ATO), has been found to be an effective chemotherapeutic for acute promyelocytic leukemia but its effect on solid tumors has not been fully explored. "( Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors.
Griffin, RJ; Lee, SH; Lew, YS; Lyons, JC; Park, H; Rood, KL; Song, CW; Stewart, MJ,
)
2.03
"Arsenic trioxide has been shown to be effective in treating acute promyelocytic leukemia (APL), with minimal overall toxicity reported to date. "( Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide.
Adkins, DR; Brown, RA; Curtin, P; DiPersio, JF; Hurd, D; Khoury, H; Ley, TJ; Luger, SM; Ma, MK; Westervelt, P, 2001
)
1.98
"Arsenic trioxide has recently been shown to inhibit growth and induce apoptosis in acute promyelocytic leukemia (APL), but little is known about the molecular mechanisms mediating these effects. "( Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells.
Baek, SH; Choi, YJ; Jang, MA; Kwon, TK; Lim, JH; Park, JW; Passaniti, T, 2001
)
3.2
"Arsenic trioxide (As(2)O(3)) has been confirmed to have remission induction effects on APL."( Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation.
Buyukececi, F; Omay, SB; Sanli, UA; Saydam, G; Terzioglu, E; Uslu, R; Yuksel, S, 2002
)
2.48
"Arsenic trioxide (As2O3) has recently been identified as an effective drug in the treatment of newly diagnosed and relapsed acute promyelocytic leukemia (APL) without cross-resistance to all-trans retinoic acid and achieved complete remission rates of 80-90% according to most reports. "( Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies.
Cai, X; Chen, GQ; Chen, SJ; Chen, Z; Shen, Y; Shen, ZX; Wang, ZY; Xu, L; Zhao, WL,
)
1.83
"Arsenic trioxide (As2O3; ATO) has considerable efficacy in the treatment of relapsed acute promyelocytic leukemia (APL), inducing partial differentiation and promoting apoptosis of malignant promyelocytes. "( Molecular targets of arsenic trioxide in malignant cells.
Miller, WH, 2002
)
2.08
"Arsenic trioxide (ATO), which has significant activity in patients with relapsed and refractory acute promyelocytic leukemia, is a potential addition to the therapeutic arsenal."( Multifaceted approach to the treatment of bcr-abl-positive leukemias.
O'Dwyer, M, 2002
)
1.04
"Arsenic trioxide (As(2)O(3)) has been shown to be an active agent against acute promyelocytic leukemia. "( Arsenic trioxide as a novel anticancer agent against human transitional carcinoma--characterizing its apoptotic pathway.
Chen, J; Guan, JY; Hour, TC; Huang, CY; Lu, SH; Pu, YS, 2002
)
3.2
"Arsenic trioxide (ATO) has been reported to be a safe and effective treatment for relapsed acute promyelocytic leukemia (APL). "( Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.
Annunziata, M; Ciolli, S; Fanci, R; Ferrara, F; Gianfaldoni, G; Leoni, F; Nozzoli, C, 2002
)
3.2
"Arsenic trioxide (ATO) has been shown to cause degradation of PML-RAR alpha, promoting differentiation."( Arsenic trioxide: mechanisms of action.
Davison, K; Mann, KK; Miller, WH, 2002
)
2.48
"Arsenic trioxide (ATO) has recently been licensed for use in patients with relapsed/refractory APL."( Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy.
Dombret, H; Fenaux, P; Soignet, SL; Tallman, MS, 2002
)
1.25
"Arsenic trioxide (As(2)O(3)) has been shown to be effective for treatment of patients with refractory or relapsed acute promyelocytic leukemia and a variety of other malignant hematopoetic disorders. "( Inhibition by arsenic trioxide of human hepatoma cell growth.
Arima, T; Ishibashi, K; Ishitsuka, K; Kohara, K; Komorizono, Y; Oketani, M; Tuvdendorj, D, 2002
)
2.12

Actions

Arsenic trioxide poisoning can cause damage to the nervous system, heart, liver, kidney and other organs, with a lethal dose of 0.8-2.0 mg/kg. Arsenic Trioxide may reactivate the expression of HoxC9 by downregulating EZH2.

ExcerptReferenceRelevance
"Arsenic trioxide may reactivate the expression of HoxC9 by downregulating EZH2, which leads to restoring RA sensitivity and promoting the differentiation and apoptosis of RA-resistant NB cells."( Arsenic trioxide induces the differentiation of retinoic acid-resistant neuroblastoma cells via upregulation of HoxC9.
Chen, Y; Feng, C; Li, C; Li, P; Li, Y; Peng, X; Wang, Z; Wu, P; Xiong, X, 2022
)
3.61
"Arsenic trioxide poisoning can cause damage to the nervous system, heart, liver, kidney and other organs, with a lethal dose of 0.8-2.0 mg/kg. "( [Clinical features analysis of 10 cases of acute arsenic trioxide poisoning].
Dong, ZP; Fan, ZM; Liu, WW; Shao, HY, 2020
)
2.26
"Arsenic trioxide can inhibit the human acute myeloid leukemia HL-60 cell proliferation, and its mechanism may be related with up-regulation of Mad2 expression and down-regulation of Cdc20 expression."( [Effects of Arsenic Trioxide on Cdc20 and Mad2 in Acute Myeloid Leukemia HL-60 Cell Line].
Ding, SM; Kan, JY; Wang, Y; Xu, RR, 2018
)
2.3
"Arsenic trioxide can inhibit the proliferation of retinoblastoma cell HXO-RB(44) in vitro by apoptosis induction. "( [Arsenic trioxide induced apoptosis in retinoblastoma cells in vitro and its possible mechanism].
Li, Y; Shen, HW; Tang, LS, 2008
)
2.7
"Arsenic trioxide (As2O3) displays apoptogenic properties against various types of hematopoietic malignancies. "( Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C).
Bachelez, H; Degos, L; Dombret, H; Dubertret, L; Dupuy, A; Jean-Louis, F; Michel, L; Musette, P; Poupon, J; Sors, A; Viguier, M, 2003
)
3.2
"Arsenic trioxide was shown to suppress the action of estrogen through the regulation of the ERalpha signaling pathway."( Suppression of cell proliferation and regulation of estrogen receptor alpha signaling pathway by arsenic trioxide on human breast cancer MCF-7 cells.
Chan, JY; Chow, SK; Fung, KP, 2004
)
1.26
"Arsenic trioxide can obviously inhibit the growth of hepatoma cell line BEL-7402 through inducing hepatoma cell apoptosis. "( [The effect and mechanism of arsenic trioxide on hepatocellular carcinoma].
Chen, W; Guo, HX; Jiang, HC; Liu, LX; Liu, ZH; Wang, XQ; Wu, M; Zhang, TD; Zhu, AL, 2005
)
2.06
"Arsenic trioxide can inhibit LMP1 expression and dictate apoptosis and alterations of cell cycle distribution as well as growth retardation. "( Downregulation of Epstein-Barr virus-encoded latent membrane protein-1 by arsenic trioxide in nasopharyngeal carcinoma cells.
Chen, J; Du, C; Hong, C; Hong, X; Li, D; Lin, W; Lin, Y; Peng, X; Wen, B; Wu, M; Xie, L; Zheng, Y,
)
1.8
"Arsenic trioxide is known to cause electrocardiographic abnormalities, such as ventricular tachycardia and prolongation of QT interval."( Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy.
Kobayashi, M; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Takeshita, A; Tobita, T, 2006
)
1.28
"Arsenic trioxide can inhibit proliferation and induce apoptosis in multiple myeloma (MM) cells in vitro and in vivo. "( Arsenic trioxide: an emerging therapy for multiple myeloma.
Munshi, NC, 2001
)
3.2
"Arsenic trioxide could activate the expression of p15 gene and reverse cell cycle negative regulation."( [p15 gene expression in acute lymphoblastic leukemia cell line Molt4 induced by arsenic trioxide].
Jin, H; Lou, F; Yu, L, 2001
)
1.98

Treatment

Arsenic trioxide (ATO) treatment effectively prolongs the overall survival of patients with acute promyelocytic leukemia (APL) Treatment is relatively safe with minimal side effects.

ExcerptReferenceRelevance
"Arsenic trioxide (ATO) treats Acute Promyelocytic Leukemia (APL). "( The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients.
Allen, S; Budman, D; Calabro, A; Devoe, C; Dhingra, R; Ghiuzeli, CM; Saunders, J; Stýblo, M, 2022
)
2.44
"Arsenic trioxide (ATO) treatment effectively prolongs the overall survival of patients with acute promyelocytic leukemia (APL). "( miR-603 promotes cell proliferation and differentiation by targeting TrkB in acute promyelocytic leukemia.
Fan, S; Fu, Y; Guo, D; Hou, J; Lei, R; Li, H; Liu, J; Tang, L; Wu, Y; Zhao, Y, 2023
)
2.35
"Arsenic trioxide in the treatment of acute promyelocytic leukaemia is relatively safe with minimal side effects. "( Arsenic trioxide associated toothache.
Duggan, J; Siderov, J, 2010
)
3.25
"Arsenic trioxide (ATO) treatment is a useful therapy against human acute promyelocytic leukemia (APL), however, it concomitantly brings potential adverse consequences including serious side effect, human carcinogenicity and possible development of resistance. "( Cytotoxicity of arsenic trioxide is enhanced by (-)-epigallocatechin-3-gallate via suppression of ferritin in cancer cells.
Cheng, IC; Lee, TC; Shue, JJ; Wang, TC, 2011
)
2.16
"Arsenic trioxide (ATO) treatment induces clinical remission in acute promyelocytic leukemia patients."( Potentiation of arsenic trioxide-induced apoptosis by 8-bromo-7-methoxychrysin in human leukemia cells involves depletion of intracellular reduced glutathione.
Tang, X; Wang, C; Xiao, G; Yao, C, 2011
)
1.44
"Arsenic trioxide (As2O3) treatment results in the total degradation of PML-RARalpha without increasing AcH3 or AcH4 or inducing differentiation in R4 cells."( Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia.
Jing, Y; Waxman, S; Xia, L, 2002
)
1.04
"Arsenic trioxide treatment of U937 cells leads to apoptosis, which is accompanied by activation of caspase 3 (as measured by decreased levels of the 32 kDa inactive form and increased proteolytic cleavage of PLC-gamma1)."( Arsenic trioxide-induced apoptosis in U937 cells involve generation of reactive oxygen species and inhibition of Akt.
Bae, JH; Choi, YJ; Kim, SP; Kwon, TK; Mun, KC; Park, JW; Song, DK; Suh, SI, 2002
)
2.48
"Arsenic trioxide (As(2)O(3)) treatment induces apoptosis in acute promyelocytic leukemia cells through an incompletely understood mechanism."( Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis.
Hayakawa, F; Privalsky, ML, 2004
)
1.27
"Arsenic trioxide treatment consisting of an initial loading dose followed by maintenance therapy has moderate activity in MDS, inducing hematologic responses in both lower- and higher-risk patients. "( Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
Bosly, A; Bowen, D; Burnett, A; Casadevall, N; Dennis, M; Dombret, H; Dreyfus, F; Fenaux, P; Feremans, W; Guerci, A; Legros, L; Ribrag, V; Vey, N, 2006
)
3.22
"Arsenic trioxide treatment, in contrast, significantly increased the percentage of apoptotic T-lymphocytes from asthmatic patients, but slightly affected the cells from the control group."( [Effects of arsenic trioxide on apoptosis of peripheral T-lymphocytes from asthmatic patients and normal subjects in vitro].
Liang, B; Liu, JL; Qin, DY; Wu, T, 2007
)
1.44
"Arsenic trioxide treatment, however, significantly increased the apoptosis of T cells of the asthmatic group and showed a slight effect on the control group."( In vitro arsenic trioxide induces apoptosis in T cells of asthmatic patients by a Bcl-2 related mechanism.
Huang, R; Qin, DY; Wu, T, 2008
)
1.48
"Arsenic trioxide treated cells displayed aggregated mitochondria."( The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells.
Cai, WJ; Hong, C; Shen, J; Shen, ZY; Zheng, MH, 2000
)
1.28
"Arsenic trioxide (As2O3)-treatment is effective in acute promyelocytic leukemia (APL) patients with t(15;17). "( Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis.
Akao, Y; Kitamura, K; Kiyoi, H; Minami, Y; Naoe, T; Saito, H; Yamamoto, K, 2000
)
2
"When treated with arsenic trioxide (1-5μM iAs(III)(As(III) ions)), the levels of Hex2Cer in the human multiple myeloma cell line U266 decreased, and the levels of S1P and dhS1P in the human gastric cancer cell line MGC-803 decreased."( Evaluation of the change in sphingolipids in the human multiple myeloma cell line U266 and gastric cancer cell line MGC-803 treated with arsenic trioxide.
Chen, Z; Ma, X; Shen, L; Yu, Y; Zhang, G; Zhou, L; Zhu, F; Zou, J, 2015
)
0.94
"Treatment with arsenic trioxide (As(2)O(3)) by inducing apoptosis and partial differentiation of acute promyelocytic leukemia (APL) cells results in clinical remission in APL patients resistant to chemotherapy and all-trans-retinoic acid. "( Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells.
Chen, GQ; Chen, Z; Jing, Y; Styblo, M; Walton, F; Waxman, S; Weinberg, R; Zhou, L, 2003
)
0.97
"Treatment with arsenic trioxide may be associated with the APL differentiation syndrome, leukocytosis, and electrocardiographic abnormalities."( Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
Douer, D; Tallman, MS, 2005
)
2.11
"Treatment with arsenic trioxide (ATO; 2-200 microM) inhibited NF-kappaB activity in normal marrow, primary MDS, and ML1 cells, even in the presence of exogenous TNF-alpha (20 ng/mL), and down-regulated NF-kappaB-dependent antiapoptotic proteins, B-cell leukemia XL (Bcl-XL), Bcl-2, X-linked inhibitor of apoptosis (XIAP), and Fas-associated death domain (FADD)-like interleukin-1beta-converting enzyme (FLICE) inhibitory protein (FLIP), leading to apoptosis."( NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs).
Abbasi, N; Deeg, HJ; Kerbauy, DM; Lesnikov, V; Scott, B; Seal, S, 2005
)
0.98
"Treatment with arsenic trioxide led to impressive morphological changes in CNS cellularity consistent with the induction of a differentiation syndrome."( Arsenic-induced APL differentiation in cerebrospinal fluid.
Ehninger, G; Helwig, A; Illmer, T; Klemm, M; Röllig, C; Schüttig, R; Wassilew, N, 2007
)
0.68
"Treatment with arsenic trioxide (As2O3) lowers Bcr-Abl protein levels and induces apoptosis of the Bcr-Abl-positive leukemic blasts (Blood 2000; 95: 1014)."( Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells.
Bhalla, KN; Nguyen, D; Nimmanapalli, R; Perkins, C; Porosnicu, M; Worthington, E, 2001
)
0.65

Toxicity

Arsenic trioxide (ATO) treatment is a useful therapy against human acute promyelocytic leukemia (APL) It concomitantly brings potential adverse consequences including serious side effect, human carcinogenicity and possible development of resistance.

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Instead of using death as the principal criterion of toxicity, it is based on a careful, standardized clinical assessment of toxic signs measured in the nonlethal dose range."( Acute toxicity testing in the nonlethal dose range: a new approach.
Sigg, H; Tamborini, P; Zbinden, G, 1990
)
0.28
" Survival time was prolonged in rats treated with the toxic metals by pretreatment with NKK-105."( Effects of diiospropyl-1,3-dithiol-2-ylidene malonate (NKK-105) on acute toxicity of various drugs and heavy metals.
Hosokawa, T; Kitagawa, H; Saito, H; Sakamoto, K; Sugimoto, T; Yanaura, S, 1982
)
0.26
" From the present study, the toxic potency of these particles was provisionally estimated to be in the following order: InAs > GaAs > As2O3, at the dosage level used in this study."( Comparative study of the toxic effects of gallium arsenide, indium arsenide and arsenic trioxide following intratracheal instillations to the lung of Syrian golden hamsters.
Gotoh, K; Hirata, M; Inoue, N; Makita, Y; Omura, M; Tanaka, A; Yamazaki, K; Zhao, M, 2000
)
0.53
" it is not more toxic to the conceptus than to the maternal organism), nor does it exhibit any propensity to cause neural tube defects, even at maternally toxic dose levels."( Evaluation of the prenatal developmental toxicity of orally administered arsenic trioxide in rats.
Clevidence, KJ; Farr, CH; Holson, JF; Knapp, JF; Stump, DG, 2000
)
0.54
" Conclusion Fluoride-arsenic exposure has adverse effects on the reproductive system and the development of rats' offspring."( [Toxic effect of fluoride-arsenic on the reproduction and development of rats].
Ling, B; Liu, J; Wang, G; Zhang, C, 2000
)
0.31
"4% of the 28 cases of APL showed cardiac toxic reaction in different degree in the first week after As(2)O(3) intravenous infusion in general dose, mainly expressing rapid heart rate or prolonged QT interval."( [Study on cardiac toxicity in acute promyelocyte leukemia treatment of arsenic trioxide intravenous infusion in general dose].
Lü, CF; Meng, R; Wang, W; Yang, BF; Zhou, J, 2003
)
0.55
"Cardiotoxicity is a major side effect of various antineoplastic agents, particularly the anthracyclines."( Prevention and management of cardiotoxicity from antineoplastic therapy.
Chanan-Khan, A; Czuczman, MS; Srinivasan, S,
)
0.13
" Taken together, these results suggest an innovative and safe chemotherapeutic strategy that uses natural anthraquinone derivatives as ROS generators to increase the susceptibility of tumor cells to cytotoxic therapeutic agents."( Anthraquinones sensitize tumor cells to arsenic cytotoxicity in vitro and in vivo via reactive oxygen species-mediated dual regulation of apoptosis.
Chen, YY; Guo, QS; Hu, QS; Kang, XL; Li, H; Lu, Y; Shi, GY; Tang, XM; Wang, XJ; Yang, J; Yi, J, 2004
)
0.32
" Its toxic effects are due to its ability to bind to sulfhydryl groups of proteins and to inhibit energy production."( Cytogenetic evaluation of arsenic trioxide toxicity in Sprague-Dawley rats.
Patlolla, AK; Tchounwou, PB, 2005
)
0.63
"Arsenic is an environmental toxicant, and one of the major mechanisms by which it exerts its toxic effect is through an impairment of cellular respiration by inhibition of various mitochondrial enzymes, and the uncoupling of oxidative phosphorylation."( Serum acetyl cholinesterase as a biomarker of arsenic induced neurotoxicity in sprague-dawley rats.
Patlolla, AK; Tchounwou, PB, 2005
)
0.33
" The regimen was well tolerated, with most adverse events being mild or moderate."( Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial.
Abou-Jawde, RM; Andresen, S; Baz, R; Hussein, M; Karam, MA; Kelly, M; Reed, J; Walker, E, 2006
)
0.58
" Specific grade 3/4 haematological (3%) or cardiac adverse events occurred infrequently."( Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
Berenson, JR; Bessudo, A; Boccia, R; Bozdech, M; Ferretti, D; Flam, M; Jilani, S; Louie, R; Lutzky, J; Moss, R; Patel, R; Russell, K; Siegel, D; Stadtmauer, E; Steis, R; Swift, RA; Talisman Pomeroy, J; Volk, J; Wong, SF; Yeh, HS, 2006
)
0.61
"Anthracyclines are a well-known cause of cardiotoxicity, but a number of other drugs used to treat cancer can also result in cardiac and cardiovascular adverse effects."( Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs.
Ewer, MS; Jones, RL, 2006
)
0.33
" Moreover, we examined a potential renal toxic mechanism(s) of arsenic trioxide by using a toxicity-related gene and investigated potential treatments to reduce the renal toxicity of arsenic trioxide."( An approach to elucidate potential mechanism of renal toxicity of arsenic trioxide.
Fujimura, A; Oshima, Y; Sasaki, A, 2007
)
0.82
" We investigated the toxic mechanisms of As(2)O(3) in H9c2 cardiomyocytes."( Arsenic trioxide-induced apoptosis in H9c2 cardiomyocytes: implications in cardiotoxicity.
Chen, H; Feng, T; Lu, Y; Shan, H; Yang, B; Zhang, Y; Zhao, X, 2008
)
1.79
"The sludge produced in sewage treatment plants can contain toxic substances."( Evaluation of the genotoxicity of treated urban sludge in the Tradescantia micronucleus assay.
Matta, ME; Mielli, AC; Nersesyan, A; Saldiva, PH; Umbuzeiro, GA, 2009
)
0.35
" Arsenic is known to be one of the most toxic metalloids naturally occurring in the environment giving rise to severe toxic manifestations including cancer."( As2O3 toxicity in rat hepatocytes: manifestation of caspase-mediated apoptosis.
Agarwal, S; Bhattacharya, S; Ray, A; Roy, S, 2008
)
0.35
" The exact molecular mechanism of cardiovascular adverse effect due to ATO exposure has not been fully elucidated except for alteration on ion channels."( Characterization of cytotoxicity induced by arsenic trioxide (a potent anti-APL drug) in rat cardiac myocytes.
Cherian, OL; Raghu, KG, 2009
)
0.61
" Accordingly, a direct toxicity assessment (DTA) based on chronoamperometry was proposed to detect the effect of toxic chemicals on microorganisms."( Direct toxicity assessment of toxic chemicals with electrochemical method.
Dong, S; Liu, C; Sun, T; Xu, X, 2009
)
0.35
"To compare the efficacy and adverse effects between arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) in patients with acute promyelocytic leukemia (APL)."( [Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia].
Duan, MH; Han, B; Jiao, L; Shen, T; Wang, SJ; Xu, Y; Zhang, W; Zhao, YQ; Zhou, DB; Zhu, TN; Zhuang, JL; Zou, N, 2009
)
0.85
" Compared with ATRA, ATO induction therapy has shorter time to achieve CR and less adverse effects, and therefore may be the first-line therapy for APL."( [Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia].
Duan, MH; Han, B; Jiao, L; Shen, T; Wang, SJ; Xu, Y; Zhang, W; Zhao, YQ; Zhou, DB; Zhu, TN; Zhuang, JL; Zou, N, 2009
)
0.6
" Results revealed that curcumin efficiently ameliorates the toxic effect of As and F by reducing the frequency of structural aberrations (>60%), hypoploidy (>50%) and primary DNA damage."( Curcumin supplementation protects from genotoxic effects of arsenic and fluoride.
Rao, MV; Tiwari, H, 2010
)
0.36
"Arsenic trioxide (ATO) treatment is a useful therapy against human acute promyelocytic leukemia (APL), however, it concomitantly brings potential adverse consequences including serious side effect, human carcinogenicity and possible development of resistance."( Cytotoxicity of arsenic trioxide is enhanced by (-)-epigallocatechin-3-gallate via suppression of ferritin in cancer cells.
Cheng, IC; Lee, TC; Shue, JJ; Wang, TC, 2011
)
2.16
"The clinical use of arsenic trioxide (ATO) is often limited because of its adverse effects."( Protective effect of α-lipoic acid against arsenic trioxide-induced acute cardiac toxicity in rats.
Ando, H; Fujimura, A; Hosohata, K; Koshimizu, TA; Kumazaki, M; Oshima, Y; Sasaki, A; Ushijima, K, 2011
)
0.96
" There were no statistically significant differences between two treatments in terms of early death and main adverse events."( The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis.
Chen, HZ; Chen, XY; Qi, H; Rong, ZX; Wang, BS; Wang, H, 2011
)
0.67
"9%) achieved a hematologic complete remission, and the most common adverse event during remission induction was leukocytosis (63."( Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia.
Fan, S; Han, L; Han, X; Hu, L; Li, J; Li, L; Li, X; Li, Y; Lv, C; Su, Y; Wang, S; Zhang, X; Zhang, Y; Zhang, Z; Zhao, H; Zhao, Y; Zhou, J, 2013
)
0.67
"The results indicate that the single-agent ATO regimen is safe and effective with long-term durable remission, and could be used as first-line treatment for elderly patients with de novo APL."( Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia.
Fan, S; Han, L; Han, X; Hu, L; Li, J; Li, L; Li, X; Li, Y; Lv, C; Su, Y; Wang, S; Zhang, X; Zhang, Y; Zhang, Z; Zhao, H; Zhao, Y; Zhou, J, 2013
)
0.67
" The authors conclude that As(2) O(3) -induced DNA damage and apoptosis are mediated by oxidative stress and selenium and that, although toxic at higher concentrations, selenium provides significant protection against As(2) O(3) effects in PLHC-1 cells."( Protective and antioxidant role of selenium on arsenic trioxide-induced oxidative stress and genotoxicity in the fish hepatoma cell line PLHC-1.
Murray, E; Selvaraj, V; Yeager-Armstead, M, 2012
)
0.64
"The present study was designed to investigate the toxic mechanism of arsenic in cardiac tissue at its clinically relevant concentrations."( Myocardial toxicity of acute promyelocytic leukaemia drug-arsenic trioxide.
Abhilash, M; Abhilash, S; Manju, A; Mathews, VV; Nair, RH; Paul, MV, 2013
)
0.63
" The least toxic condition was 25 °C-S 17."( Acute toxicity of arsenic under different temperatures and salinity conditions on the white shrimp Litopenaeus vannamei.
Fernández-Bringas, L; Núñez-Nogueira, G; Valentino-Álvarez, JA, 2013
)
0.39
"Cardiotoxicity is an aggravating side effect of many clinical antineoplastic agents such as arsenic trioxide (As2O3), which is the first-line treatment for acute promyelocytic leukemia (APL)."( Arsenic trioxide and resveratrol show synergistic anti-leukemia activity and neutralized cardiotoxicity.
Chen, M; Fan, Y; Fang, K; Meng, J; Tu, Y; Wan, L; Yu, L; Zhu, W, 2014
)
2.07
"Arsenic is a metalloid that is toxic to living organisms."( Evaluation of arsenic trioxide genotoxicity in wheat seedlings using oxidative system and RAPD assays.
Aksakal, O; Esim, N, 2015
)
0.78
"Inhibition of early steps of autophagy by 3-MA or Beclin 1 knockdown decreased the toxic effect of arsenic trioxide (ATO) in GBM cell lines."( Impact of autophagy inhibition at different stages on cytotoxic effect of autophagy inducer in glioblastoma cells.
Bi, Y; Chen, X; Cho, K; Hou, X; Li, C; Liu, H; Liu, Y; Peng, F; Shen, C; Wang, K; Wang, X; Yang, Z; Zhang, J; Zhang, W; Zhang, X; Zhao, S; Zheng, Z; Zhong, C; Zou, H, 2015
)
0.63
"Arsenic (As) is a widely distributed trace element which is known to be associated with numerous adverse effects on human beings and animals."( The Role of Oxidative Stress in Gastrointestinal Tract Tissues Induced by Arsenic Toxicity in Cocks.
Guo, G; Guo, Y; Hu, Z; Tian, L; Xing, M; Zhang, K; Zhang, W; Zhao, P, 2015
)
0.42
" In addressing key issues of reducing toxic side effects and improving pharmacokinetic profiles of the therapeutic agents, we have developed a new formulation by co-packaging DAC and ATO into alendronate-conjugated bone-targeting nanoparticles (BTNPs)."( Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.
Ferrari, M; Hu, Z; Nizzero, S; Ramirez, MR; Shen, H; Shi, C; Wu, X; Zhang, G; Zhou, J, 2017
)
0.7
"Arsenic trioxide (ATO) has been verified as a breakthrough with respect to the management of acute promyelocytic leukemia (APL) in recent decades but associated with some serious adverse phenomena, particularly cardiac functional abnormalities."( The Cardiotoxicity Induced by Arsenic Trioxide is Alleviated by Salvianolic Acid A via Maintaining Calcium Homeostasis and Inhibiting Endoplasmic Reticulum Stress.
Du, Y; Sun, G; Sun, X; Wang, M; Wang, R; Wang, S; Xie, X; Ye, J; Ye, T; Zhang, J, 2019
)
2.25
"The present investigation was done to study the toxic effects of heavy metal arsenic [As(III)] on medaka (Oryzias latipes)."( Cytotoxic and genotoxic effects of arsenic on erythrocytes of Oryzias latipes: Bioremediation using Spirulina platensis.
Kashiwada, S; Kitamura, D; Mitani, H; Oda, S; Sayed, AH, 2019
)
0.51
"Medaka was exposed to As for 15 days at two toxic sublethal concentrations (7 ppm and 10 ppm) in combination with Spirulina platensis (SP) treatment as antioxidant algae at 200 mg/L."( Cytotoxic and genotoxic effects of arsenic on erythrocytes of Oryzias latipes: Bioremediation using Spirulina platensis.
Kashiwada, S; Kitamura, D; Mitani, H; Oda, S; Sayed, AH, 2019
)
0.51
"Arsenic is a toxic metalloid that can cause male reproductive malfunctions and is widely distributed in the environment."( Toxic effects of arsenic trioxide on spermatogonia are associated with oxidative stress, mitochondrial dysfunction, autophagy and metabolomic alterations.
Chen, H; Hu, L; Kang, Z; Li, Y; Liao, J; Liu, B; Liu, G; Pang, C; Qiao, N; Yang, F; Zeng, Q, 2020
)
0.9
" Eligible studies had to be randomized-controlled studies that compared efficacy and/or adverse effects of oral arsenic versus intravenous arsenic for treatment of patients with acute promyelocytic leukemia."( Efficacy and the Adverse Effects of Oral Versus Intravenous Arsenic for Acute Promyelocytic Leukemia: A Meta-Analysis of Randomized-Controlled Studies.
Jahn, N; Owattanapanich, W; Sasijareonrat, N; Ungprasert, P,
)
0.13
" Clinically, the continuously slow intravenous infusion is adopted to maintain effective blood concentration and reduce toxic effects, but it causes poor patient' compliance for a considerable infusion period."( Development of arsenic trioxide sustained-release pellets for reducing toxicity and improving compliance.
Jiang, Y; Liu, J; Liu, X; Widjaya, AS; Yang, Y; Zhou, P, 2020
)
0.91
" It is likely that the therapeutic and adverse effects of ATO is probably associated with its distinct pattern of metabolism and direct or indirect effects on different organs."( Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia.
Hua, HY; Naranmandura, H; Wang, QQ; Zhu, HH, 2020
)
0.8
" The primary endpoint was the occurrence of adverse events (AEs) and secondary endpoints were the number of SLE Responder Index 4 (SRI-4) responders at week 24 and reduction of corticosteroid dosage."( Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic).
Amoura, Z; Ebbo, M; Gaborit, B; Hachulla, E; Hamidou, M; Hardouin, JB; Néel, A; Poupon, J; Rieger, F; Sibilia, J; Viallard, JF; Volteau, C, 2021
)
0.88
" Thus, cardiomyocytes are sensitive to mitochondrial dysfunction and are likely to be targeted by mitochondrial toxic drugs."( Effects of anticancer drugs on the cardiac mitochondrial toxicity and their underlying mechanisms for novel cardiac protective strategies.
Choi, KC; Kim, CW, 2021
)
0.62
" Various adverse effects of ATO or/and Sb on sperm parameters, oxidative stress, autophagy, and apoptosis were determined in testis of mice."( Evaluation of toxic effects induced by arsenic trioxide or/and antimony on autophagy and apoptosis in testis of adult mice.
Hu, L; Hu, T; Huang, R; Hussain, R; Jiang, X; Lan, J; Rao, G; Tang, L; Tang, Z; Wan, F; Wu, S; Zhang, H; Zhong, G, 2021
)
0.89
" Previous studies have demonstrated that HKL exerts cardio-protective effects on ischemia/reperfusion (I/R) or chemical-induced cardiotoxicity by counteracting the toxic effects on mitochondria."( Honokiol attenuate the arsenic trioxide-induced cardiotoxicity by reducing the myocardial apoptosis.
Cheng, P; Cheng, TT; Huang, AL; Ji, XL; Liao, DY; Ma, L; Peng, DD; Xia, XG; Yang, F; Zhang, L; Zhou, L, 2022
)
1.03
" Recently, several studies highlighted that Se treatment can effectively antagonize the toxic effects induced by arsenic."( Selenium Supplementation Protects Against Arsenic-Trioxide-Induced Cardiotoxicity Via Reducing Oxidative Stress and Inflammation Through Increasing NAD
Li, WD; Mao, S; Yang, HB; Yuan, W, 2023
)
0.91
" ATO did not increase the risk of common adverse events compared to supportive therapy [(OR = 0."( The efficacy and adverse events of arsenic trioxide for the patients with myelodysplastic syndrome: a systematic review and component network meta-analysis.
Huang, X; Liu, R; Liu, Y; Yang, H; Zou, X, 2023
)
1.19

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic study was carried out in eight patients."( Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage.
Chen, J; Chen, SJ; Chen, Z; Li, JM; Li, XS; Liu, YF; Niu, C; Shen, Y; Shen, ZX; Tang, W; Wang, ZY; Wu, F; Wu, W; Xiong, SM; Yan, H; Zeng, XY; Zhao, WL, 2001
)
0.55
"The plasma concentrations of AsIII and AsV on day 1 reached the similar Cmax (12."( Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide.
Fujisawa, S; Hashimoto, H; Kaise, T; Kinoshita, K; Kobayashi, M; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shimoya, M; Shinjo, K; Suzuki, Y; Takeshita, A, 2007
)
0.55
"We have used a semimechanistic pharmacodynamic model to characterize concentration-effect relationships of ATO and HSP90 inhibitors on constitutive STAT3 activity, HSP70 expression, and cell death in a cell line model."( Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity--pharmacodynamic drug-drug interaction modeling.
Brady, MT; Earp, JC; Jusko, WJ; Keng, MK; Wetzler, M, 2007
)
0.67
"This study evaluated the pharmacokinetic and safety profiles of arsenic trioxide given twice per week in adult cancer patients with advanced malignancies and varying degrees of renal function."( A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment.
D'Andrea, DM; Darwish, M; Porter, JM; Remick, SC; Sweeney, CJ; Takimoto, C; Tracewell, WG; Wood, L, 2010
)
0.85
" The pharmacokinetic profiles of the pharmacologically active arsenical species, arsenious acid (As(III)), and its metabolites, monomethylarsonic acid (MMA(V)) and dimethylarsinic acid (DMA(V)), were evaluated during the first cycle for 72 h following doses on days 1 and 22."( A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment.
D'Andrea, DM; Darwish, M; Porter, JM; Remick, SC; Sweeney, CJ; Takimoto, C; Tracewell, WG; Wood, L, 2010
)
0.61
" Three mL blood samples were collected before and 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h and 24 h after the drug infusion on days 1 and 14, as well as once every other day from day 2, for measurement of plasma concentrations using an atom fluorescent assay and analysis of pharmacokinetic parameters with the PKBP-N1 program."( Pharmacokinetics of arsenic trioxide (As₂O₃) in Chinese primary hepatocarcinoma patients.
Hua, H; Li, J; Qin, S; Rui, J, 2011
)
0.69
" The mean plasma maximal peak concentration (Cpmax) was 136."( Pharmacokinetics of arsenic trioxide (As₂O₃) in Chinese primary hepatocarcinoma patients.
Hua, H; Li, J; Qin, S; Rui, J, 2011
)
0.69

Compound-Compound Interactions

Arsenic trioxide combined with itraconazole can inhibit the KG1a cell proliferation and induce apoptosis. In vitro data suggest that the use of ZOL at appropriate doses could be explored clinically in bortezomib-resistant MM patients.

ExcerptReferenceRelevance
" As203 alone or in combination with ATRA induced neither differentiation nor apoptosis."( Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid.
Hoshi, S; Kitamura, K; Kiyoi, H; Koike, M; Naoe, T; Saito, H, 2000
)
0.58
"To investigate whether ascorbic acid could enhance the efficacy of arsenic trioxide (As(2)O(3)) combined with 2, 3-dimethoxy-1, 4-naphthoquinone (DMNQ) in inducing the apoptosis of leukemia cell line U937 and its possible mechanism."( [Ascorbic acid enhances the apoptosis of U937 cells induced by arsenic trioxide in combination with DMNQ and its mechanism].
Gao, F; Li, H; Shi, G; Shi, X; Tang, X; Wang, Z; Yi, J, 2002
)
0.79
"To investigate the potential effects of arsenic trioxide (As(2)O(3)) combined with 8-(4-chlorophenylthio) adenosine 3', 5'-cyclic monophosphate (8-CPT-cAMP) on the retinoic acid (RA)-resistant acute promyelocytic leukemia (APL) cells."( [In vitro study of the effects of arsenic trioxide combined with 8-CPT-cAMP on differentiation induction in retinoic acid resistant acute promyelocytic leukemia cells].
Cai, X; Chen, SJ; Chen, Z; Jia, PM; Tong, JH; Wang, ZY; Yu, Y; Zhu, Q, 2003
)
0.87
"As(2)O(3) combined with 8-CPT-cAMP could induce differentiation of RA-resistant APL cells."( [In vitro study of the effects of arsenic trioxide combined with 8-CPT-cAMP on differentiation induction in retinoic acid resistant acute promyelocytic leukemia cells].
Cai, X; Chen, SJ; Chen, Z; Jia, PM; Tong, JH; Wang, ZY; Yu, Y; Zhu, Q, 2003
)
0.6
" It is concluded that after introduction into EJ cell, Ad-p16 shows enhanced therapeutic efficacy for EJ cell when used in combination with CDDP or As2O3."( Effect of Ad-p16 combined with CDDP or As2O3 on human bladder cancer cells.
Lin, C; Xing, S; Zhu, Z, 2003
)
0.32
"MTT assay was used to detect the cytotoxicity of As(2)O(3) in combination with daunorubicin (DNR), cytosine arabinoside (Ara-C), harringtonine (H) and vincristine (VCR) respectively on leukemic cells from 23 newly diagnosed cases with acute non-promyelocytic leukemia (ANPL) and 16 cases of relapsed, refractory ANPL."( [Cytotoxic effects of arsenic trioxide in combination with chemotherapeutic drugs on acute non-promyelocytic leukemia cells].
Lin, MF; Wei, GQ; Zhang, SL; Zou, DB, 2004
)
0.64
"(3) Additivity and synergism of the cytotoxicity was found in most of the ANPL patients when As(2)O(3) was combined with the four chemotherapy drugs and the combination of As(2)O(3) with DNR or VCR enhanced the cytotoxicity significantly (P<0."( [Cytotoxic effects of arsenic trioxide in combination with chemotherapeutic drugs on acute non-promyelocytic leukemia cells].
Lin, MF; Wei, GQ; Zhang, SL; Zou, DB, 2004
)
0.64
"To study the synergistic effect of STI571, an inhibitor of tyrosine kinase in combination with arsenic trioxide (As(2)O(3)) on a multidrug-resistant leukemia cell line expressing bcr-abl."( [Synergistic inhibitory effect of STI571 in combination with arsenic trioxide on a multidrug-resistant leukemia cell line expressing bcr-abl].
Chen, L; Fei, XH; Gao, L; Huang, ZX; Lou, JW; Wang, JM; Xu, XP, 2004
)
0.78
"The cytotoxic effect of STI571 alone or in combination with different concentrations of As(2)O(3) on both bcr-abl and mdr1 positive leukemia cell line K562-n/VCR was detected by MTT method."( [Synergistic inhibitory effect of STI571 in combination with arsenic trioxide on a multidrug-resistant leukemia cell line expressing bcr-abl].
Chen, L; Fei, XH; Gao, L; Huang, ZX; Lou, JW; Wang, JM; Xu, XP, 2004
)
0.56
" Paricalcitol, when combined with As2O3, showed a markedly enhanced antiproliferative effect against acute myeloid leukemia (AML) cells."( 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia.
Desmond, JC; Hewison, M; Hughes, SV; Koeffler, HP; Kumagai, T; O'Kelly, J; Shih, LY, 2005
)
0.56
" The ability of 17-AAG to abrogate the function of heat-shock protein Hsp90 and modulate cellular sensitivity to anticancer agents has prompted recent research to use this compound in drug combination therapy."( Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.
Andreeff, M; Carew, JS; Huang, P; Keating, MJ; McQueen, TJ; Pelicano, H; Plunkett, W, 2006
)
0.54
" To elucidate the basic mechanisms of simultaneous exposure, the interaction of the carcinogens and environmental toxicants cadmium and two arsenic compounds, arsenite and arsenic trioxide, in combination with gamma-radiation in human lymphoblastoid cells (TK6) were investigated."( Comparative investigations of sodium arsenite, arsenic trioxide and cadmium sulphate in combination with gamma-radiation on apoptosis, micronuclei induction and DNA damage in a human lymphoblastoid cell line.
Gomolka, M; Hornhardt, S; Jung, T; Walsh, L, 2006
)
0.78
"This study was aimed to investigate the modulating effects on telomere length and telomerase activity in K562 cells treated by arsenic trioxide, ginseng saponin, beta-elemene alone or in combination with cyclophosphamide (CTX) and to explore the possible mechanism and new therapy for acute leukemia."( Effect of ginseng saponin, arsenic trioxide, beta-elemene combined with CTX on telomere-telomerase system in K562 cell line.
Fang, MY; Wang, Y, 2006
)
0.84
"To investigate the effect of bortezomib alone and in combination with arsenic trioxide on apoptosis of HL-60 cells."( [HL-60 cell apoptosis induced by bortezomib alone or in combination with arsenic trioxide in vitro].
Fu, YB; Li, L; Meng, FY; Sun, QX; Tian, S, 2007
)
0.81
"HL-60 cells were treated with bortezomib alone or in combination with arsenic trioxide for 12 to 48 h and the cell proliferation was analyzed with MTT assay, and cell apoptosis detected by DNA gel electrophoresis, fluorescence microscopy and flow cytometry."( [HL-60 cell apoptosis induced by bortezomib alone or in combination with arsenic trioxide in vitro].
Fu, YB; Li, L; Meng, FY; Sun, QX; Tian, S, 2007
)
0.81
" Electrophoretic mobility shift assay (EMSA) and immunohistochemistry were used to detect the activation of NF-kappaB in the cells after treatment of As(2)O(3) and the combination with Ad-IkappaBalphaM."( [A study on the apoptosis of gastric carcinoma cells induced by arsenic trioxide combined with Ad-IkappaBalphaM].
Guan, JM; Hu, LH; Jiang, HC; Liu, BR; Liu, D, 2007
)
0.58
"To assess the antitumor efficacy and adverse effects of bortezomib either used alone or in combination with arsenic trioxide for transplanted tumor in nude mice."( [Effect of bortezomib used alone or in combination with arsenic trioxide on HL-60 cell xenograft in nude mice].
Cai, YX; Fu, YB; Li, L; Meng, FY; Sun, QX, 2007
)
0.8
"Bortezomib alone and in combination with arsenic trioxide could both inhibit the growth of the transplanted tumors, prolong the survival of the nude mice, and induce cell apoptosis and growth inhibition of the HL-60 cells in vivo, and the combined administration exhibited even better effects."( [Effect of bortezomib used alone or in combination with arsenic trioxide on HL-60 cell xenograft in nude mice].
Cai, YX; Fu, YB; Li, L; Meng, FY; Sun, QX, 2007
)
0.85
"Bortezomib in combination with arsenic trioxide has significant antitumor effect in nude mice bearing HL-60 cell xenografts possibly by inducing HL-60 cell apoptosis and growth inhibition without producing no significant adverse effects."( [Effect of bortezomib used alone or in combination with arsenic trioxide on HL-60 cell xenograft in nude mice].
Cai, YX; Fu, YB; Li, L; Meng, FY; Sun, QX, 2007
)
0.87
"0 micromol/L) alone or combined with BSO (100 micromol/L)."( [The effect of arsenic trioxide (As2O3) combined with BSO on K562/ADM cell and its mechanisms].
Ma, LM; Qiao, ZH; Wang, HW; Wang, T; Yang, LH; Zhang, HP, 2007
)
0.69
"The aim of this study was to investigate the effect of arsenic trioxide (As(2)O(3)) combined with bortezomib on the proliferation, apoptosis and beta-catenin level in myeloma cell lines."( [Effect of arsenic trioxide combined with bortezomib on proliferation, apoptosis and beta-catenin level in myeloma cell lines].
Fu, WJ; Hou, J; Wang, DX; Yuan, ZG; Zhou, LL, 2008
)
0.98
"To study synergistic effect of Vitamin C (VitC) combined with arsenic trioxide (As2 O3)-on human laryngocarcinoma Hep-2 cell line apoptosis."( [Effects of vitamin C combined with arsenic trioxide on the apoptosis of Hep-2 cell].
Hu, J; Shu, C; Xu, W; Ye, Y, 2008
)
0.86
"To investigate the inhibitory effect of sorafenib in combination with arsenic trioxide (As2O3) on hepatocellular carcinoma cells and explore the mechanisms of the synergetic antitumor effects of the two agents."( [Inhibitory effect of sorafenib combined with arsenic trioxide on hepatocellular carcinoma cells].
Cui, YZ; Luo, RC; Wu, J; Zhang, H, 2008
)
0.84
"To investigate the apoptosis-inhancing effect of the combination of arsenic trioxide (As2O3 ) and buthionine sulfoximine (BSO) on multidrug-resistant human leukemic K562/ADM cells, to compare the effect of As2O3 alone and As2O3 combined with BSO and As2O3 alone, and to determine the effect of intracellular GSH content on this treatment."( [Arsenic trioxide combined with buthionine sulfoximine enhances apoptosis in multidrug-resistant human leukemia K562/ADM cells in vitro].
Ma, LM; Qiao, ZH; Wang, HW; Wang, T; Yang, LH; Zhang, HP, 2008
)
1.49
"This study was aimed to investigate the effect of recombinant mutant human TNF-related apoptosis-inducing ligand (rmhTRAIL) combined with As(2)O(3) on inducing apoptosis of adriamycin-resistant leukemia cell line K562/A02 (mdr-1(+))."( [Apoptosis of the adriamycin-resistant leukemia cell line induced by the recombinant mutant human TNF-related apoptosis-inducing ligand combined with arsenic trioxide].
Wang, FX; Wang, YR; Wen, L; Wen, SP; Yang, BY; Yang, JC; Yang, SF; Zhang, XJ, 2008
)
0.55
"To investigate the effect of bortezomib alone or combined with harringtonine (HT) or arsenic trioxide (As2O3) on the proliferation capacity and apoptosis of HL-60/ADM cell line and fresh cells from refractory/relapse acute leukemia patients."( [In vitro effect of bortezomib alone or in combination with harringtonine or arsenic trioxide on proliferation and apoptosis of multidrug resistant leukemia cells].
Cai, YX; Fu, YB; Li, L; Meng, FY; Sun, QX, 2008
)
0.8
"HL-60/ADM cells or refractory/relapse leukemia cells were incubated with bortezomib at different doses alone and in combination with HT or As2O3."( [In vitro effect of bortezomib alone or in combination with harringtonine or arsenic trioxide on proliferation and apoptosis of multidrug resistant leukemia cells].
Cai, YX; Fu, YB; Li, L; Meng, FY; Sun, QX, 2008
)
0.57
" 15 micromol/L As2O3 or 752 nmol/L HT combined with different doses of bortezomib could inhibit proliferation and induce apoptosis of HL-60/ADM cells."( [In vitro effect of bortezomib alone or in combination with harringtonine or arsenic trioxide on proliferation and apoptosis of multidrug resistant leukemia cells].
Cai, YX; Fu, YB; Li, L; Meng, FY; Sun, QX, 2008
)
0.57
"Bortezomib can inhibit proliferation and induce apoptosis of HL-60/ADM cells and fresh refractory/relapse acute leukemia cells, especially combined with HT or As2O3."( [In vitro effect of bortezomib alone or in combination with harringtonine or arsenic trioxide on proliferation and apoptosis of multidrug resistant leukemia cells].
Cai, YX; Fu, YB; Li, L; Meng, FY; Sun, QX, 2008
)
0.57
" The inhibition ratio of tumors after Fe(2)O(3) and As(2)O(3)/Fe(2)O(3) injections combined with induced hyperthermia in xenograft human hepatocarcinoma was calculated."( Nanosized As2O3/Fe2O3 complexes combined with magnetic fluid hyperthermia selectively target liver cancer cells.
Song, J; Wang, ZY; Zhang, DS, 2009
)
0.35
"To determine the effect of arsenic trioxide combined with adriamycin(ADM) on the proliferation and apoptosis of human lymphoma cells."( [Effect of arsenic trioxide combined with adriamycin on the proliferation and apoptosis of human lymphoma cells].
Huang, R; Huang, X; Li, W; Li, X; Yang, X, 2009
)
1.04
" Human lymphoma cells Raji were treated with As(2)O(3) combined with ADM."( [Effect of arsenic trioxide combined with adriamycin on the proliferation and apoptosis of human lymphoma cells].
Huang, R; Huang, X; Li, W; Li, X; Yang, X, 2009
)
0.74
" Compared with As(2)O(3) or ADM alone, As(2)O(3) combined with ADM could increase the inhibition ratio significantly (P<0."( [Effect of arsenic trioxide combined with adriamycin on the proliferation and apoptosis of human lymphoma cells].
Huang, R; Huang, X; Li, W; Li, X; Yang, X, 2009
)
0.74
" As(2)O(3) combined with ADM has synergistic anti-lymphoma cell effect in vitro."( [Effect of arsenic trioxide combined with adriamycin on the proliferation and apoptosis of human lymphoma cells].
Huang, R; Huang, X; Li, W; Li, X; Yang, X, 2009
)
0.74
"The studies have demonstrated that arsenic trioxide (ATO) in combination with all-trans retinoic acid (ATRA) takes effects in treatment of acute promyelocytic leukemia (APL) through different underlying mechanisms."( [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Chen, JP; Liu, JP; Xia, Y; Xu, SN, 2009
)
1.54
"To assess the efficacy and safety of ATO in combination with ATRA for APL."( [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Chen, JP; Liu, JP; Xia, Y; Xu, SN, 2009
)
1.26
"There were apoptosis synergism on MR2 cell induced by Tan II A combined with As2O3, at the same time reduced the expression of Pgp in the cells."( [Apoptosis of MR2 cells induced by Tanshinone II A combined with arsenic trioxide].
Li, L; Zhang, ZH; Zhao, WD, 2009
)
0.59
"To evaluate the synergistic effects of Tanshinone II A (Tan II A) combined with arsenic trioxide (ATO) on apoptosis and differentiation of NB4 cells."( [Apoptosis of NB4 cells induced by Tanshinone II A combined with arsenic trioxide].
Meng, WT; Yang, YM; Zhang, G; Zhou, J, 2010
)
0.83
"The NB4 cells were treated with Tan II A, ATO, and Tan II A combined with ATO, respectively."( [Apoptosis of NB4 cells induced by Tanshinone II A combined with arsenic trioxide].
Meng, WT; Yang, YM; Zhang, G; Zhou, J, 2010
)
0.6
" With the purpose of evaluating whether the combination of ATO and bortezomib would be an option for patients with acute leukemia, we incubated HL60 leukemic cells with ATO alone and in combination with bortezomib."( Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
Canestraro, M; Cine, N; Galimberti, S; Guerrini, F; Metelli, MR; Nagy, B; Palumbo, GA; Petrini, M; Piaggi, S; Savli, H; Tibullo, D, 2010
)
0.63
" Furthermore, we evaluated As(2)O(3) treatment alone or in combination with blocking monoclonal antibodies (mAb) against co-stimulatory molecules (LFA-1 and CD154) in the prevention of heart transplant rejection in alloantigen-primed mice."( Arsenic trioxide combined with co-stimulatory molecule blockade prolongs survival of cardiac allografts in alloantigen-primed mice.
Chen, J; Kang, X; Lan, T; Li, Z; Qi, Z; Wang, F; Xing, J; Xu, S, 2010
)
1.8
" The STI571 combined with As₂O₃ can enhance these two effects, increase the expression of caspase-3 mRNA and decrease the expression of bcl-xL mRNA."( [Effects of STI571 combined with As₂O₃ on proliferation, apoptosis and caspase 3, Bcl-xL expression of K562 cells].
Chen, NY; Wang, J; Wang, XM; Wang, YM; Yan, B; Yan, ZY; Zhang, HX; Zhang, S, 2010
)
0.36
"To clarify the source of deviations of drug combination effects evaluated with different drug interaction mathematical models, the cytotoxicity of SAHA and arsenic trioxide and their combinations were observed in a series of human cancer cell lines and a normal cell line."( [Three different drug interaction mathematical models used to evaluate the cytotoxicity of SAHA and arsenic trioxide in combination].
Liu, ZJ; Lu, N; Wang, N; Yan, Z, 2010
)
0.77
" Finally, we show an additive effect of arsenic trioxide on apoptosis when used in combination with ZOL."( The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.
Abeltino, M; Agnelli, L; Bolzoni, M; Bonomini, S; Colla, S; Giuliani, N; Neri, A; Rizzoli, V; Storti, P; Todoerti, K, 2011
)
0.83
"Our in vitro data suggest that the use of ZOL at appropriate doses could be explored clinically in bortezomib-resistant MM patients and combined with arsenic trioxide to increase its proapoptotic effect."( The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.
Abeltino, M; Agnelli, L; Bolzoni, M; Bonomini, S; Colla, S; Giuliani, N; Neri, A; Rizzoli, V; Storti, P; Todoerti, K, 2011
)
0.76
"This study was aimed to investigate the apoptosis induced by bortezomib combined with As(2)O(3) in APL cell line NB4 and its mechanism."( [NB4 cell apoptosis induced by bortezomib combined with As(2)O(3) and its mechanism].
Chen, XW; Xia, HL; Xia, RX, 2011
)
0.37
"The purpose of the study was to characterize the involvement of reactive oxygen species (ROS) in mediating the cytotoxic effects of arsenic trioxide (ATO) in combination with sulindac or its metabolites: sulfide (SS) and sulfone (SF) on human leukemic cell lines."( Assessment of the involvement of oxidative stress and Mitogen-Activated Protein Kinase signaling pathways in the cytotoxic effects of arsenic trioxide and its combination with sulindac or its metabolites: sulindac sulfide and sulindac sulfone on human leu
Arkusz, J; Ferlińska, M; Gradecka-Meesters, D; Smok-Pieniążek, A; Stańczyk, M; Stępnik, M, 2012
)
0.79
"To investigate the effect of deferoxamine (DFO) and DFO in combination with arsenic trioxide (ATO) on inhibition of HL-60 cells xenograft tumor growth in nude mice and its mechanism."( [The inhibition effect of DFO alone and in combination with ATO on xenograft tumor growth of HL-60 cells in nude mice and its possible mechanism].
Liu, YF; Yu, RH; Zeng, L, 2011
)
0.6
" Both DFO alone and in combination with ATO could inhibit the growth of transplanted tumors, and the combination group exhibited more effects, with no vital organ damages in the tumor-bearing mice."( [The inhibition effect of DFO alone and in combination with ATO on xenograft tumor growth of HL-60 cells in nude mice and its possible mechanism].
Liu, YF; Yu, RH; Zeng, L, 2011
)
0.37
" (2) DFO combined with ATO, is well tolerated with no significant adverse effects in the nude mice."( [The inhibition effect of DFO alone and in combination with ATO on xenograft tumor growth of HL-60 cells in nude mice and its possible mechanism].
Liu, YF; Yu, RH; Zeng, L, 2011
)
0.37
"This study was aimed to investigate the effect of bortezomib alone or combined with arsenic trioxide on the apoptosis of Jurkat cells and expression of livin mRNA."( [Effects of bortezomib alone or combined with arsenic trioxide on the apoptosis of Jurkat cells and expression of livin mRNA].
Sun, ZQ; Tan, DW, 2011
)
0.85
"To evaluate the toxicity and maximum tolerated dose (MTD) of arsenic trioxide (ATO) in combination with temozolomide (TMZ) and radiation therapy (RT) in malignant gliomas."( Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas.
Chandler, JP; Grimm, SA; Jovanovic, B; Levy, RM; Marymont, M; McCarthy, K; Muro, K; Newman, SB; Raizer, JJ, 2012
)
0.96
"To study the demethylation effect of arsenic trioxide (As2O3) on ERα-negative human breast cancer MDA-MB-435s cells and its possible mechanisms, and to observe its treatment efficacy in combination with tamoxifen (TAM) after ERα re-expression."( [Arsenic trioxide restores ERα expression in ERα-negative human breast cancer cells and its treatment efficacy in combination with tamoxifen in xenografts in nude mice].
Fan, QX; Wang, F; Wang, LX; Wang, R; Wu, XA; Xu, DF; Zhang, WJ, 2012
)
1.56
"MTT assay was used to examine the inhibitory effect of As2O3 treatment alone or in combination with TAM on cell proliferation."( [Arsenic trioxide restores ERα expression in ERα-negative human breast cancer cells and its treatment efficacy in combination with tamoxifen in xenografts in nude mice].
Fan, QX; Wang, F; Wang, LX; Wang, R; Wu, XA; Xu, DF; Zhang, WJ, 2012
)
1.29
"The level of proliferation of the MDA-MB-435s cells was significantly suppressed after treatment with different concentration of As2O3 alone or As2O3 combined with TAM, and the 4 µmol/L As2O3 + TAM treatment for 72 h showed the highest inhibition rate (62."( [Arsenic trioxide restores ERα expression in ERα-negative human breast cancer cells and its treatment efficacy in combination with tamoxifen in xenografts in nude mice].
Fan, QX; Wang, F; Wang, LX; Wang, R; Wu, XA; Xu, DF; Zhang, WJ, 2012
)
1.29
" As2O3 combined with TAM may provide a new therapeutic approach for patients with ERα-negative breast cancer in the clinic."( [Arsenic trioxide restores ERα expression in ERα-negative human breast cancer cells and its treatment efficacy in combination with tamoxifen in xenografts in nude mice].
Fan, QX; Wang, F; Wang, LX; Wang, R; Wu, XA; Xu, DF; Zhang, WJ, 2012
)
1.29
"This study was aimed to investigate the proliferation inhibition and apoptosis induction of cucurmosin (CUS) combined with all trans-retinoic acid (ATRA) or arsenic trioxide (ATO) on human acute promyelocytic leukemia cell line NB4."( [Effects of cucurmosin combined with common chemotherapeutics on proliferation and apoptosis of NB4 cells].
Chen, MH; Liu, M; Liu, TB; Xle, JM; Yang, AQ; Yang, P, 2012
)
0.58
"This study was aimed to investigate the effect of arsenic trioxide (As(2)O(3)) alone and in combination with bortezomib (Bor) on proliferation and apoptosis of leukemia cell line K562, and to analyze the potential mechanism."( [Effects of arsenic trioxide combined with bortezomib on proliferation and apoptosis of K562 cells and their mechanism].
Hao, LM; Huang, JQ; Li, XM; Wang, SM; Wei, LY; Wu, HY, 2012
)
1.01
"To observe the therapeutic effects of arsenic trioxide combined with transcatheter arterial chemoembolization on treatment of primary liver cancer with pulmonary metastases."( [The clinical therapeutic effects of arsenic trioxide combined with transcatheter arterial chemoembolization in treating primary liver cancer with pulmonary metastases].
Cheng, HT; Guo, CY; Hu, HT; Li, HL; Luo, JP; Meng, YL; Xiao, JC; Yao, QJ, 2012
)
0.92
"To study the clinical outcome, adverse effect and treatment cost of homoharringtonine (HHT) in combination with all-trans retinoic acid (ATRA) and arsenic trioxide (AS2O3) for newly diagnosed with patients acute promyelocytic leukemia (APL)."( [Clinical investigation of homoharringtonine in combination with all-transretinoic acid and arsenic trioxide for acute promyelocytic leukemia].
Cao, JJ; Chen, D; Chen, LG; Du, XH; Fan, Z; Li, SY; Lin, L; Liu, XH; Ma, JX; Pei, RZ; Sha, KY; Shi, XW; Tang, SH; Wu, JY; Ye, PP; Zhang, BB; Zhang, PS; Zhuang, XX, 2013
)
0.81
"HHT in combination with ATRA and AS2O3 regimen for newly diagnosed APL has a better efficacy, a higher long-term survival rate, and a lower costs, which is one of the reasonable choice."( [Clinical investigation of homoharringtonine in combination with all-transretinoic acid and arsenic trioxide for acute promyelocytic leukemia].
Cao, JJ; Chen, D; Chen, LG; Du, XH; Fan, Z; Li, SY; Lin, L; Liu, XH; Ma, JX; Pei, RZ; Sha, KY; Shi, XW; Tang, SH; Wu, JY; Ye, PP; Zhang, BB; Zhang, PS; Zhuang, XX, 2013
)
0.61
" We investigated the anti-leukemic effect of low-dose 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) in combination with As(2)O(3) on the human AML cell lines HL-60 and K562."( Low-dose 1,25-dihydroxyvitamin D(3) combined with arsenic trioxide synergistically inhibits proliferation of acute myeloid leukemia cells by promoting apoptosis.
Bae, JY; Kim, I; Kim, JW, 2013
)
0.64
"To study the inhibitory effect of Arsenic Trioxide (As2O3) combined with diamminedichloroplatinum (DDP) on the growth of human nasopharyngeal carcinoma cell strain CNE-2Z xenograft in nude mice, and to explore the possible effect mechanisms of the antitumor."( [Inhibitory effect of arsenic trioxide combined with cisplatin on human nasopharyngeal carcinoma xenograft and DAPK in nude mice].
Hu, J; Huang, X; Wang, X; Zhang, Y; Zhou, H; Zhou, K, 2013
)
0.98
" RPMI 8266 cells were treated with ATO alone and in combination with bortezomib for 24 hours, and cell viability was assessed by modified MTT."( Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells.
Cui, JW; Elmahi, AY; Hao, SS; Li, D; Li, W; Niu, C; Wang, GJ, 2013
)
0.78
"The objective of the present study was to investigate the anticancer efficacy of dimercaptosuccinic acid modified iron oxide (DMSA-Fe3O4) magnetic nanoparticles (MNPs) combined with arsenic trioxide (As2O3) and doxorubicin (ADM) in non-Hodgkin's lymphoma (NHL) cell line (Raji cells)."( Antitumor efficacy of DMSA modified Fe3O4 magnetic nanoparticles combined with arsenic trioxide and adriamycin in Raji cells.
Bao, W; Cai, X; Chen, B; Chen, Y; He, Z; Hua, W; Shen, F; Shi, Y; Wang, C; Wang, X; Xia, G; Yu, L; Zhang, Y, 2014
)
0.82
"The aim of this study is to investigate the growth-inhibitory and apoptosis-inducing effect of deferoxamine (DFO) combined with arsenic trioxide (ATO) on the human HL-60 xenografts in nude mice and its mechanism."( The growth-inhibitory and apoptosis-inducing effect of deferoxamine combined with arsenic trioxide on HL-60 xenografts in nude mice.
Liu, Y; Ren, X; Wang, D; Yu, R; Zeng, L, 2014
)
0.83
"To investigate the inhibitory effect of arsenic trioxide (As₂O₃) combined with tetradecanoylphorbol acetate (TPA) on the proliferation of Kasumi-1 cell line and its mechanism."( [The inhibitory effect of As₂O₃ combined with phorbol ester on the proliferation of Kasumi-1 cells and its mechanism].
Fan, R; Mi, R; Wei, X; Xu, J; Yin, Q; Yuan, F, 2014
)
0.67
"Kasumi-1 cells were treated with 200 nmol/L TPA, different concentrations of As₂O₃ alone and combined with 200 nmol/L TPA."( [The inhibitory effect of As₂O₃ combined with phorbol ester on the proliferation of Kasumi-1 cells and its mechanism].
Fan, R; Mi, R; Wei, X; Xu, J; Yin, Q; Yuan, F, 2014
)
0.4
"The proliferation inhibition rates of Kasumi-1 cells by TPA combined with different concentrations of As₂O₃ (0."( [The inhibitory effect of As₂O₃ combined with phorbol ester on the proliferation of Kasumi-1 cells and its mechanism].
Fan, R; Mi, R; Wei, X; Xu, J; Yin, Q; Yuan, F, 2014
)
0.4
"This study was aimed to investigate the effects of arsenic trioxide (As2O3) combined with TPA on cell cycle, cell differentiation and apoptosis of K562 cell line, and their possible mechanisms."( [Effects of As2O3 in combination with TPA on K562 cells].
Fan, RH; Mi, RH; Wei, XD; Yin, QS; Yuan, FF; Zhang, XH, 2014
)
0.65
"This study was aimed to investigate the apoptosis-inducing effect of valproic acid (VPA) combined with arsenic trioxide (ATO) on human multiple myeloma RPMI 8226 cells and its mechanism."( [Apoptosis-inducing effect of valproic acid combined with arsenic trioxide on RPMI 8226 cells and its mechanism].
Wang, XN; Zhang, M, 2014
)
0.86
"To investigate the effect of arsenic trioxide (As2O3) combined with cisplatin on expression of RASSF1A in nude mice with human nasopharyngeal carcinoma xenograft."( [Effects of arsenic trioxide combined with cisplatin on the growth of human nasopharyngeal carcinoma cells and reversion of RASSF1A hympermethylation].
Hu, J; Huang, X; Wang, X; Zhang, Y; Zhou, H, 2014
)
1.07
" Especially As2O3 combined with DDP were superior to the single drug use."( [Effects of arsenic trioxide combined with cisplatin on the growth of human nasopharyngeal carcinoma cells and reversion of RASSF1A hympermethylation].
Hu, J; Huang, X; Wang, X; Zhang, Y; Zhou, H, 2014
)
0.78
"This study was aimed to explore the effect of arsenic trioxide combined with curcumin on proliferation and apoptosis of KG1a cells and its potential mechanism."( [Synergistic killing effect of arsenic trioxide combined with curcumin on KG1a cells].
Fan, JX; Guo, KY; Li, YM; Li, ZQ; Weng, GY; Wu, JW; Zeng, YJ; Zheng, R, 2014
)
0.95
" In this study, we aimed to investigate the synergistic cytotoxic effect of low-dose arsenic trioxide (As2O3) combined with aclacinomycin A (ACM) on the human AML cell lines KG-1a and HL-60, and to clarify the underlying mechanism."( Low-dose arsenic trioxide combined with aclacinomycin A synergistically enhances the cytotoxic effect on human acute myelogenous leukemia cell lines by induction of apoptosis.
Bai, X; Guo, K; Guo, Z; He, H; He, X; Qiu, D; Wang, J; Weng, G; Xu, X; Ye, Y; Yi, W; Zhang, M; Zhou, R, 2015
)
1.06
"The objective of this study was to determine the efficacy and safety of locoregional therapy (LRT) combined with arsenic trioxide (As2 O3 ) treatment in primary hepatocellular carcinoma (HCC) patients."( Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma.
Jin, G; Liu, D; Liu, Y; Sun, Z; Wang, C; Wang, H; Wang, X; Yu, S; Zhang, B, 2015
)
0.86
"LRT combined with As2 O3 treatment prevents extrahepatic metastasis and prolongs the survival time for primary HCC patients."( Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma.
Jin, G; Liu, D; Liu, Y; Sun, Z; Wang, C; Wang, H; Wang, X; Yu, S; Zhang, B, 2015
)
0.65
" However, the effects and mechanism of the two drugs in combination in multiple myeloma (MM) have not been established."( Effects and mechanism of arsenic trioxide in combination with rmhTRAIL in multiple myeloma.
Chen, T; Chen, W; Deng, H; Jian, Y; Li, J; Shan, Z; Zeng, H; Zhang, J; Zhou, H, 2016
)
0.74
"To investigate the efficacy of arsenic trioxide combined with all trans retinoic acid (ATRA) for patients with acute promyelocytic leukemia (APL)."( [Efficacy Analysis of Arsenic Trioxide Combined with All Trans Retinoic Acid for Acute Promyelocytic Leukemia].
Ren, YQ; Wang, LL, 2015
)
1.02
"To explore the effect of magnetic iron nanoparticles ( Fe₃O₄- MNP) in combination with arsenic trioxide and adriamycin on apoptosis and autophagy of Raji cells, a non-Hodgkin's lymphoma (NHL) cell line."( [Influence of Fe₃O₄Magnetic Nanoparticles Combined with As2O3 and Adriamycin on Raji Cell Apoptosis and Autophagy].
Cai, XH; Chen, BA; Cheng, J; He, ZM; Sheng, F; Wang, CL; Zhang, LJ; Zhang, Y, 2015
)
0.64
"The Fe3O4 - MNP combined with ADM and As₂O₃can increase the antitumor efficacy on Raji cells by promoting apoptosis and inducing autophagy."( [Influence of Fe₃O₄Magnetic Nanoparticles Combined with As2O3 and Adriamycin on Raji Cell Apoptosis and Autophagy].
Cai, XH; Chen, BA; Cheng, J; He, ZM; Sheng, F; Wang, CL; Zhang, LJ; Zhang, Y, 2015
)
0.42
" Arsenic trioxide (AsO3) is used for the treatment of acute promyelocytic leukemia in combination with retinoids."( The Effects of Arsenic Trioxide in Combination with Retinoic Acids on Cutaneous T-Cell Lymphoma Cell Lines.
Assaf, C; Beyer, M; Cosagarea, I; Möbs, M; Touba, R; Vandersee, S, 2016
)
1.7
" We found that treatment with As2 O3 combined with leflunomide can significantly prolong the survival of heart xenograft by inhibiting Th1 and Th2 differentiation and reducing the production of IgG and IgM."( As2 O3 combined with leflunomide prolongs heart xenograft survival via suppressing the response of Th1, Th2, and B cells in a rat model.
Cheng, LN; Fu, JZ; Jiao, ZX; Jin, N; Leng, Y; Ni, SB; Qi, ZQ; Wang, JH; Wu, HQ; Xia, JJ, 2016
)
0.43
"To investigate the antitumor effect of arsenic trioxide (ATO) combined with itraconazole (ITRA) on human multiple myeloma NCI-H929 cells by synergistically inhibiting Hedgehog (HH) signaling pathway."( [Synergistic Inhibitory Effect of Arsenic Trioxide Combined with Itraconazole on Hedgehog Pathway of Multiple Myeloma NCI-H929 Cells].
Che, FF; Cheng, J; Huang, XB; Shi, Y; Wang, CS; Wang, XD, 2016
)
0.98
"ATO combined with ITRA significantly inhibited NCI-H929 cell proliferation as compared with a single administration."( [Synergistic Inhibitory Effect of Arsenic Trioxide Combined with Itraconazole on Hedgehog Pathway of Multiple Myeloma NCI-H929 Cells].
Che, FF; Cheng, J; Huang, XB; Shi, Y; Wang, CS; Wang, XD, 2016
)
0.71
"ATO combined with ITRA can more strongly suppress the growth of multiple myeloma NCI-H929 cells, as compared with a single administration."( [Synergistic Inhibitory Effect of Arsenic Trioxide Combined with Itraconazole on Hedgehog Pathway of Multiple Myeloma NCI-H929 Cells].
Che, FF; Cheng, J; Huang, XB; Shi, Y; Wang, CS; Wang, XD, 2016
)
0.71
"To explore the effect of arsenic trioxide combined with itraconazole on proliferation and apoptosis of KG1a cells and its potential mechanism."( [Synergistic Killing Effects of Arsenic Trioxide Combined with Itraconazole on KG1a Cells].
Fan, JX; Guo, KY; Li, YM; Wu, JW; Xiao, WT; Ye, YB; Zeng, YJ; Zhen, R, 2017
)
1.04
"Arsenic trioxide combined with itraconazole can inhibit the KG1a cell proliferation and induce apoptosis, which may be related with the inhibition of Hh signaling pathway and upregulation of both Caspase-3 and BAX protein expression, and provided experimental data of arsenic trioxide combined with itraconazole for the treatment of refractory AML."( [Synergistic Killing Effects of Arsenic Trioxide Combined with Itraconazole on KG1a Cells].
Fan, JX; Guo, KY; Li, YM; Wu, JW; Xiao, WT; Ye, YB; Zeng, YJ; Zhen, R, 2017
)
2.18
"The superiority of adjuvant As2O3 therapy combined with TACE in PHC individuals will outweigh alone TACE therapy, especially in PHC populations with pulmonary metastasis."( Arsenic trioxide combined with transarterial chemoembolization for unresectable primary hepatic carcinoma: A systematic review and meta-analysis.
Hai, Y; Li, H; Li, Y; Ma, W; Song, P; Wang, X; Wu, Z; Xie, Q; Zhao, L, 2018
)
1.92
"To retrospectively analyze the safety and efficacy of low dose subcutaneous decitabine combined with arsenic trioxide in patients with intermediate or high-risk myelodysplastic syndrome (MDS)."( [The safety and efficacy of low dose subcutaneous decitabine combined with arsenic trioxide in patients with inermediate or higer-risk myelodysplastic syndrome].
Ai, H; Chen, L; Mi, RH; Song, YP; Wang, Q; Wei, XD; Yin, QS, 2019
)
0.96
"To investigate the efficacy and safety of arsenic trioxide combined with ATRA and chemo- therapy for treatment of relapsed acute promyelocytic leukemia (APL) patients."( [Efficacy of Arsenic Trioxide Combined with ATRA and Chemotherapy for Relapsed Acute Promyelocytic Leukemia Patients].
Gong, BF; Gong, XY; Li, Y; Lin, D; Liu, BC; Liu, KQ; Liu, YT; Mi, YC; Wang, JX; Wang, Y; Wei, H; Wei, SN; Zhang, GJ; Zhou, CL, 2020
)
1.19
" It can be combined with platinum drugs to treat cervical cancer."( Effects of arsenic trioxide combined with platinum drugs in treatment of cervical cancer: A protocol for systematic review and meta-analysis of randomized controlled trials.
He, Z; Huang, J; Li, D; Li, H; Pan, D; Yang, H; Zhang, Y, 2020
)
0.95
"English and Chinese literature about AS2O3 combined with platinum drugs treatment for cervical cancer published before August 31, 2020 will be systematic searched in PubMed, Embase, Web of Science, Cochrane Library, Open Grey, Clinicaltrials."( Effects of arsenic trioxide combined with platinum drugs in treatment of cervical cancer: A protocol for systematic review and meta-analysis of randomized controlled trials.
He, Z; Huang, J; Li, D; Li, H; Pan, D; Yang, H; Zhang, Y, 2020
)
0.95
"Efficacy and safety of AS2O3 combined with platinum drugs in the treatment of cervical cancer will be assessed."( Effects of arsenic trioxide combined with platinum drugs in treatment of cervical cancer: A protocol for systematic review and meta-analysis of randomized controlled trials.
He, Z; Huang, J; Li, D; Li, H; Pan, D; Yang, H; Zhang, Y, 2020
)
0.95
"The purpose of this study was to evaluate the efficacy and safety of different doses of anthracyclines combined with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) for induction in newly diagnosed acute promyelocytic leukemia (APL)."( Safety and efficacy of different doses of anthracyclines combined with arsenic trioxide and all-trans retinoic acid in the treatment of de novo acute promyelocytic leukemia.
Chen, S; Han, Y; Hu, X; Ke, P; Li, C; Ma, X; Qiu, H; Sun, A; Tang, X; Wu, D; Wu, Y; Zhou, H, 2021
)
1.06
"Arsenic combined with all-trans retinoic acid (ATRA) is the standard of care for adult acute promyelocytic leukemia (APL)."( Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study.
Chen, Y; Dai, Y; Fang, Y; Feng, X; Gao, H; Han, Y; Hao, G; He, Z; Hu, Q; Hu, S; Jiang, H; Jin, R; Ju, X; Li, F; Li, J; Li, L; Liang, H; Liao, N; Lin, L; Ling, Y; Liu, A; Liu, W; Luo, J; Luo, X; Pan, K; Peng, X; Peng, Y; Qu, L; Shen, D; Sun, L; Tao, Y; Tian, X; Wang, L; Wang, N; Wang, T; Xiao, P; Yan, M; Yin, Q; Zhai, X; Zhang, J; Zhang, R; Zhang, Y; Zheng, H; Zhou, M; Zhu, J, 2021
)
0.62
"Arsenic combined with ATRA is effective and safe in pediatric patients with APL, although long-term follow-up is still needed."( Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study.
Chen, Y; Dai, Y; Fang, Y; Feng, X; Gao, H; Han, Y; Hao, G; He, Z; Hu, Q; Hu, S; Jiang, H; Jin, R; Ju, X; Li, F; Li, J; Li, L; Liang, H; Liao, N; Lin, L; Ling, Y; Liu, A; Liu, W; Luo, J; Luo, X; Pan, K; Peng, X; Peng, Y; Qu, L; Shen, D; Sun, L; Tao, Y; Tian, X; Wang, L; Wang, N; Wang, T; Xiao, P; Yan, M; Yin, Q; Zhai, X; Zhang, J; Zhang, R; Zhang, Y; Zheng, H; Zhou, M; Zhu, J, 2021
)
0.62
"The present study aimed to investigate the efficacy and safety for alternate application of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) combined with idarubicin (IDA)/daunorubicin (DNR) in treatment of acute promyelocytic leukemia (APL)."( Alternate application of all-trans-retinoic acid and arsenic trioxide combined with idarubicin/daunorubicin in treatment of acute promyelocytic leukemia.
Mao, Y; Tang, F; Xu, X; Zhu, X, 2022
)
1.18
" It was found that not only could ENZ combination with ATO significantly inhibit cell proliferation and angiogenesis, but also induce cell arrest and apoptosis in C4-2B cells."( Enzalutamide combination with Arsenic trioxide suppresses the progression of castration-resistant prostate cancer.
Feng, T; Guo, P; Han, Y; Jiang, Y; Li, M; Li, Q; Luo, Y; Wang, Y; Wei, D; Yang, X; Zhao, J, 2023
)
1.2

Bioavailability

Orpiment and realgar are less soluble and poorly absorbed from the gastrointestinal tract. The bioavailability of arsenic trioxide is similar to inorganic arsenic salts such as sodium arsenite.

ExcerptReferenceRelevance
" We therefore developed an oral formulation, administered it to patients and set out to assess the resulting systemic bioavailability of arsenic."( Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies.
Au, WY; Kou, M; Kumana, CR; Kwong, YL; Lam, CW; Lee, NS; Mak, RW, 2002
)
0.31
" Systemic bioavailability was inferred from the area under the arsenic level versus time curve (AUC) using the trapezoidal rule."( Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies.
Au, WY; Kou, M; Kumana, CR; Kwong, YL; Lam, CW; Lee, NS; Mak, RW, 2002
)
0.31
" dosing, our oral As2O3 formulation was more convenient and cost effective, and the ensuing systemic bioavailability of arsenic appeared similar."( Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies.
Au, WY; Kou, M; Kumana, CR; Kwong, YL; Lam, CW; Lee, NS; Mak, RW, 2002
)
0.31
" The development of new generations of orally bioavailable inorganic, as well as new organic, arsenic compounds with improved toxicity profiles may bolster the therapeutic application of arsenic derivatives in hematologic malignancies such as leukemia, multiple myeloma and myelodysplastic syndromes."( Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Beran, M; Freireich, E; Giles, F; Kantarjian, H; Perez, N; Quintás-Cardama, A; Ravandi-Kashani, F; Verstovsek, S, 2006
)
0.33
" Orpiment and realgar are less soluble and poorly absorbed from the gastrointestinal tract, whereas the bioavailability of arsenic trioxide is similar to inorganic arsenic salts such as sodium arsenite."( Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite.
Goyer, RA; Liu, J; Lu, Y; Waalkes, MP; Wu, Q, 2008
)
0.55
" Further in vivo experiments on laboratory animals and analysis of absorption rate and side effects are required."( Arsenic trioxide sensitizes cancer stem cells to chemoradiotherapy. A new approach in the treatment of inoperable glioblastoma multiforme.
Cernea, D; Cocis, A; Fischer-Fodor, E; Florian, IS; Ioani, H; Irimie, A; Kacso, G; Petrescu, M; Soritau, O; Timis, T; Tomuleasa, C; Virag, P,
)
1.57
" The activities and bioavailability of realgar NPs are much influenced by their sizes, making realgar an interesting biomedical and pharmaceutical research candidate."( The medicinal use of realgar (As₄S₄) and its recent development as an anticancer agent.
Chen, G; Ho, PC; Liu, J; Shao, Y; Wu, J, 2011
)
0.37
"Experience in the treatment of patients with acute promyelocytic leukaemia (APL) and accelerated phase chronic myeloid leukaemia with orally administered arsenic trioxide (ATO) in our institution since 1999 has demonstrated that bioavailability of oral ATO is comparable with intravenous administration, and similar outcomes are produced in treatment of APL."( Oral administration of arsenic trioxide in the treatment of acute promyelocytic leukaemia and accelerated phase chronic myeloid leukaemia: an Australian single-centre study.
Firkin, F, 2012
)
0.89
" To achieve an equivalent effect, a 10-fold dosage of genistein was required, thus highlighting the dose advantage of resveratrol, as poor bioavailability is a common concern for its clinical application."( Arsenic trioxide and resveratrol show synergistic anti-leukemia activity and neutralized cardiotoxicity.
Chen, M; Fan, Y; Fang, K; Meng, J; Tu, Y; Wan, L; Yu, L; Zhu, W, 2014
)
1.85
" In conclusion, data suggest that arsenic-induced reduction in vasomotion frequency of the isolated aortic rings is associated with a decreased bioavailability of NO, an increase in QTc and a decrease in the frequency of the pulse wave generated by the cardiac cycle in anesthetized rats."( Synchronization in the Heart Rate and the Vasomotion in Rat Aorta: Effect of Arsenic Trioxide.
Cifuentes, F; Nwokocha, CR; Palacios, J, 2016
)
0.66
"Delivery of arsenic trioxide (ATO), a clinical anticancer drug, has drawn much attention to improve its pharmacokinetics and bioavailability for efficient cancer therapy."( Real-time monitoring of arsenic trioxide release and delivery by activatable T(1) imaging.
Chi, X; Gao, J; Li, H; Liu, H; Wang, X; Yin, Z; Zhang, H; Zhang, Z; Zhao, Z; Zhu, X, 2015
)
1.1
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" However, the transition from bench to bedside turned out to be challenging, especially in terms of the drug bioavailability and concentration reaching tumor tissues."( Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors.
Bunzen, H; Kerl, K; Sönksen, M, 2022
)
0.97
" However, time-consuming challenges, especially the optimal concentration in tumor tissue and bioavailability of ATO, remain to be overcome for its transition from the bench to the bedside."( Nanocarrier-based delivery of arsenic trioxide for hepatocellular carcinoma therapy.
Cheng, M; Li, B; Li, F; Piao, JG; Sun, J; Wei, Y; Ye, T; Zheng, H; Zhou, M, 2022
)
1.01

Dosage Studied

Arsenic trioxide (ATO) can be safely and effectively incorporated into induction therapy of newly diagnosed acute promyelocytic leukaemia (APL) in patients with severe chronic renal failure. Continual exposure of arsenic trioxide suppressed 3T3-L1 cell differentiation into fat cells by inhibiting the expression of PPARgamma and C/EBPalpha.

ExcerptRelevanceReference
" injection of arsenic trioxide, at the dosage range of 1/4 to 1/40 LD50 into hybrid mice (CBA X C57B1/6J)F1, no induction of dominant lethals in male germ cells was observed."( [Arsenic trioxide inhibition of the thiophosphamide induction of mutations in mouse germ and somatic cells].
Kozachenko, VI; Pashin, IuV; Toroptsev, SN, 1984
)
1.54
" Dose-response experiments with melarsoprol (10(-7) to 10(-9) mol/L) were performed over 96 hours."( Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines.
Gabrilove, JL; Jakubowski, A; König, A; Pandolfi, PP; Rivi, R; Warrell, RP; Wrazel, L, 1997
)
0.56
" When females were dosed chronically for periods that included pregnancy, the primary effect of arsenic on reproduction was a dose-dependent increase in conceptus mortality and in postnatal growth retardation."( Developmental and reproductive toxicity of inorganic arsenic: animal studies and human concerns.
Baumrind, N; Golub, MS; Macintosh, MS,
)
0.13
" There was a close relationship between nitric oxide and anomalies in fetal development, with a dose-response pattern, showed by inducible nitric oxide synthetase (iNOS) histochemical examinations."( [Teratogenic effects of arsenic on rats].
Li, Y; Pan, Y; Zhu, H, 1998
)
0.3
" Induction of apoptosis in arsenic-treated Meg-01 and UT7 cells was accompanied by a dose-response decrease of Bcl-2 protein, whereas As2O3 had no effect on this measurement in HL60, ZR75, and MCF7 cell lines."( Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines.
Alemany, M; Caen, JP; Han, ZC; Levin, J; Lu, M; Sequeira-Le Grand, A; Sulpice, E, 1999
)
0.71
" Most of these studies involved treatment of limited numbers of animals with maternally toxic doses of arsenic (generally As(V)), without defining a dose-response relationship."( Comparative effects of single intraperitoneal or oral doses of sodium arsenate or arsenic trioxide during in utero development.
Farr, CH; Fleeman, TL; Holson, JF; Nemec, MD; Stump, DG, 1999
)
0.53
" From the present study, the toxic potency of these particles was provisionally estimated to be in the following order: InAs > GaAs > As2O3, at the dosage level used in this study."( Comparative study of the toxic effects of gallium arsenide, indium arsenide and arsenic trioxide following intratracheal instillations to the lung of Syrian golden hamsters.
Gotoh, K; Hirata, M; Inoue, N; Makita, Y; Omura, M; Tanaka, A; Yamazaki, K; Zhao, M, 2000
)
0.53
" The median duration to CR ranged from 38 to 51 days, with accumulative As2O3 dosage of 340-430 mg."( Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
Chen, YC; Huan, SY; Yang, CH, 2000
)
1.75
" In conclusion, we demonstrated that low-dose As2O3 had the same effect as the conventional dosage and the mechanism of low-dose arsenic seemed to primarily induce differentiation of APL cells."( Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage.
Chen, J; Chen, SJ; Chen, Z; Li, JM; Li, XS; Liu, YF; Niu, C; Shen, Y; Shen, ZX; Tang, W; Wang, ZY; Wu, F; Wu, W; Xiong, SM; Yan, H; Zeng, XY; Zhao, WL, 2001
)
0.55
" dosing was taken to be 100% and that attributed to oral dosing (day 2) was then calculated."( Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies.
Au, WY; Kou, M; Kumana, CR; Kwong, YL; Lam, CW; Lee, NS; Mak, RW, 2002
)
0.31
"Respective day-2 mean plasma and blood AUCs attributed to oral dosing were 99% and 87% of corresponding day-1 values."( Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies.
Au, WY; Kou, M; Kumana, CR; Kwong, YL; Lam, CW; Lee, NS; Mak, RW, 2002
)
0.31
" The potentiation of apoptosis was dependent on the dosage of CDA-II."( Synergistic effect of cell differential agent-II and arsenic trioxide on induction of cell cycle arrest and apoptosis in hepatoma cells.
Liu, JW; Shen, Y; Tang, Y; Zhong, XY, 2003
)
0.57
" The dosage of As2O3 used was 2 mg/kg."( [Effect of arsenic trioxide on apoptosis of pulmonary eosinophile in asthmatic guinea-pigs].
Yin, KS; Zhou, LF, 2002
)
0.7
" As mechanisms for the reduced methylation efficiency, the saturation of the enzymatic process of arsenic methylation, the high dosage of antidote DMPS, which might inhibit the activity of the methyl transferases, and analytical reasons are discussed."( Arsenic species excretion after dimercaptopropanesulfonic acid (DMPS) treatment of an acute arsenic trioxide poisoning.
Angerer, J; Heinrich-Ramm, R; Horn, J; Schaller, H, 2003
)
0.54
" These results suggest that As2O3 at a high dosage (5 micromol/l) causes cell apoptosis and at a low dosage (0."( Reactive oxygen species and antioxidants in apoptosis of esophageal cancer cells induced by As2O3.
Chen, MH; Shen, J; Shen, WY; Shen, ZY; Zeng, Y, 2003
)
0.32
" When both lateral tumors had grown to about 10x8x5 mm(3), the right tumors were treated with an intratumoral injection of As2O3 in dosage of 1, 5 and 10 microg per day, respectively, for 10 days sequentially."( The inhibition of growth and angiogenesis in heterotransplanted esophageal carcinoma via intratumoral injection of arsenic trioxide.
Chen, MH; Shen, J; Shen, ZY; Wu, MH; Wu, XY; Zeng, Y,
)
0.34
" Data obtained from the MTT assay indicated a strong dose-response relationship with respect to arsenic trioxide toxicity."( Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2).
Dorsey, WC; Tchounwou, PB; Yedjou, CG, 2003
)
1.98
"To investigate cardiac effects of arsenic trioxide (As(2)O(3)) at conventional dosage in acute promyelocytic leukemia (APL) patients."( [Clinical and experimental study of cardiac effects of conventional dosage arsenic trioxide in APL patients].
Li, BX; Liu, Y; Meng, R; Wang, W; Yang, BF; Zhou, J, 2004
)
0.83
" The blood and organ concentrations of the arsenic species, including As(III), dimethylarsinic acid (DMA), and monomethylarsonic acid (MMA), were studied on day 1 (single-dose study), day 30 (multiple dosing study), and day 60 (reversibility study)."( Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective.
Cheng, AL; Hsueh, YM; Lin, CJ; Sun, SS; Wu, MH, 2005
)
0.54
" Continual exposure of arsenic trioxide, at the clinic achievable dosage that does not induce apoptosis, suppressed 3T3-L1 cell differentiation into fat cells by inhibiting the expression of PPARgamma and C/EBPalpha and disrupting the interaction between PPARgamma and RXRalpha, which determines the programming of the adipogenic genes."( The role of Akt on arsenic trioxide suppression of 3T3-L1 preadipocyte differentiation.
Chen, Q; Jiang, CS; Jin, HJ; Liu, L; Wang, XH; Wang, ZX; Wu, Q, 2005
)
0.97
" After the patient achieved CR, 1 additional ATO course at the same dosage was administered for 25 days."( Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies.
Fujisawa, S; Kobayashi, M; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Takeshita, A, 2005
)
1.77
" The requirement for slow dosage increases of arsenic and the time required to achieve a pharmacologic active dose in patients is a major obstacle because median survival of patients with ATL is about 6 months."( Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1.
Bellon, M; Brown, M; Nicot, C, 2007
)
0.62
" Less dosage and shorter course can be expected when arsenic trioxide, ginseng saponin, and beta-elemene are used in combination with CTX."( Effect of ginseng saponin, arsenic trioxide, beta-elemene combined with CTX on telomere-telomerase system in K562 cell line.
Fang, MY; Wang, Y, 2006
)
0.88
"The mice bearing NPCX were treated with radiation alone (2, 4, and 6 Gy), ATO alone (4 mg/kg/day x 6 days), and ATO plus radiation at the same dosage levels."( Synergistic therapeutic effect of arsenic trioxide and radiotherapy in BALB/C nude mice bearing nasopharyngeal carcinoma xenografts.
Chen, JY; Du, CW; Hong, CQ; Li, DR; Lin, XH; Xie, LX, 2007
)
0.62
" Further studies using ATO and AA with TMZ with this dosing schedule in advanced melanoma are not warranted."( Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
Bael, TE; Gollob, JA; Peterson, BL, 2008
)
0.68
" No mice died in any dosage group."( Arsenic trioxide impairs spermatogenesis via reducing gene expression levels in testosterone synthesis pathway.
Chiou, TJ; Chu, ST; Huang, YC; Liao, CJ; Tzeng, WF, 2008
)
1.79
" This multi-institution phase II study investigated a novel dosing schedule of As(2)O(3) and AA in patients with relapsed or refractory lymphoid malignancies."( Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study.
Ahuja, HG; Bailey, HH; Chang, JE; Kahl, BS; Kim, K; Kolesar, JM; Rodriguez, GA; Sanchez, FA; Voorhees, PM; Werndli, J, 2009
)
0.69
" With these drug therapies has come a more targeted approach to treatment enabling not only improved antimyeloma efficacy but also the use of decreased dosing enhancing the safety and tolerability of these regimens."( New drugs in multiple myeloma.
Berenson, JR; Yellin, O, 2008
)
0.35
" The results of this study indicate a significant dose-response relationship with the highest concentration of arsenic producing the greatest amount of TPO inhibition."( The minimal arsenic concentration required to inhibit the activity of thyroid peroxidase activity in vitro.
Jansen, KP; Palazzolo, DL, 2008
)
0.35
"It has been well documented that long-term exposure to inorganic arsenic induces cancers and vascular diseases in a dose-response relationship."( Arsenic trioxide mutational spectrum analysis in the mouse lymphoma assay.
Creus, A; Marcos, R; Soriano, C, 2008
)
1.79
" pallida three were positive, although no clear dose-response were observed for both plants."( Evaluation of the genotoxicity of treated urban sludge in the Tradescantia micronucleus assay.
Matta, ME; Mielli, AC; Nersesyan, A; Saldiva, PH; Umbuzeiro, GA, 2009
)
0.35
" Our results showed the increased level of As concentration in cerebellar tissue of the exposed mice in a dose-response manner, longer escape latency in the experimental group than controls and the down-regulated expression of Ca(2+)/calmodulin dependent protein kinase IV (Camk4), a very important regulator in the LTD pathway."( Arsenic down-regulates the expression of Camk4, an important gene related to cerebellar LTD in mice.
Hong, Y; Li, S; Liu, P; Piao, F; Wang, Y; Zhao, Y,
)
0.13
" Western Blot and densitometric analyses demonstrated a strong dose-response relationship with regard to p53 and RARE expression within the dose-range of 0-8 microg/ml."( Modulation of p53, c-fos, RARE, cyclin A, and cyclin D1 expression in human leukemia (HL-60) cells exposed to arsenic trioxide.
Tchounwou, PB; Yedjou, CG, 2009
)
0.56
" The patient numbers were generally small, treatment regimens differed both regarding the dosage of ATO and combinations with other drugs."( The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review.
Illmer, T; Röllig, C, 2009
)
0.7
" But the dosage and administration ways are undetermined yet."( Effects of arsenic trioxide under different administration ways on T-cell lymphoma xenografts in nude mice: in vivo and in vitro experiments.
Bu, Q; Cai, QQ; Gao, Y; Huang, HQ; Li, S; Liao, H; Zhou, Y, 2009
)
0.74
"Shortening the administration course and increasing the daily dosage of As(2)O(3) can be considered as a reasonable model for treating advanced/refractory lymphomas."( Effects of arsenic trioxide under different administration ways on T-cell lymphoma xenografts in nude mice: in vivo and in vitro experiments.
Bu, Q; Cai, QQ; Gao, Y; Huang, HQ; Li, S; Liao, H; Zhou, Y, 2009
)
0.74
" Since increasing the dosage of chemotherapeutic agents could also elevate toxicity, a solution to how one could achieve maximum therapeutic effect with the minimum dosage possible is imminent."( Synergistic mitosis-arresting effects of arsenic trioxide and paclitaxel on human malignant lymphocytes.
Chen, GQ; Duan, XF; Wang, XD; Wu, YL; Xu, HZ; Yan, H; Zhao, M; Zhuang, HY, 2010
)
0.63
"Renal impairment did increase the systemic exposure to arsenic and its methylated metabolites following standard daily dosing of arsenic trioxide."( A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment.
D'Andrea, DM; Darwish, M; Porter, JM; Remick, SC; Sweeney, CJ; Takimoto, C; Tracewell, WG; Wood, L, 2010
)
0.82
"Complete remission was observed in 17 (85%) patients with the median duration of 28 days (18-38) and cumulative dosage of median 280 mg (180-350)."( The expression of p38, ERK1 and Bax proteins has increased during the treatment of newly diagnosed acute promyelocytic leukemia with arsenic trioxide.
Alimoghaddam, K; Ghaffari, SH; Ghahremani, MH; Ghavamzadeh, A; Hosseini, R; Mandegary, A; Rostami, S, 2010
)
0.56
" This synergistic effects is related to the dosage and treatment time."( [Apoptosis of NB4 cells induced by Tanshinone II A combined with arsenic trioxide].
Meng, WT; Yang, YM; Zhang, G; Zhou, J, 2010
)
0.6
"Flow cytometry data showed a strong dose-response relationship between ATO exposure and Annexin-V positive HL-60 cells."( Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells.
Jenkins, J; McMurray, R; Tchounwou, P; Yedjou, C, 2010
)
0.68
"Twenty-four experimental canines were equally divided into 4 groups, the three tested groups were deployed by stents with different dosage of As2O3 (1."( [Effects of control-releasing arsenic trioxide-eluting stent on intimal smooth muscle cells and type III collagen in canine coronary artery post-stent model].
Sun, BG; Wen, QZ; Zhao, JL, 2010
)
0.65
" We demonstrated that when dose-response curves were fitted with the same method, similar evaluated results for drug combinations would be derived with different models."( [Three different drug interaction mathematical models used to evaluate the cytotoxicity of SAHA and arsenic trioxide in combination].
Liu, ZJ; Lu, N; Wang, N; Yan, Z, 2010
)
0.58
" In the chronic study, two of four rats suddenly died by the repeated dosing of ATO, whereas no deaths were observed in combination with LA."( Protective effect of α-lipoic acid against arsenic trioxide-induced acute cardiac toxicity in rats.
Ando, H; Fujimura, A; Hosohata, K; Koshimizu, TA; Kumazaki, M; Oshima, Y; Sasaki, A; Ushijima, K, 2011
)
0.63
" Clinical therapeutic dosage of ATO was intraperitoneally injected into C57 mice, and the numbers of circulating platelets were significantly reduced after five days of continuous injection."( Arsenic trioxide induces apoptosis in human platelets via C-Jun NH2-terminal kinase activation.
Dai, J; Dai, K; Ruan, C; Wu, Y; Yan, R; Zhang, W; Zhang, Y, 2014
)
1.85
"With the increase of sodium arsenite or arsenic trioxide concentrations, cellular viability, colony formation rate and GSH contents decreased; inhibition of colony formation, cellular apoptotic rate, reactive oxygen species level and frequency of micronuclei increased, and dosed cells were both arrested in G2/M phase of cell cycle."( [Research on the sodium arsenite and arsenic trioxide induced proliferation and apoptosis effects on human hepatocyte].
Chen, C; Hu, Y; Jiang, X; Zhang, Z; Zhao, W, 2014
)
0.94
" To achieve an equivalent effect, a 10-fold dosage of genistein was required, thus highlighting the dose advantage of resveratrol, as poor bioavailability is a common concern for its clinical application."( Arsenic trioxide and resveratrol show synergistic anti-leukemia activity and neutralized cardiotoxicity.
Chen, M; Fan, Y; Fang, K; Meng, J; Tu, Y; Wan, L; Yu, L; Zhu, W, 2014
)
1.85
"3 µM) dosage increased lysosomal activity and induced autophagy and higher (1."( Realgar (As4S4) nanoparticles and arsenic trioxide (As2O3) induced autophagy and apoptosis in human melanoma cells in vitro.
Balaz, P; Bujnakova, Z; Cholujova, D; Duraj, J; Gronesova, P; Hunakova, L; Lee, TC; Pastorek, M; Sedlak, J, 2014
)
0.68
"To determine the potential for arsenic trioxide (ATO) to be safely and effectively incorporated into induction therapy of newly diagnosed acute promyelocytic leukaemia (APL) in patients with severe chronic renal failure (CRF) by reduction of the ATO dosage to compensate for reduced renal elimination of arsenic in CRF."( Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
Firkin, F; Ho, WK; Roncolato, F, 2015
)
1.06
" ATO dosage schedules were adjusted to obtain comparable whole-blood arsenic levels to those in APL patients with normal renal function who achieved molecular remission (MR) while receiving 10 mg ATO daily for 28 d."( Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
Firkin, F; Ho, WK; Roncolato, F, 2015
)
0.78
"The observations in this pilot study have demonstrated whole-blood arsenic levels can provide a guide to adjustments of ATO dosage schedules that permit safe and effective therapeutic outcomes in APL patients with severely compromised renal function."( Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
Firkin, F; Ho, WK; Roncolato, F, 2015
)
0.78
" The connection between arsenic dosage and inflammation-related genes was assessed."( Inflammatory Factor Alterations in the Gastrointestinal Tract of Cocks Overexposed to Arsenic Trioxide.
Chai, H; Guo, G; Guo, Y; He, Y; Tian, L; Xing, M; Zhang, K; Zhang, W; Zhao, P, 2015
)
0.64
" Dose adjustments are recommended to be considered in severe renal impairment although dosage reduction guidelines are not provided."( Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
Eyler, R; Moeller, J; Patel, K; Perreault, S; Pham, T; Podoltsev, N; Russell, K, 2016
)
0.89
" Continuous dosing may be required to fully inhibit the HH pathway and achieve clinical response."( Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma.
Ally, MS; Atwood, SX; Bailey-Healy, I; Beachy, PA; Chang, AL; Colevas, AD; Kim, J; Oro, A; Ransohoff, K; Rezaee, M; Sarin, K; Tang, JY, 2016
)
0.71
" Thus, the present data strongly indicate that low dosage As2O3 reduces the formation of VM in HB cell line HepG2 cells, independent of cell apoptosis in vivo and in vitro, and may represent as a candidate drug for HB targeting VM."( Low dosage of arsenic trioxide inhibits vasculogenic mimicry in hepatoblastoma without cell apoptosis.
Fu, Y; Guo, BB; Jiang, HY; Li, S; Liu, LY; Wang, KK; Wu, CJ; Zhang, CM; Zhang, F; Zhang, Y, 2018
)
0.84
" Cell viability was detected by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and the appropriate dosage and time were screened."( Mechanism of As2O3 induces apoptosis of glioma U87 cells.
Hu, J; Liu, JH; Wang, GB; Xue, K, 2017
)
0.46
" Our data further showed that the conventional dosage of ATO reached a plasma concentration substantially below the required concentration to inhibit platelets."( Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
Chen, L; Chen, SJ; Chen, Z; Cui, W; Gao, MQ; Hu, J; Li, JM; Mi, JQ; Nie, RM; Shen, ZX; Wang, J; Wang, KK; Wang, ZY; Xi, XD; Zhao, LL; Zhu, HM, 2018
)
1.92
" Evaluation of the timeline and responses of acute promyelocytic leukemia (APL) cells to the arsenic trioxide (ATO) treatment is essential for determining the oral dosage in leukemia prognosis."( Probing arsenic trioxide (ATO) treated leukemia cell elasticities using atomic force microscopy.
Fortier, H; Gies, V; Variola, F; Wang, C; Zou, S, 2020
)
1.21
" Overall, mean corticosteroid dosage decreased from 11."( Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic).
Amoura, Z; Ebbo, M; Gaborit, B; Hachulla, E; Hamidou, M; Hardouin, JB; Néel, A; Poupon, J; Rieger, F; Sibilia, J; Viallard, JF; Volteau, C, 2021
)
0.88
" ATO is dosed on actual body weight and high ATO doses in overweight patients may contribute to increased toxicity."( Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia.
Baer, MR; DeZern, A; Duong, VH; Emadi, A; Gehrie, E; Ghiaur, G; Gojo, I; Hambley, B; Hickey, E; Kashanian, S; Levis, MJ; Li, A; Newman, MJ; Smith, BD; Varadhan, R; Zacholski, K, 2022
)
2.16
" However, high-quality clinical trials are expected to explore its broad-spectrum anticancer effects, wide application, appropriate route of administration, and compound dosage form."( The application of arsenic trioxide in cancer: An umbrella review of meta-analyses based on randomized controlled trials.
Chen, J; Chen, S; Luo, H; Wang, S; Wu, W, 2023
)
1.24
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
insecticideStrictly, a substance intended to kill members of the class Insecta. In common usage, any substance used for preventing, destroying, repelling or controlling insects.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
arsenic oxide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency28.69540.005612.367736.1254AID624032
lamin isoform A-delta10Homo sapiens (human)Potency7.07950.891312.067628.1838AID1487
TDP1 proteinHomo sapiens (human)Potency33.49830.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency17.11290.000221.22318,912.5098AID743035; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency8.26590.000214.376460.0339AID720692; AID720719
estrogen nuclear receptor alphaHomo sapiens (human)Potency19.68820.000229.305416,493.5996AID743069; AID743078; AID743079; AID743080; AID743091
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency24.38220.001019.414170.9645AID743094; AID743140
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency3.98110.10009.191631.6228AID1346983
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency9.62380.000323.4451159.6830AID743065; AID743067
Cellular tumor antigen p53Homo sapiens (human)Potency23.71010.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
14-3-3 protein etaHomo sapiens (human)Kd110.00000.07000.07000.0700AID1859478
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (136)

Processvia Protein(s)Taxonomy
regulation of sodium ion transport14-3-3 protein etaHomo sapiens (human)
glucocorticoid catabolic process14-3-3 protein etaHomo sapiens (human)
intracellular protein transport14-3-3 protein etaHomo sapiens (human)
substantia nigra development14-3-3 protein etaHomo sapiens (human)
intracellular glucocorticoid receptor signaling pathway14-3-3 protein etaHomo sapiens (human)
regulation of neuron differentiation14-3-3 protein etaHomo sapiens (human)
positive regulation of DNA-templated transcription14-3-3 protein etaHomo sapiens (human)
regulation of synaptic plasticity14-3-3 protein etaHomo sapiens (human)
negative regulation of dendrite morphogenesis14-3-3 protein etaHomo sapiens (human)
membrane depolarization during action potential14-3-3 protein etaHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission14-3-3 protein etaHomo sapiens (human)
regulation of sodium ion transmembrane transporter activity14-3-3 protein etaHomo sapiens (human)
signal transduction14-3-3 protein etaHomo sapiens (human)
protein localization14-3-3 protein etaHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (40)

Processvia Protein(s)Taxonomy
actin binding14-3-3 protein etaHomo sapiens (human)
insulin-like growth factor receptor binding14-3-3 protein etaHomo sapiens (human)
protein binding14-3-3 protein etaHomo sapiens (human)
sodium channel regulator activity14-3-3 protein etaHomo sapiens (human)
enzyme binding14-3-3 protein etaHomo sapiens (human)
protein domain specific binding14-3-3 protein etaHomo sapiens (human)
nuclear glucocorticoid receptor binding14-3-3 protein etaHomo sapiens (human)
identical protein binding14-3-3 protein etaHomo sapiens (human)
transmembrane transporter binding14-3-3 protein etaHomo sapiens (human)
protein heterodimerization activity14-3-3 protein etaHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (24)

Processvia Protein(s)Taxonomy
cytoplasm14-3-3 protein etaHomo sapiens (human)
cytosol14-3-3 protein etaHomo sapiens (human)
plasma membrane14-3-3 protein etaHomo sapiens (human)
intercalated disc14-3-3 protein etaHomo sapiens (human)
extracellular exosome14-3-3 protein etaHomo sapiens (human)
presynapse14-3-3 protein etaHomo sapiens (human)
cerebellar granule cell to Purkinje cell synapse14-3-3 protein etaHomo sapiens (human)
cytoplasm14-3-3 protein etaHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (53)

Assay IDTitleYearJournalArticle
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID328594Inhibition of NADPH-reduced rat recombinant TrxR1 by DTNB reduction assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
AID1154295Cytotoxicity against human HL60 cells assessed as inhibition of proliferation after 72 hrs by MTT assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Dithiaarsanes induce oxidative stress-mediated apoptosis in HL-60 cells by selectively targeting thioredoxin reductase.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID328601Reduction of human MCF7 cell growth at 2.5 uM after 48 hrs by XTT assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID328608Inhibition of NADPH-reduced rat recombinant TrxR1 at 0.25 uM attenuated in presence of 1 mM Glutathione after 30 minis2007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1154297Cytotoxicity against human HeLa cells assessed as inhibition of proliferation after 48 hrs by MTT assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Dithiaarsanes induce oxidative stress-mediated apoptosis in HL-60 cells by selectively targeting thioredoxin reductase.
AID328595Inhibition of human thioredoxin2007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID328606Effect on human thioredoxin redox state change in MCF7 cells assessed as decrease in 12-kDa monomer part at 5.0 uM after 48 hrs by Western blot2007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID328599Inhibition of Escherichia coli thioredoxin upto 5 uM by insulin reduction method2007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID328600Inhibition of human MCF7 cell growth after 24 hrs by XTT assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
AID328602Reduction of human MCF7 cell growth at 5.0 uM after 48 hrs by XTT assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID328604Inhibition of human thioredoxin in MCF7 cell lysates by insulin assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID328607Inhibition of NADPH-reduced rat recombinant TrxR1 at 0.1 uM attenuated in presence of 1 mM Glutathione after 30 minis2007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
AID328603Inhibition of TrxR1 in human MCF7 cell lysates at 5.0 uM by insulin assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
AID328596Inhibition of NADPH-reduced rat recombinant TrxR1 assessed as NADPH oxidase activity by DTNB reduction assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
AID1154298Cytotoxicity against human HepG2 cells assessed as inhibition of proliferation after 48 hrs by MTT assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Dithiaarsanes induce oxidative stress-mediated apoptosis in HL-60 cells by selectively targeting thioredoxin reductase.
AID328597Inhibition of NADPH-reduced rat recombinant TrxR1 in presence of superoxide dismutase by DTNB reduction assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID328605Effect on human thioredoxin redox state change in MCF7 cells assessed as decrease in 12-kDa monomer part at 2.5 uM after 48 hrs by Western blot2007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
AID1154294Cytotoxicity against human HL60 cells assessed as inhibition of proliferation after 48 hrs by MTT assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Dithiaarsanes induce oxidative stress-mediated apoptosis in HL-60 cells by selectively targeting thioredoxin reductase.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID328609Inhibition of NADPH-reduced rat recombinant TrxR1 at >0.5 uM attenuated in presence of 1 mM Glutathione after 30 minis2007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID328598Inhibition of NADPH-reduced rat recombinant TrxR1 in presence of catalase by DTNB reduction assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-24, Volume: 104, Issue:30
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1154296Cytotoxicity against human SSMC-7721 cells assessed as inhibition of proliferation after 48 hrs by MTT assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Dithiaarsanes induce oxidative stress-mediated apoptosis in HL-60 cells by selectively targeting thioredoxin reductase.
AID1204580Induction of apoptosis in human NB4 cells assessed as cell death2015European journal of medicinal chemistry, Jun-15, Volume: 98Synthesis and antiproliferative activity of α-branched α,β-unsaturated ketones in human hematological and solid cancer cell lines.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1846001Antiproliferative activity against human Daoy cells assessed as inhibition of cell proliferation measured after 4 days by WST-1 assay2021European journal of medicinal chemistry, Apr-05, Volume: 215Medulloblastoma drugs in development: Current leads, trials and drawbacks.
AID1893961Antiproliferative activity against human NB-4 cells2021European journal of medicinal chemistry, Jan-15, Volume: 210Xanthenes in Medicinal Chemistry - Synthetic strategies and biological activities.
AID1846002Antiproliferative activity against human D556 Med cells assessed as inhibition of cell proliferation measured after 4 days by WST-1 assay2021European journal of medicinal chemistry, Apr-05, Volume: 215Medulloblastoma drugs in development: Current leads, trials and drawbacks.
AID1373910Cytotoxicity against human lymphocytes after 24 to 48 hrs by MTT assay2018Bioorganic & medicinal chemistry, 02-15, Volume: 26, Issue:4
Optimization of antimalarial, and anticancer activities of (E)-methyl 2-(7-chloroquinolin-4-ylthio)-3-(4-hydroxyphenyl) acrylate.
AID1373912Cytotoxicity against human HL60 cells after 24 hrs by MTT assay2018Bioorganic & medicinal chemistry, 02-15, Volume: 26, Issue:4
Optimization of antimalarial, and anticancer activities of (E)-methyl 2-(7-chloroquinolin-4-ylthio)-3-(4-hydroxyphenyl) acrylate.
AID1373911Cytotoxicity against human Jurkat E6-1 cells after 24 hrs by MTT assay2018Bioorganic & medicinal chemistry, 02-15, Volume: 26, Issue:4
Optimization of antimalarial, and anticancer activities of (E)-methyl 2-(7-chloroquinolin-4-ylthio)-3-(4-hydroxyphenyl) acrylate.
AID1373913Selectivity index, ratio of IC50 for human lymphocytes to IC50 for human Jurkat E6-1 cells2018Bioorganic & medicinal chemistry, 02-15, Volume: 26, Issue:4
Optimization of antimalarial, and anticancer activities of (E)-methyl 2-(7-chloroquinolin-4-ylthio)-3-(4-hydroxyphenyl) acrylate.
AID1373914Selectivity index, ratio of IC50 for human lymphocytes to IC50 for human HL60 cells2018Bioorganic & medicinal chemistry, 02-15, Volume: 26, Issue:4
Optimization of antimalarial, and anticancer activities of (E)-methyl 2-(7-chloroquinolin-4-ylthio)-3-(4-hydroxyphenyl) acrylate.
AID1859478Binding affinity to 14-3-3 eta (unknown origin) assessed as dissociation constant by biolayer interferometry assay2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and antitumor evaluation of novel 1H-indole-2-carboxylic acid derivatives targeting 14-3-3η protein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,032)

TimeframeStudies, This Drug (%)All Drugs %
pre-199080 (2.64)18.7374
1990's130 (4.29)18.2507
2000's1155 (38.09)29.6817
2010's1330 (43.87)24.3611
2020's337 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 64.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index64.20 (24.57)
Research Supply Index8.10 (2.92)
Research Growth Index5.30 (4.65)
Search Engine Demand Index112.51 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (64.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Trials160 (5.13%)5.53%
Reviews1 (14.29%)6.00%
Reviews2 (40.00%)6.00%
Reviews340 (10.90%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Case Studies245 (7.86%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Observational1 (0.03%)0.25%
Other6 (85.71%)84.16%
Other3 (60.00%)84.16%
Other2,373 (76.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (131)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Clinical Research on Efficacy and Safety of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma:A Prospective,Single-arm, Open-label, Multi-center Study [NCT03503864]Phase 265 participants (Anticipated)Interventional2019-01-01Recruiting
Phase II Study of Arsenic Trioxide in Neuroblastoma and Other Pediatric Solid Tumors [NCT00024258]Phase 222 participants (Actual)Interventional2001-03-31Completed
Clinical Research on Efficacy and Safety of Arsenic Trioxide Combined With Chemotherapy in p53-mutated Pediatric Cancer Patients:A Prospective,Single-arm, Multi-center Study [NCT06088030]Phase 250 participants (Anticipated)Interventional2023-12-13Recruiting
Phase II Study of First Line Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide [NCT02966301]Phase 221 participants (Actual)Interventional2016-12-31Completed
A Long-Term Retrospective and Prospective Safety Study of Arsenic Trioxide in Patients With Newly Diagnosed, Low- to Intermediate-Risk Acute Promyelocytic Leukemia (APL) [NCT03751917]100 participants (Anticipated)Observational2020-04-14Recruiting
Phase I Study of the Combination of Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI [NCT02066870]Phase 19 participants (Anticipated)Interventional2014-01-31Recruiting
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid [NCT02339740]Phase 3158 participants (Actual)Interventional2015-07-21Active, not recruiting
A Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of Arsenic Trioxide for Injection in Patients With Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation [NCT04489706]20 participants (Anticipated)Interventional2020-06-28Recruiting
Multicenter Phase II Trial of Arsenic Trioxide in Relapsed and Refractory Hodgkin's Disease [NCT00005595]Phase 22 participants (Actual)Interventional2000-06-30Terminated(stopped due to Unable to accrue subjects in a timely fashion.)
Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO) [NCT01409161]Phase 2151 participants (Anticipated)Interventional2011-10-05Recruiting
A Phase I Study of Intravenous Decitabine in Combination With Arsenic Trioxide and Ascorbic Acid in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia [NCT00671697]Phase 113 participants (Actual)Interventional2008-05-31Completed
Leukemia SPORE Phase II Randomized Study of Decitabine Versus Decitabine and Carboplatin Versus Decitabine and Arsenic in Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) [NCT02190695]Phase 292 participants (Actual)Interventional2013-04-01Completed
Frontline Oral Arsenic Trioxide-based Induction in Newly Diagnosed Acute Promyelocytic Leukaemia [NCT04687176]Phase 2100 participants (Anticipated)Interventional2021-01-01Recruiting
A Randomised Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA Versus Standard ATRA and Anthracycline-Based Chemotherapy (AIDA Regimen) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia [NCT00482833]Phase 3276 participants (Actual)Interventional2007-08-31Completed
A Prospective, Multi-center, Single Armed Registry to Evaluate The Safety and Efficacy of 'AVI' Stent for Treating Coronary Revascularization [NCT02117843]1,200 participants (Anticipated)Interventional2013-07-31Recruiting
A Prospective, Multi-center, Randomized Trial To Evaluate The Safety and Efficacy of 'AVI' Stent Comparing With Firebird2® For Treating Coronary Revascularization [NCT02133287]2,000 participants (Anticipated)Interventional2013-08-31Active, not recruiting
A Phase I Trial of Tamibarotene and Arsenic Trioxide for the Treatment of Relapsed Acute Promyelocytic Leukemia [NCT00985530]Phase 14 participants (Actual)Interventional2009-10-31Terminated(stopped due to Supporting agency withdrew funding for study.)
Phase I/II Study of the Combination of Bortezomib With Arsenic Trioxide, Ascorbic Acid and High-Dose Melphalan for Patients With Multiple Myeloma [NCT00469209]Phase 1/Phase 260 participants (Actual)Interventional2006-06-30Completed
A Pilot Phase II Study of Decitabine, Arsenic Trioxide and Ascorbic Acid for Patients With Myelodysplastic Syndrome [NCT00621023]Phase 27 participants (Actual)Interventional2007-11-30Completed
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® ) During Consolidation [NCT00866918]Phase 3106 participants (Actual)Interventional2009-03-09Completed
Implement Randomized, Controlled, International Multi-center Clinical Trial of Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Non-high-risk Acute Promyelocytic Leukaemia [NCT04175587]Phase 3109 participants (Anticipated)Interventional2019-12-01Not yet recruiting
A Phase I Study of the Combination of Radiation Therapy (RT), Arsenic Trioxide (ATO) and Temozolomide (TMZ) in Patients With Newly-Diagnosed Glioblastoma Multiforme (GBM) [NCT00720564]Phase 118 participants (Anticipated)Interventional2008-04-30Completed
A Multicenter and Randomized Prospective Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia [NCT02200978]Phase 4176 participants (Actual)Interventional2011-09-30Completed
Molecular Remission With Arsenic Trioxide in Acute Promyelocytic Leukemia: Indian APL Study Group - IAPLSG [NCT00517712]Phase 2/Phase 3400 participants (Anticipated)Interventional2004-06-30Recruiting
Combination of Ibrutinib and As2O3 in the Treatment of CLL [NCT02757040]Phase 370 participants (Anticipated)Interventional2016-12-31Not yet recruiting
A Pilot Phase II Protocol Of Arsenic Trioxide (Trisenox) In Subjects With Advanced Non-Small Cell Carcinoma Of The Lung [NCT00075426]Phase 230 participants (Anticipated)Interventional2002-11-30Completed
Targeting of the Leukemia Stem Cell Population With Arsenic Trioxide and Tyrosine Kinase Inhibitors for CML [NCT01397734]Phase 17 participants (Actual)Interventional2011-09-30Terminated(stopped due to Lack of enrollment and limited funding)
Feasibility Study of Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide on Ambulatory Schedule [NCT00850304]Phase 210 participants (Actual)Interventional2007-10-31Completed
Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid (ATRA) [NCT05297123]Phase 130 participants (Anticipated)Interventional2019-02-03Recruiting
Phase I/II Trial of Arsenic Trioxide (As2O3) With Ascorbic Acid in the Treatment of Relapsed/Refractory Multiple Myeloma [NCT00006021]Phase 1/Phase 222 participants (Actual)Interventional2000-06-30Completed
Phase II Study of Arsenic Trioxide (NSC #706363) Therapy for Fludarabine Refractory or Relapsed Chronic Lymphocytic Leukemia [NCT00006090]Phase 20 participants (Actual)Interventional2000-06-30Withdrawn(stopped due to No enrollment.)
A Phase I/II Trial of Infusional Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia [NCT00008697]Phase 1/Phase 213 participants (Actual)Interventional1998-11-30Completed
A Phase II Study of Arsenic Trioxide (NSC #706363) in Patients With Advanced Cervical Carcinoma [NCT00005999]Phase 20 participants Interventional2000-04-30Completed
A Phase II Trial of Arsenic Trioxide (NSC #706363) for Relapsed or Refractory Acute Lymphoblastic Leukemia [NCT00006008]Phase 20 participants Interventional2000-06-30Completed
Phase II Study Of Combined Modality Postremission Therapy As Determined By Molecular Response (Adaptive Regulation) In The Treatment Of Acute Promyelocytic Leukemia (APL) [NCT00016159]Phase 235 participants (Anticipated)Interventional2000-11-30Completed
Phase II Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-APL Acute Myelogenous Leukemia [NCT00184054]Phase 211 participants (Actual)Interventional2002-04-30Terminated(stopped due to Competing studies)
An Open-Label, Randomized Study of Low-Dose Cytarabine in Combination With Arsenic Trioxide Compared With Low-Dose Cytarabine Alone for the Treatment of Elderly Patients With Acute Myeloid Leukemia [NCT00513305]Phase 367 participants (Actual)Interventional2007-10-31Terminated(stopped due to Study has been stopped by sponsor decision)
Phase II Trial of Arsenic Trioxide and Thalidomide in the Treatment of Patients With Refractory Multiple Myeloma [NCT00193544]Phase 240 participants Interventional2002-03-31Completed
A Phase II Study of Arsenic Trioxide in Combination With Thalidomide, Dexamethasone, and Ascorbic Acid [NCT00227682]Phase 22 participants (Actual)Interventional2004-06-30Terminated(stopped due to Terminated early due to funding suspension by grant sponsor.)
A Phase I Multicenter Study of Arsenic Trioxide and Azacitidine in Patients With Myelodysplastic Syndromes [NCT00234000]Phase 11 participants (Actual)Interventional2007-02-28Terminated(stopped due to The study was closed due to poor enrollment)
Combined Retinoic Acid,Arsenic Trioxide and Chemotherapy for Newly-diagnosed Acute Promyelocytic Leukemia: Chinese National Multi-center Randomized Study [NCT01987297]Phase 4738 participants (Anticipated)Interventional2012-06-30Active, not recruiting
A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome [NCT00251511]Phase 260 participants (Actual)Interventional2004-08-31Terminated(stopped due to Sponsor terminated trial)
Clinical Application Study of Transarterial Chemoembolization Containing Arsenic Trioxide in the Treatment of Hepatocellular Carcinoma [NCT02018757]Phase 2250 participants (Anticipated)Interventional2014-01-31Not yet recruiting
Arsenic Trioxide Therapy for Interferon Alpha Refractory or Intolerant Chronic Phase Chronic Myelogenous Leukemia [NCT00006091]Phase 20 participants (Actual)Interventional2000-06-19Withdrawn(stopped due to No enrollment.)
Arsenic Trioxide Alone or With ATRA (Vesanoid) for Resistant Hematologic Malignancy [NCT00006220]Phase 1/Phase 25 participants (Actual)Interventional1999-06-30Terminated(stopped due to Study drug became commercially available.)
Evaluation of Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy (Phase 1b) [NCT00571116]Phase 19 participants (Actual)Interventional2006-09-30Terminated(stopped due to Halted because of slow accrual and lack of study funding)
Phase I/II Study of Arsenic Trioxide (Trisenox), Ascorbic Acid and Bortezomib Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma [NCT00590603]Phase 125 participants (Actual)Interventional2008-07-31Terminated(stopped due to Poor accrual - terminated during Phase I; Phase II never started.)
Oral Arsenic Trioxide and Itraconazole for the Treatment of Patients With Advanced Basal Cell Carcinoma [NCT02699723]Early Phase 10 participants (Actual)Interventional2020-12-31Withdrawn(stopped due to Logistics)
Phase II Study of NRX 195183 Induction and NRX 195183 Combined With Arsenic Trioxide (As2o3) as Initial Consolidation Therapy Followed by Continuous NRX 195183 Maintenance Therapy for Patients With Untreated Acute Promyelocytic Leukemia [NCT00670150]Phase 20 participants (Actual)Interventional2010-05-31Withdrawn(stopped due to sponsor withdrew support)
A Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS) [NCT00225992]Phase 20 participants Interventional2004-02-29Terminated(stopped due to terminated due to lack of accrual.)
A Phase II Trial of Trisenox in Women With Recurrent or Metastatic Endometrial Adenocarcinoma [NCT01184053]Phase 23 participants (Actual)Interventional2010-03-31Terminated(stopped due to Accrual was very low. No subject had been enrolled in a year.)
A Pilot Study of Arsenic Trioxide-Based Consolidation Therapy for the Primary Treatment of Acute Promyelocytic Leukemia [NCT00276601]Phase 20 participants Interventional2004-10-31Completed
A Phase II Trial Of Arsenic Trioxide (TRISENOX) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [NCT00193518]Phase 241 participants Interventional2004-04-30Completed
Phase II Study of Melphalan, Arsenic Trioxide, and Ascorbic Acid in Patients With Relapsed or Refractory Multiple Myeloma [NCT00085345]Phase 20 participants (Actual)InterventionalWithdrawn
A Phase II Study of Arsenic Trioxide for Induction Therapy of Adult Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia and Previously Untreated Chronic Myeloid Leukemia With Blast Crisis [NCT00006092]Phase 22 participants (Actual)Interventional2000-08-31Terminated(stopped due to low accrual)
Decitabine and Arsenic Trioxide(ATO) in the Treatment of Myelodysplasic Syndrome [NCT03377725]Phase 30 participants (Actual)Interventional2018-03-20Withdrawn(stopped due to No patient was involved.)
A Phase II Study Of Arsenic Trioxide In Patients With Adenocarcinoma Of The Pancreas Refractory To Gemcitabine [NCT00053222]Phase 213 participants (Actual)Interventional2003-02-28Completed
Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma [NCT00185861]Phase 112 participants (Actual)Interventional2003-12-31Completed
Targeting Structural p53 Mutations With Arsenic Trioxide for Intractable Cancer [NCT04695223]Phase 230 participants (Anticipated)Interventional2021-01-01Recruiting
An Open-label Phase 1 Study to Evaluate Pharmacokinetics, Safety, and Tolerability of SY-2101 in Adult Patients With Acute Promyelocytic Leukemia [NCT04996030]Phase 116 participants (Actual)Interventional2021-09-17Suspended(stopped due to Prioritization)
Arsenic Trioxide TACE and Intravenous Administration Compared With Arsenic Trioxide TACE Alone in Unresectable Hepatocellular Carcinoma: a Randomized, Parallel, Controlled, Multi-center Clinical Study [NCT01861912]Phase 2/Phase 3258 participants (Anticipated)Interventional2013-06-30Enrolling by invitation
Treatment of Non-high-risk Acute Promyelocytic Leukemia With Realgar-Indigo Naturalis Formula (RIF) and All-trans Retinoid Acid (ATRA) [NCT02899169]Phase 3110 participants (Anticipated)Interventional2016-09-01Recruiting
Measurable-residual Disease (MRD) Monitoring of Nucleophosmin 1 (NPM1)-Mutated Acute Myeloid Leukaemia (AML) and Pre-emptive Therapy With Oral Arsenic Trioxide-based Regimen [NCT04689815]Phase 250 participants (Anticipated)Interventional2021-01-01Recruiting
Phase II Study of Arsenic Trioxide (NSC #706363) in Relapsed and Refractory Intermediate and High-Grade Non-Hodgkin's Lymphoma [NCT00005040]Phase 20 participants Interventional2000-01-31Completed
Phase I Clinical Trial of Dose Escalated Bortezomib + ATO (Arsenic Trioxide) + Melphalan as a Conditioning Regimen for Multiple Myeloma [NCT00504101]Phase 10 participants (Actual)Interventional2007-06-30Withdrawn(stopped due to Temporarily closed to accrual pending availablity of drug.)
APL-R2007: Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) [NCT00504764]Phase 460 participants (Anticipated)Interventional2007-07-31Completed
A Phase I Study of Oral Arsenic Trioxide With or Without Ascorbic Acid in Adults With Myelofibrosis [NCT01014546]Phase 15 participants (Actual)Interventional2010-04-30Terminated(stopped due to low accrual)
A Prospective Multicenter Randomized Controlled Open-label Trial of Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients [NCT02956772]Phase 2190 participants (Anticipated)Interventional2016-11-30Not yet recruiting
Phase I Study of Arsenic Trioxide [NCT00003630]Phase 10 participants Interventional1998-08-31Completed
A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail to Achieve a Complete Response to Initial Gleevec Treatment [NCT00250042]Phase 26 participants (Actual)Interventional2004-04-30Completed
A Pilot Phase II Protocol Of Arsenic Trioxide (TRISENOX) In Subjects With Advanced Carcinoma Of The Breast [NCT00075413]Phase 20 participants (Actual)Interventional2002-11-30Withdrawn(stopped due to Unable to identify qualified subjects willing to participate in this study)
Therapy of Advanced Stage Myelodysplastic Syndrome (MDS) With Arsenic Trioxide Given in Combination With Etanercept: A Phase I/II Study [NCT00093366]Phase 1/Phase 232 participants (Anticipated)Interventional2004-06-30Completed
Arsenic Trioxide, High-Dose Cytarabine and Idarubicin Induction Therapy in Previously Untreated de Novo and Secondary Adult Acute Myeloid Leukemia Patients < 60 Years Old - A Phase I Study [NCT00093483]Phase 161 participants (Actual)Interventional2002-04-30Completed
Phase I Trial of Arsenic Trioxide in Combination With Pamidronate Disodium [NCT00124605]Phase 124 participants (Actual)Interventional2005-04-30Completed
A Phase I Trial of Arsenic Trioxide in the Treatment of Infiltrating Gliomas of Childhood [NCT00095771]Phase 136 participants (Anticipated)Interventional2004-11-30Completed
A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome [NCT00454480]Phase 2/Phase 32,000 participants (Anticipated)Interventional2006-08-31Completed
A Phase I Study of 5-FU (Plus Leucovorin) and Arsenic Trioxide for Patients With Refractory/Relapsed Metastatic Colorectal Carcinoma [NCT00449137]Phase 113 participants (Actual)Interventional2005-06-30Completed
A Phase II Study of Arsenic Trioxide in Combination With 5-Azacitidine in Myelodysplastic Syndromes [NCT00118196]Phase 21 participants (Actual)Interventional2005-04-30Terminated(stopped due to Due to limited resources available to conduct study)
Effectiveness and Safety of Therapy Based on Attenuated Arsenic Trioxide Plus Low Doses of All-trans Retinoic Acid as Remission Induction Therapy in Patients With Acute Promyelocytic Leukemia Phase 1/2 Clinical Trial [NCT05497310]Phase 1/Phase 215 participants (Anticipated)Interventional2022-07-01Recruiting
Treatment of Acute Promyelocytic Leukemia (APL) With All-Trans Retinoic Acid, and Arsenic +/- Idarubicin [NCT00413166]Phase 278 participants (Actual)Interventional2006-12-31Completed
Phase II Study of Combined All-Trans Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy [NCT00528450]Phase 21 participants (Actual)Interventional2007-09-30Terminated(stopped due to Lack of accrual)
Phase I/II Study of Arsenic Trioxide in Combination With Cytosine Arabinoside in Patients With High-risk Myelodysplastic Syndrome and Poor-prognosis Acute Myelogenous Leukemia [NCT00195104]Phase 1/Phase 287 participants (Actual)Interventional2003-09-17Completed
Prospective Pilot Trial of Arsenic Trioxide (Trisenox®) in Combination With Cytosine Arabinoside in Patients With Advanced or Transformed Myelofibrosis [NCT00572065]Early Phase 121 participants (Actual)Interventional2008-02-29Completed
Fuzuloparib Plus Arsenic Trioxide in Patients With Platinum Resistance Relapsed Ovarian Cancer [NCT04518501]Phase 1/Phase 250 participants (Anticipated)Interventional2020-07-01Recruiting
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation [NCT04869475]Phase 220 participants (Anticipated)Interventional2021-04-20Recruiting
Phase II Trial of Arsenic Trioxide and Dose-Escalated Cholecalciferol in Myelodysplastic Syndrome [NCT00104806]Phase 25 participants (Actual)Interventional2004-11-30Terminated(stopped due to sponsor discontinues support)
Phase II Study of Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Patients With Previously Untreated High-Risk or Relapsed or Refractory Multiple Myeloma [NCT00112879]Phase 20 participants (Actual)InterventionalWithdrawn
A Phase II Study of Trisenox (Arsenic Trioxide) in the Treatment of Unresectable Liver Cancer [NCT00128596]Phase 225 participants (Anticipated)Interventional2004-06-30Completed
A PHASE II STUDY OF ARSENIC TRIOXIDE (NSC #706363, IND #57974) IN UROTHELIAL CANCER [NCT00009867]Phase 235 participants (Actual)Interventional2000-12-31Completed
Phase II Study of Arsenic Trioxide in Patients With Multiple Myeloma [NCT00017433]Phase 20 participants Interventional2001-01-31Terminated
Phase I Study of Combined Radiotherapy and Arsenic Trioxide for the Treatment of Newly Diagnosed Malignant Glioma [NCT00045565]Phase 130 participants (Actual)Interventional2002-10-31Completed
A Phase I/II Study To Determine The Safety, Tolerability, And Anti-Leukemic Effects of Trisenox (Arsenic Trioxide) In Combination With Gleevec (STI571) In Patients With Resistant Chronic Myelogenous Leukemia In Chronic Phase [NCT00053248]Phase 1/Phase 216 participants (Actual)Interventional2002-10-31Completed
An Exploratory Phase I/II Single-center Clinical Trial of the Efficacy, Tolerability and Safety of Intravenous D-isoascorbic Acid With Arsenic Trioxide in Patients With Advanced/Metastatic Colorectal Cancer Who Have Exhausted Standard Therapy [NCT05721872]Phase 1/Phase 238 participants (Anticipated)Interventional2023-02-15Recruiting
A Phase I/II Study to Determine Safety and Efficacy of Arsenic Trioxide (Trisneox™) in Combination With Imatinib (STI571, Gleevec™) in Patients With Chronic Myelogenous Leukemia in Accelerated or Blastic Phase Disease or Ph+ Acute Lymphoblastic Leukemia [NCT00081133]Phase 1/Phase 20 participants Interventional2003-12-31Completed
A Phase I/II Trial of Arsenic Trioxide and Temozolomide in Combination With Radiation Therapy for Patients With Malignant Gliomas [NCT00275067]Phase 1/Phase 250 participants (Anticipated)Interventional2005-05-31Active, not recruiting
CTI 1060: A Phase II Clinical Trial of Arsenic Trioxide and Dexamethasone as Therapy for Relapsed or Refractory Multiple Myeloma [NCT00017069]Phase 20 participants Interventional2001-02-28Terminated
Phase I Trial and Pharmacokinetic Study of Arsenic Trioxide in Pediatric Patients With Refractory Leukemia or Lymphoma [NCT00020111]Phase 10 participants Interventional2000-03-31Completed
Phase Two Multicenter Study Of Arsenic Trioxide In Patients With Myelodysplastic Syndromes [NCT00020969]Phase 20 participants Interventional2001-03-31Terminated
Phase II Study Of Arsenic Trioxide In Patients With Refractory Germ Cell Malignancies [NCT00036842]Phase 20 participants Interventional2002-04-30Completed
Treatment of Relapsed Acute Promyelocytic Leukemia With Arsenic Trioxide (Phase IV Study) [NCT00196768]Phase 430 participants (Anticipated)Interventional2005-01-31Recruiting
A Phase II Study of Arsenic Trioxide (NSC 706363) in Patients With Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction [NCT00061958]Phase 250 participants (Actual)Interventional2003-06-30Terminated(stopped due to Administratively complete.)
A Phase II Study of Low Dose Arsenic Trioxide in Patients With Malignancies as a Potential Chemotherapy Protector [NCT01428128]Phase 250 participants (Actual)Interventional2011-04-30Completed
Combination of Decitabine and ATO to Treat AML/MDS Expressing a Classified Type of Mutant p53 [NCT03855371]Phase 15 participants (Anticipated)Interventional2018-01-10Recruiting
Risk-stratified Frontline Oral Arsenic Trioxide-based Induction in Newly Diagnosed Acute Promyelocytic Leukaemia [NCT03624270]Phase 260 participants (Anticipated)Interventional2018-08-15Recruiting
Phase II Trial of Pegylated Liposomal Doxorubicin (Doxil), Vincristine, and Dexamethasone (DVd) in Combination With Arsenic Trioxide (Trisenox) in Untreated Patients With Symptomatic Multiple Myeloma [NCT00201695]Phase 212 participants (Actual)Interventional2004-07-31Completed
A Phase I Study of Arsenic Trioxide and Ascorbic Acid (ATO/AA) in Combination With Low Dose Velcade-Thalidomide-Dexamethasone (VTD) in Relapsed/Refractory Multiple Myeloma (MM) [NCT00258245]Phase 15 participants (Actual)Interventional2005-05-31Completed
A Phase II Trial of Combination Therapy With Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients With Chronic Idiopathic Myelofibrosis or Overlap Myelodysplastic/Myeloproliferative Disorders [NCT00274820]Phase 215 participants (Actual)Interventional2005-10-31Completed
Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) [NCT01738360]Phase 211 participants (Actual)Interventional2013-07-31Terminated(stopped due to Difficulty of inclusions and a sufficient number of relevant clinical information)
An Open-label, Biomarker Study of Arsenic Trioxide for the Treatment of Patients With Basal Cell Carcinoma [NCT01791894]Phase 1/Phase 25 participants (Actual)Interventional2013-04-30Completed
Phase II Study of Arsenic Trioxide in Relapsed/Refractory Acute Leukemia and Blast Crisis of Chronic Myeloid Leukemia [NCT00003885]Phase 260 participants (Anticipated)Interventional1997-11-30Active, not recruiting
A Randomized Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA and Idarubicin Versus Standard ATRA and Anthracyclines-based Chemotherapy (AIDA Regimen) for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia [NCT02688140]Phase 3280 participants (Anticipated)Interventional2016-06-30Active, not recruiting
Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With or Without Arsenic Trioxide (AS2O3) (NSC # 706363) as Initial Consolidation Therapy Followed by Maintenance Therapy With Intermittent Tretinoin Versus Intermittent Tretinoin Plus Mer [NCT00003934]Phase 3420 participants (Actual)Interventional1999-06-30Completed
A Single Arm, Two-Stage Phase II Study of Arsenic Trioxide in Previously Treated Small Cell Lung Cancer [NCT01470248]Phase 220 participants (Actual)Interventional2011-08-31Completed
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia [NCT00551460]Phase 278 participants (Actual)Interventional2007-11-15Completed
A Phase II Trial of Combination Therapy With Arsenic Trioxide (Trisenox) and Gemtuzumab Ozogamicin (Mylotarg) for the Treatment of Adult Patients With Advanced Myelodysplastic Syndrome [NCT00274781]Phase 230 participants (Actual)Interventional2004-02-29Completed
Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia [NCT03031249]Phase 1/Phase 280 participants (Anticipated)Interventional2017-02-08Recruiting
A Pilot Study of Arsenic Trioxide in the Treatment of Relapsed and Refractory Indolent Lymphomas [NCT00005786]25 participants (Actual)Interventional2001-01-31Terminated(stopped due to Administratively complete.)
A Randomized Trial Assessing the Role of Arsenic Trioxide and/or ATRA During Consolidation Course in Newly Diagnosed Acute Promyelocytic Leukemia (APL) [NCT00378365]Phase 3800 participants (Anticipated)Interventional2006-10-31Recruiting
A Phase II Trial of Arsenic Trioxide in Advanced Hormone-Refractory Prostate Cancer [NCT00004149]Phase 237 participants (Actual)Interventional1999-09-30Completed
Phase II Study of Arsenic Trioxide, NSC 706363, in Relapsed of Refractory Chronic Myelogenous Leukemia [NCT00005618]Phase 20 participants Interventional2000-02-29Completed
Phase II Study of Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy [NCT01404949]Phase 217 participants (Actual)Interventional2011-07-31Completed
A Phase II Study of Arsenic Trioxide in Patients With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Mutated Nucleophosmin 1 (NPM1) Gene [NCT01835288]Phase 20 participants (Actual)Interventional2013-05-31Withdrawn
Risk Analysis of Cardiotoxic Medication Use Due to Sodium Arsenite Chloride Injection [NCT06060132]400 participants (Anticipated)Observational2023-01-29Recruiting
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver [NCT00582400]Phase 29 participants (Actual)Interventional2004-09-30Terminated(stopped due to recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated)
Dose-Ranging Study of Arsenic Trioxide in Advanced Hematologic Cancers [NCT00003395]Phase 10 participants Interventional1998-04-30Completed
Phase II Trial of Arsenic Trioxide (NSC #706363) in Patients With Advanced Renal Cell Carcinoma [NCT00005069]Phase 20 participants Interventional2000-01-31Completed
Phase I/II Study of the Combination of Arsenic Trioxide With Ascorbic Acid and High-Dose Melphalan for Patients With Multiple Myeloma [NCT00661544]Phase 1/Phase 248 participants (Actual)Interventional2004-03-31Completed
Phase II Trial of Arsenic Trioxide in Relapsed and Refractory Acute Myeloid Leukemia, Secondary Leukemia, and/or Newly-Diagnosed Patients Greater Than or Equal to 65 Years Old [NCT00005795]Phase 211 participants (Actual)Interventional2000-02-29Completed
Decitabine,Cytarabine(Ara-C) and Arsenic Trioxide(ATO) in the Treatment of Acute Myeloid Leukemia With p53 Mutations [NCT03381781]Phase 2100 participants (Anticipated)Interventional2018-03-31Not yet recruiting
The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART [NCT03980665]Phase 120 participants (Anticipated)Interventional2019-04-01Recruiting
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia [NCT04793919]Phase 289 participants (Anticipated)Interventional2019-10-09Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00024258 (1) [back to overview]Response Rate After Every 3 Courses During Treatment and Then Every 2-3 Months for 1 Year After Completion of Treatment
NCT00184054 (2) [back to overview]Number of Participants With a Response (Complete Remissions (CR) and Complete Remission With Incomplete Blood Count Recovery (CRi)
NCT00184054 (2) [back to overview]Number of Participants With Severe (Grades 3-5) Adverse Events
NCT00274781 (3) [back to overview]Overall Survival
NCT00274781 (3) [back to overview]Complete and Partial Remission Per the International Working Group (IWG) Criteria for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
NCT00274781 (3) [back to overview]Tolerability
NCT00413166 (1) [back to overview]Complete Response (CR) Rate
NCT00469209 (1) [back to overview]Number of Patients Reaching Complete Response (CR)
NCT00513305 (6) [back to overview]Proportion of Participants Surviving at 6 Months and 12 Months Using the Kaplan Meier Estimate
NCT00513305 (6) [back to overview]Proportion of Participants With Relapse-Free Survival (RFS)Using the Kaplan-Meier Estimate
NCT00513305 (6) [back to overview]Number of Participants Who Died or Were Censored by 24 Months
NCT00513305 (6) [back to overview]Number of Participants Who Experienced Early Death
NCT00513305 (6) [back to overview]Number of Participants Who Experienced Induction (Thirty-Day) Mortality
NCT00513305 (6) [back to overview]Percentage of Participants in Complete Remission (CR)
NCT00528450 (1) [back to overview]Molecular Remission Rate
NCT00551460 (3) [back to overview]Continuous Complete Remission at 3 Years
NCT00551460 (3) [back to overview]Frequency of Toxicities
NCT00551460 (3) [back to overview]Mortality Rate at 6 Weeks
NCT00582400 (3) [back to overview]Number of Patients With Response to Treatment (RECIST Criteria)
NCT00582400 (3) [back to overview]Number of Participants With Treatment Related Toxicity.
NCT00582400 (3) [back to overview]Duration of Response.
NCT00621023 (2) [back to overview]Number of Patients With an Unacceptable Toxicity
NCT00621023 (2) [back to overview]Number of Patients With an Overall Response of Complete Response (CR) or Partial Response (PR)
NCT00661544 (1) [back to overview]Response Rate
NCT00866918 (4) [back to overview]Overall Survival (OS)
NCT00866918 (4) [back to overview]Hematologic, Molecular, and Cytogenetic Remission Rate
NCT00866918 (4) [back to overview]Hematologic Remission Rate
NCT00866918 (4) [back to overview]Event-free Survival (EFS)
NCT01184053 (3) [back to overview]Overall Survival
NCT01184053 (3) [back to overview]Progression Free Survival in Patients Treated With Trisenox®
NCT01184053 (3) [back to overview]Objective Response (CR+PR) Rate of Subjects Given Trisenox
NCT01404949 (1) [back to overview]Participants Who Experienced a Complete Remission
NCT01428128 (1) [back to overview]Dose of Arsenic That Blocks Activation of p53
NCT01470248 (2) [back to overview]Overall Survival
NCT01470248 (2) [back to overview]Progression-free Survival
NCT01791894 (4) [back to overview]Incidence of Grade 3/4 Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0
NCT01791894 (4) [back to overview]Patients With Progressive Disease Post Treatment by RECIST Criteria
NCT01791894 (4) [back to overview]Patients With Stable Disease Post Treatment
NCT01791894 (4) [back to overview]Percent Change in Biomarker (GLI2 Protein) Levels
NCT02339740 (2) [back to overview]Event-free Survival (EFS) in Standard Risk Acute Promyelocytic Leukemia (APL) Patients
NCT02339740 (2) [back to overview]EFS in High Risk APL Patients
NCT02966301 (5) [back to overview]Average Dose of Corticosteroids
NCT02966301 (5) [back to overview]Number of Participants With Complete or Partial Remission of Chronic Graft Versus Host Disease After a First Line Treatment With Arsenic Trioxide
NCT02966301 (5) [back to overview]Number of Adverse Events
NCT02966301 (5) [back to overview]Failure Free Survival
NCT02966301 (5) [back to overview]Cumulative Incidence for Non-relapse Mortality (NRM)

Response Rate After Every 3 Courses During Treatment and Then Every 2-3 Months for 1 Year After Completion of Treatment

(NCT00024258)
Timeframe: 1 year

Interventionparticipants (Number)
Progression of DiseaseStable Disease
Arsenic Trioxide165

[back to top]

Number of Participants With a Response (Complete Remissions (CR) and Complete Remission With Incomplete Blood Count Recovery (CRi)

Complete Remission (CR): ANC >=1000/mcl, Platelet count >=100,000/mcl, Bone marrow <5% blasts. Complete Remission with incomplete blood count recovery (CRi): Same as CR but ANC may be <1,000/mcl and/or platelet count <100,000/mcl. Patients who failed to achieve CR or CRi after two cycles were considered treatment failures. Patients who did not complete at least two cycles were not evaluated for response. (NCT00184054)
Timeframe: Up to 1 year

Interventionparticipants (Number)
CRCRiTreatment FailureNot Evaluable
Arsenic Trioxide (ATO) Plus Ascorbic Acid1541

[back to top]

Number of Participants With Severe (Grades 3-5) Adverse Events

Patients who received any amount of ATO plus Ascorbic Acid are included in the safety analyses. (NCT00184054)
Timeframe: Days 1, 8, 15, 21, 28, 35 of each cycle and at end of treatment (30 days after last dose or start of new therapy)

InterventionParticipants (Number)
AnorexiaAlanine aminotransferase increasedConjunctivitis infectiveDifferentiation syndromeElectrocardiogram QT corrected interval prolongedNeuropathy: sensorySepsis
Arsenic Trioxide (ATO) Plus Ascorbic Acid1121114

[back to top]

Overall Survival

Patient's Overall Survival from date of enrollment to a minimum of three years for survival. (NCT00274781)
Timeframe: From date of enrollment to a minimum of three years for survival

Interventionmonths (Median)
Overall SurvivalResponders Overall SurvivalNonresponders Overall Survival
ATO (0.25mg/kg) and GO (3mg/m2)9.728.67.6

[back to top]

Complete and Partial Remission Per the International Working Group (IWG) Criteria for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

The null hypothesis to be tested was the percentage who will respond to combination arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) therapy is <10%. A total of >/= 9 responses observed in 30 evaluable patients was taken as evidence warranting further study of the regimen, provided the toxicity profile also appears favorable. The IWG Criteria standardizes the clinical responses in MDS and AML based upon hematologic improvement, quality of life and cytogenic improvement. These standardizations allow for the responses to be determined as either complete responses or partial responses. (NCT00274781)
Timeframe: at 12 weeks post treatment

Interventionpercentage of patients (Number)
Responses according to IWG MDS CriteriaResponses according to IWG AML CriteriaResponses according to Both Criteria
ATO + GO302510

[back to top]

Tolerability

Tolerability of Therapy was assessed through use of the National Cancer Institute Common Toxicity Criteria (version 3.0). Treatment tolerability was determined based upon whether or not the physician determined therapy was in the patient's best interest, whether the patient wanted to continue therapy or not, whether patients discontinued treatment due to progressive disease, or whether patients discontinued treatment due to toxicity. (NCT00274781)
Timeframe: 12 Weeks

Interventionparticipants (Number)
Patients Who Completed 1 12-Week Cycle (C1)Patients Who Completed 2 12-Week Cycles (C2)Discontinue Tx During C1: Patient/Physician ChoiceDiscontinue Tx During C1: Progressive DiseaseDiscontinue Tx During C1:Treatment ToxicityDiscontinue Tx After C1: Progressive DiseaseDiscontinue Tx After C1: Treatment Toxicity
ATO (0.25mg/kg) and GO (3mg/m2)17755382

[back to top]

Complete Response (CR) Rate

"Response defined as CR (marrow with <5% blasts and no abnormal promyelocytes together with neutrophil count >1000 and platelet count >100,000) and toxicity as Acute promyelocytic leukemia (APL) differentiation syndrome, arrhythmia, peripheral neuropathy.~Bone marrow aspirate performed to check the status of the disease." (NCT00413166)
Timeframe: 1 month, up to day 85 of treatment

InterventionParticipants (Count of Participants)
ATRA + ATO: Low Risk (WBC<10,000)55
ATRA+ATO+IDA: High Risk (WBC >10,000)5
ATO+ATRA+GO15

[back to top]

Number of Patients Reaching Complete Response (CR)

Number of participants with CR at Day 180 who had maintained CR for at minimum of 4 weeks, and who had: No monoclonal protein in urine/serum when analyzed by immunofixation electrophoresis; bone marrow normal by morphological examination with <5% plasma cells, <1% aneuploid light chain restricted population by flow cytometry for DNA/cIg; and, while healing of bony lesion is not required, no new lytic lesion should appear. Further compression fracture of spine not considered progressive disease. (NCT00469209)
Timeframe: Baseline through Day 180, with assessments at Day 90 and Day 180

Interventionparticipants (Number)
No Bortezomib4
Bortezomib 1.0 mg/m^21
Bortezomib 1.5 mg/m^24

[back to top]

Proportion of Participants Surviving at 6 Months and 12 Months Using the Kaplan Meier Estimate

The duration of overall survival was defined for all patients and was measured from the date of randomization until death from any cause. For a patient who was not known to have died by the end of the follow-up period, observation of overall survival was censored on the date the patient was last known to be alive. The estimate of likelihood of survival at 6 and 12 months after Baseline using the Kaplan Meier Estimate is presented here. (NCT00513305)
Timeframe: Baseline through 12 months

,
InterventionProportion of Participants (Number)
Month 6 (95% Confidence Interval)Month 12 (95% Confidence Interval)
Low-dose Cytarabine Alone0.6498.51
Low-dose Cytarabine Plus Arsenic Trioxide0.62612.22

[back to top]

Proportion of Participants With Relapse-Free Survival (RFS)Using the Kaplan-Meier Estimate

RFS is defined for patients who achieved a complete remission (CR), complete remission with incomplete platelet recovery (CRp), or partial remission(PR), and was measured from the date of attaining CR, CRp, or PR until the date of AML relapse or death from any cause, whichever occurred first. For a patient not known to have relapsed or died by the end of the study followup, observation of relapse free survival was censored on the date of the last followup examination. The Kaplan Meier Estimate of relapse-free survival at Month 3 and Month 6 is presented here. (NCT00513305)
Timeframe: From Baseline (randomization) through 24 months following Baseline

,
InterventionProportion of participants (Number)
Month 3 (95% Confidence Interval)Month 6 (95% Confidence Interval)
Low-dose Cytarabine Alone0.8000.800
Low-dose Cytarabine Plus Arsenic Trioxide0.8180.818

[back to top]

Number of Participants Who Died or Were Censored by 24 Months

This measure (time to death or censor) was defined for all enrolled subjects from the date of randomization until death from any cause. If a subject was not known to have died by the end of the followup period, observation of overall survival was censored on the date the patient was last known to be alive. The number of participants who died or were censored is presented here. (Note: all subjects participating in this study had either died or were censored by 24 months.) (NCT00513305)
Timeframe: From Baseline through 24 months following Baseline

InterventionParticipants (Number)
Low-dose Cytarabine Plus Arsenic Trioxide33
Low-dose Cytarabine Alone34

[back to top]

Number of Participants Who Experienced Early Death

Early death is defined as death from any cause within the first 14 days after start of study drug treatment. The number of patients in each study group who experienced early death is presented here. (NCT00513305)
Timeframe: 14 days from start of study drug treatment

InterventionParticipants (Number)
Low-dose Cytarabine Plus Arsenic Trioxide0
Low-dose Cytarabine Alone2

[back to top]

Number of Participants Who Experienced Induction (Thirty-Day) Mortality

The number of subjects who died from any cause within the first 30 days after the start of study drug treatment is presented here. (NCT00513305)
Timeframe: Up to 30 days following start of study drug treatment

InterventionParticipants (Number)
Low-dose Cytarabine Plus Arsenic Trioxide3
Low-dose Cytarabine Alone2

[back to top]

Percentage of Participants in Complete Remission (CR)

The primary efficacy variable was the percentage of subjects in each treatment group who achieved complete remission after treatment with study drug. Complete remission was defined as: 1) Less than 5% blasts in normocellular bone marrow sample. 2) No blasts in bone marrow sample containing Auer rods. 3)Clearance of previous extramedullary disease. 4)Normal values for absolute neutrophil count (at least 1000/microliter), platelet count (at least 100,000/microliter), without platelet transfusions, and in absence of peripheral myeloblasts. (NCT00513305)
Timeframe: From baseline through Day 70. Assessments were performed on Day 21 in cycle 1, no later than Day 56 of cycle 1 or 2 (if applicable), and no later than Day 70 of cycle 1 or 2 (if applicable) or at any other time at the discretion of the investigator

InterventionPercentage of participants in CR (Number)
Low-dose Cytarabine Plus Arsenic Trioxide15.2
Low-dose Cytarabine Alone8.8

[back to top]

Molecular Remission Rate

# of patients with Complete Remission (NCT00528450)
Timeframe: 2 years

Interventionparticipants (Number)
All Patients1

[back to top]

Continuous Complete Remission at 3 Years

Binary variable: yes if the patient achieves complete remission and remains in continuous complete remission until at least 3 years after entering the study; otherwise no. (NCT00551460)
Timeframe: 3 years

Interventionpercentage of participants (Number)
ATRA + GO + Arsenic74

[back to top]

Frequency of Toxicities

Adverse events that were possibly, probably or definitely related to study drug are reported. (NCT00551460)
Timeframe: Up to 3 years

InterventionParticipants (Number)
ALT, SGPT (serum glutamic pyruvic transaminase)AST, SGOTAcidosis (metabolic or respiratory)Acute vascular leak syndromeAdult respiratory distress syndrome (ARDS)Albumin, serum-low (hypoalbuminemia)Alkaline phosphataseAlkalosis (metabolic or respiratory)Allergic reaction/hypersensitivityAllergic rhinitisAllergy/Immunology-OtherAnorexiaArthritis (non-septic)Ascites (non-malignant)AtelectasisAtrioventricular block - 2nd degree Mobitz Type IIAtrioventricular block - first degreeAuditory/Ear-OtherBicarbonate, serum-lowBilirubin (hyperbilirubinemia)Blood/Bone Marrow-OtherBronchospasm, wheezingBruising (in absence of Gr 3-4 thrombocytopenia)CNS cerebrovascular ischemiaCalcium, serum-high (hypercalcemia)Calcium, serum-low (hypocalcemia)Carbon monoxide diffusion capacity (DL(co))Cardiac Arrhythmia-OtherCardiac General-OtherCardiac troponin I (cTnI)Cardiac troponin T (cTnT)Cardiac-ischemia/infarctionChelitisCholesterol, serum-high (hypercholesterolemia)ConfusionConstipationCoughCreatinineCytokine release syndrome/acute infusion reactionDIC (disseminated intravascular coagulation)Dental: periodontal diseaseDermal change lymphedema, phlebolymphedemaDermatology/Skin-OtherDiarrheaDistention/bloating, abdominalDizzinessDry mouth/salivary gland (xerostomia)Dry skinDysphagia (difficulty swallowing)Dyspnea (shortness of breath)Edema, larynxEdema: head and neckEdema: limbEdema: visceraEncephalopathyEsophagitisEyelid dysfunctionFatigue (asthenia, lethargy, malaise)Febrile neutropeniaFever in absence of neutropenia, ANC lt1.0x10e9/LFibrinogenFlatulenceFlushingGGT (gamma-glutamyl transpeptidase)Gastrointestinal-OtherGlomerular filtration rateGlucose, serum-high (hyperglycemia)Glucose, serum-low (hypoglycemia)Hair loss/Alopecia (scalp or body)Hearing: pts w/o audiogram not enroll monitor prgmHeartburn/dyspepsiaHematomaHemoglobinHemorrhage, Respiratory tract NOSHemorrhage, CNSHemorrhage, GI - Lower GI NOSHemorrhage, GI - Oral cavityHemorrhage, GI - RectumHemorrhage, GI - Upper GI NOSHemorrhage, GU - BladderHemorrhage, GU - Urinary NOSHemorrhage, GU - VaginaHemorrhage, pulmo/upper resp- Bronchopulmonary NOSHemorrhage, pulmonary/upper respiratory - LungHemorrhage, pulmonary/upper respiratory - NoseHemorrhage/Bleeding-OtherHemorrhoidsHepatobiliary/Pancreas-OtherHiccoughs (hiccups, singultus)Hot flashes/flushesHypertensionHypotensionHypoxiaINR (of prothrombin time)Ileus, GI (functional obstruction of bowel)Incontinence, analInduration/fibrosis (skin and subcutaneous tissue)Inf (clin/microbio) w/Gr 3-4 neuts - BloodInf (clin/microbio) w/Gr 3-4 neuts - ColonInf (clin/microbio) w/Gr 3-4 neuts - Dental-toothInf (clin/microbio) w/Gr 3-4 neuts - LungInf (clin/microbio) w/Gr 3-4 neuts - Oral cav-gumsInf (clin/microbio) w/Gr 3-4 neuts - SkinInf (clin/microbio) w/Gr 3-4 neuts - StomachInf w/normal ANC or Gr 1-2 neutrophils - BloodInf w/normal ANC or Gr 1-2 neutrophils - LungInf w/normal ANC or Gr 1-2 neutrophils - UTIInf w/normal ANC or Gr 1-2 neutrophils - Up airwayInf w/normal ANC or Gr 1-2 neutrophils - VaginaInf w/unknown ANC - Oral cavity-gums (gingivitis)Infection (documented clinically or microbiologicaInfection with unknown ANC - BloodInfection with unknown ANC - Lung (pneumonia)Infection-OtherInjection site reaction/extravasation changesInsomniaLeak (including anastomotic), GU - BladderLeft ventricular systolic dysfunctionLeukocytes (total WBC)Liver dysfunction/failure (clinical)LymphopeniaMagnesium, serum-high (hypermagnesemia)Magnesium, serum-low (hypomagnesemia)Mental statusMetabolic/Laboratory-OtherMood alteration - agitationMood alteration - anxietyMood alteration - depressionMucositis/stomatitis (clinical exam) - Oral cavityMucositis/stomatitis (functional/symp) - Oral cavMuscle weakness, not d/t neuropathy - Extrem-lowerMuscle weakness, not d/t neuropathy - body/generalMusculoskeletal/Soft Tissue-OtherNasal cavity/paranasal sinus reactionsNauseaNeurology-OtherNeuropathy: cranial - CN II VisionNeuropathy: motorNeuropathy: sensoryNeutrophils/granulocytes (ANC/AGC)Obstruction, GU - BladderOcular/Visual-OtherOptic disc edemaPTT (Partial thromboplastin time)Pain - Abdomen NOSPain - BackPain - BonePain - ButtockPain - Cardiac/heartPain - Chest/thorax NOSPain - Dental/teeth/peridontalPain - EsophagusPain - Extremity-limbPain - EyePain - FacePain - Head/headachePain - JointPain - MusclePain - NeckPain - Oral cavityPain - PleuraPain - SinusPain - StomachPain - Throat/pharynx/larynxPain - UrethraPain-OtherPetechiae/purpura (hemorrhage into skin or mucosa)Phosphate, serum-low (hypophosphatemia)PlateletsPleural effusion (non-malignant)Pneumonitis/pulmonary infiltratesPotassium, serum-high (hyperkalemia)Potassium, serum-low (hypokalemia)Prolonged QTc intervalProteinuriaPruritus/itchingPsychosis (hallucinations/delusions)Pulmonary/Upper Respiratory-OtherRash/desquamationRenal failureRenal/Genitourinary-OtherRetinoic acid syndromeRigors/chillsSVT and nodal arrhythmia - Atrial fibrillationSVT and nodal arrhythmia - SVT arrhythmia NOSSVT and nodal arrhythmia - Sinus arrhythmiaSVT and nodal arrhythmia - Sinus bradycardiaSVT and nodal arrhythmia - Sinus tachycardiaSeizureSodium, serum-high (hypernatremia)Sodium, serum-low (hyponatremia)Soft tissue necrosis - Extremity-lowerSomnolence/depressed level of consciousnessSpeech impairment (e.g., dysphasia or aphasia)Stricture/stenosis (incl anastomotic) GI - PharynxSweating (diaphoresis)Syncope (fainting)Syndromes-OtherTaste alteration (dysgeusia)Thrombosis/embolism (vascular access-related)Thrombosis/thrombus/embolismThyroid function, low (hypothyroidism)Triglyceride, serum-high (hypertriglyceridemia)UlcerationUric acid, serum-high (hyperuricemia)Urinary frequency/urgencyUrinary retention (including neurogenic bladder)Urine color changeVaginal discharge (non-infectious)Ventricular arrhythmia - PVCsVentricular arrhythmia - Ventricular tachycardiaVision-blurred visionVision-flashing lights/floatersVision-photophobiaVitreous hemorrhageVoice changes/dysarthriaVomitingWatery eye (epiphora, tearing)Weight gainWeight loss
ATRA + GO + Arsenic3746413242348611812211272341841221121131462617511911323104111327153321213429221322112391612341382412110431982221254148111111431122312112513191326119168183141026193340214338152131482119125214477321118261574093928216121526426711352015191611924212111221411117243133239

[back to top]

Mortality Rate at 6 Weeks

(NCT00551460)
Timeframe: 6 weeks

Interventionpercentage of participants (Number)
ATRA + GO + Arsenic11

[back to top]

Number of Patients With Response to Treatment (RECIST Criteria)

Response included complete response, partial response or stable disease. (NCT00582400)
Timeframe: 6 years

Interventionparticipants (Number)
Arsenic Trioxide1

[back to top] [back to top]

Duration of Response.

Time to progression. (NCT00582400)
Timeframe: 6 years

Interventionmonths (Median)
Arsenic Trioxide8

[back to top]

Number of Patients With an Unacceptable Toxicity

Any of the following non-hematologic toxicities that causes a patient's therapy to be suspended or discontinued: Creatinine > 2x baseline value; serum glutamate oxaloacetate transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), Total bilirubin > 2x the upper limit of normal; Febrile neutropenia; Uncontrolled infection; Hepatotoxicity defined as an increase in serum bilirubin, SGOT, or alkaline phosphatase to >5 times baseline value); nephrotoxicity (defined as serum creatinine >3.5 times the ULN); neurological impairment (defined as somnolence, seizures, or impaired mentation); severe peripheral neuropathy, or any non-hematologic grade 4 toxic event. (NCT00621023)
Timeframe: During the treatment period and for 30 days after last dose of study drug

Interventionparticipants (Number)
All Participants4

[back to top]

Number of Patients With an Overall Response of Complete Response (CR) or Partial Response (PR)

Complete response and Partial response are defined using 2000 international working group (IWG) criteria. The Primary criteria for a CR is a repeat bone marrow showing < 5% myeloblasts with normal maturation of all cell lines, with no evidence for dysplasia . A PR meets all the CR criteria except Blasts decreased by >50% over pretreatment, or a less advanced myelodysplastic syndrome (MDS) French American British (FAB) classification than pretreatment. (NCT00621023)
Timeframe: after 4 cycles of therapy

Interventionparticipants (Number)
All Participants0

[back to top]

Response Rate

Bone marrow aspirate and biopsy performed to assess complete response and overall response rate. (NCT00661544)
Timeframe: 3, 6 and 12 months

InterventionParticipants (Number)
Complete ResponseOverall Response (Complete + Partial Response)
Arsenic Trioxide + Vitamin C + Melphalan1136

[back to top]

Overall Survival (OS)

OS - time from study entry to death. (NCT00866918)
Timeframe: At 3 years from study entry

InterventionPercentage of participants (Number)
Standard Risk98.4
High Risk85.7

[back to top]

Hematologic, Molecular, and Cytogenetic Remission Rate

Proportion of patients in hematologic, molecular, and cytogenetic remission at end of consolidation, course 3 and 4 are reported. Patients were determined to be in remission by all three criteria. (NCT00866918)
Timeframe: End of consolidation, course 3; up to 7 months (for Standard Risk) or end of consolidation, course 4; up to 9 months (for High Risk)

InterventionProportion of participants (Number)
Standard Risk0.8095
High Risk0.5882

[back to top]

Hematologic Remission Rate

Proportion of patients in hematologic remission at end of consolidation, course 1 are reported. (NCT00866918)
Timeframe: End of consolidation, course 1: up to 5 months

InterventionProportion of participants (Number)
Standard Risk1.0000
High Risk0.8824

[back to top]

Event-free Survival (EFS)

EFS - time from study entry until failure to achieve complete remission during consolidation, relapse, or death. For further clarification see definitions provided in the protocol. (NCT00866918)
Timeframe: At 3 years from study entry

InterventionPercentage of participants (Number)
Standard Risk95.4
High Risk82.9

[back to top]

Overall Survival

(NCT01184053)
Timeframe: 5 years

Interventiondays (Median)
Trisenox Treatment320

[back to top]

Progression Free Survival in Patients Treated With Trisenox®

Progression-Free survival is the period from start of treatment until disease progression, death, or date of last contact. (NCT01184053)
Timeframe: 28 days

InterventionParticipants (Count of Participants)
Trisenox Treatment0

[back to top]

Objective Response (CR+PR) Rate of Subjects Given Trisenox

To estimate the objective response (CR+PR) rate (as defined by the Gynecologic Oncology Group [GOG] RECIST Criteria)of Trisenox® in women with recurrent or metastatic endometrial cancer when administered at 0.25 mg/kg/day for 5 consecutive days (D1-5) every 4 weeks. (NCT01184053)
Timeframe: 28 days

InterventionParticipants (Count of Participants)
Trisenox Treatment0

[back to top]

Participants Who Experienced a Complete Remission

after induction with tretinoin and ATO (with idarubicin in patients with high-risk disease or who develop leukocytosis). (NCT01404949)
Timeframe: 4 years

InterventionParticipants (Count of Participants)
Tretinoin and Arsenic Trioxide16

[back to top]

Dose of Arsenic That Blocks Activation of p53

A main objective of this trial is to find the dose of arsenic that blocks the activation of p53. Blockage will reduce the amount of p53 production as measured by Western Blot. (NCT01428128)
Timeframe: Day 1 of chemotherapy

Interventionmg/kg (Number)
Arsenic Trioxide0.005

[back to top]

Overall Survival

Duration of time from enrollment on study until death (NCT01470248)
Timeframe: From enrolment till death on average up to 2 years

Interventionmonths (Median)
Arsenic Trioxide Treatment4.5

[back to top]

Progression-free Survival

"Defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Progression was evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1).~Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm." (NCT01470248)
Timeframe: Every 8 weeks

Interventionweeks (Mean)
Arsenic Trioxide Treatment6.26

[back to top]

Incidence of Grade 3/4 Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0

(NCT01791894)
Timeframe: Baseline to cycle 3

Interventionnumber of occurrences (Number)
IV ATO2

[back to top]

Patients With Progressive Disease Post Treatment by RECIST Criteria

Patients with a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions (NCT01791894)
Timeframe: After 3 treatment cycles (approx. 61 days)

Interventionparticipants (Number)
IV ATO1

[back to top]

Patients With Stable Disease Post Treatment

Number of patients with stable disease post treatment by RECIST criteria (NCT01791894)
Timeframe: After 3 cycles of treatment (approx. 61 days)

Interventionparticipants (Number)
Treatment (Arsenic Trioxide)3

[back to top]

Percent Change in Biomarker (GLI2 Protein) Levels

(NCT01791894)
Timeframe: baseline to day 33

Interventionpercentage decrease (Mean)
Treatment (Arsenic Trioxide)75

[back to top]

Event-free Survival (EFS) in Standard Risk Acute Promyelocytic Leukemia (APL) Patients

EFS is defined as the time from on study to failure to achieve hematological complete response (CR) prior to start of consolidation, persistence of molecular positive disease after minimal residual disease (MRD) positive consolidation course, relapse (molecular, morphologic or extramedullary), or death. The Kaplan-Meier method will be used to estimate 2-year EFS along with 90% log-minus-log transformed confidence limits. (NCT02339740)
Timeframe: Up to 24 months

Interventionpercentage of participants (Number)
Standard Risk97.9

[back to top]

EFS in High Risk APL Patients

EFS is defined as the time from on study to failure to achieve hematological CR prior to start of consolidation, persistence of molecular positive disease after MRD positive consolidation course, relapse (molecular, morphologic or extramedullary), or death. The Kaplan-Meier method will be used to estimate 2-year EFS along with 90% log-minus-log transformed confidence limits. (NCT02339740)
Timeframe: Up to 24 months

Interventionpercentage of participants (Number)
High Risk96.1

[back to top]

Average Dose of Corticosteroids

Average dose in mg/kg/day of prednisone or prednisone equivalent (NCT02966301)
Timeframe: Average dose of Prednisone at 6 months after the first infusion of ATO

Interventionmg/kg/day (Mean)
Interventional0.22

[back to top]

Number of Participants With Complete or Partial Remission of Chronic Graft Versus Host Disease After a First Line Treatment With Arsenic Trioxide

"Clinical response will be evaluated based on the Working Group Report 2015, published by the National Institute of Health Consensus.~Response definition is as follows:~Complete remission (CR) is defined as complete disappearance of any sign of chronic GvHD.~Partial remission (PR) is defined as a significant improvement as defined by the organ or site specific measurement scale without progression in any other organ or site." (NCT02966301)
Timeframe: six months

InterventionParticipants (Count of Participants)
Interventional15

[back to top]

Number of Adverse Events

"Tolerability and safety of ATO in combination with Prednisone, with or without Ciclosporine, in patients with chronic GvHD after allo-SCT.~Adverse events follow-up for all patients throughout the study" (NCT02966301)
Timeframe: 12 months after the first infusion of ATO for each patient

Interventionnumber of events (Number)
Interventional197

[back to top]

Failure Free Survival

"Treatment failure were defined by:~Initiation of a new systemic treatment for chronic GvHD;~Recurrent or progressive malignancy;~Death" (NCT02966301)
Timeframe: 6 months after first ATO infusion

Interventionpercentage of participants (Number)
Interventional90

[back to top]

Cumulative Incidence for Non-relapse Mortality (NRM)

Non-Relapse Mortality (NRM) of infectious and non-infectious origin (NCT02966301)
Timeframe: 12 months after first ATO infusion

Interventionpercentage of participants (Number)
Interventional5

[back to top]